IL92032A - Lactam-quinolones and pharmaceutical compositions containing them - Google Patents

Description

92032/2 Driw ο ^3ηη mnpn T orn D^Vpwnp-πυρ1? Lactam-quinolones and pharmaceutical compositions containing them PROCTER & GAMBLE PHARMACEUTICALS, INC.

C: 78805/9 BACKGROUND OF THE INVENTION This invention relates to novel antimicrobial compounds and compositions. The compounds of this invention contain, as integral substituents, a quinolone moiety and a lactam-containing moiety.

The chemical and medical literature describes a myriad of compounds that are said to be antimicrobial, i.e., capable of destroying or suppressing the growth or reproduction of microorganisms, such as bacteria. In particular, antibacterials include' a large variety of naturally-occurring (antibiotic), synthetic, or semi-synthetic compounds. They may be classified (for example) as the aminoglycosides, ansamacrol ides, beta-1 actams (including penicillins and cephalosporins), lincos-aminides, macro ides, nitrofurans, nucleosides, oligosaccharides, peptides and polypeptides, phenazines, polyenes, polyethers, quinolones, tetracyclines, and sulfonamides. Such antibacterials and other antimicrobials are described in Antibiotics, Chemotheraoeutics, and Antibacterial Agents for Disease Control (M. Grayson, editor, 1982), and E. Gale et al., The Molecular Basis of Antibiotic Action 2d edition (1981), both incorporated by reference herein.

The mechanism of action of these antibacterials vary. However, each can be generally classified as functioning in one or more of four ways: by inhibiting cell wall synthesis or repair; by altering cell wall permeability; by inhibiting protein synthesls; or by inhibiting synthesis of nucleic acids. For example, beta-lactam antibacterials act through inhibiting the essential penicillin binding proteins (PBPs) in bacteria, which are responsible for cell wall synthesis. On the other hand, quinolones act by inhibiting synthesis of bacterial DNA, thus preventing the bacteria from replicating.

Not surprisingly, the pharmacological characteristics of antibacterials and other antimicrobials, and their suitability for any given clinical use, also vary considerably. For example, the classes of antimicrobials (and members within a class) may vary in their relative efficacy against different types of microorganisms, and their susceptibility to development of microbial resistance. These antimicrobials may also differ in their pharmacological characteristics, such as their bioavailability, and biodistribution. Accordingly, selection of an appropriate antibacterial (or other antimicrobial) in any given clinical situation can be a complicated analysis of many factors, including the type of organism involved, the desired method of administration, and the location of the infection to be treated.

The development of microbial resistance is one factor in the selection of an appropriate antimicrobial (particularly antibacterials), which is of increasing concern in medical science. This "resistance" can be defined as existence of organisms, within a population of a given microbial species, that are less susceptible to the action of a given antimicrobial agent. Such resistant strains may subvert the mechanism of action of a particular antimicrobial, or chemically degrade the antimicrobial before it can act. For example, bacterial resistance to beta-lactam antibacterials has arisen through development of bacterial strains that produce beta-lactamase enzymes, which degrade the antibacterial.

In part as a result of the intense use of antibacterials over extended periods of time, many highly resistant strains of bacteria have evolved. This is of particular concern in environments such as hospitals and nursing homes, which are characterized by relatively high rates of infection and intense use of antibacterials. See, e.g., W. Sanders, Jr. et al., "Inductible Beta-lactamases: Clinical and Epidemiologic Implications for Use of Newer Cephalosporins", 10 Reviews of Infectious Diseases 830 (1988). Indeed, the development of resistant bacterial strains has led to a concern that pathogenic bacteria may be produced that are essentially resistant to even the newest developed antibacterial agents.

The literature describes many attempts to enhance the efficacy of antimicrobials, and to overcome the development of microbial resistance. Many such attempts involve the combination of antimicrobials. For example, Thabaut et al., 16 Presse Med. 2167 (1987) describes combinations of pefloxacin (a quinolone) with the beta-lactams cefotaxime and cefsulodin. Lenoc et al., 36 Path. Biol. 762 (1988), describes combined use of cephems with aminoglycosides, and with quinolones. Japanese Patent Publication 60/06,617, published January 14, 1985, also describes compositions containing beta-lactams and quinolones. O'Callaghan et al., 10 Antimicrobi l Agents and Chemotherapy 245 (1976), describes a mercapto pyridine-substituted cephem, which is said to liberate an active antimicrobial agent when the cephalosporin is hydrolyzed by beta-lactamase. Mobashery et al., 108 «L American Chemical Society 1684 (1986), presents a theory of employing bacterial beta-lactamase in situ to release an antibacterially-active leaving group from the 10-position of a cephem.

However, many such attempts to produce improved antimicrobials yield equivocal results. Indeed, few antimicrobials are produced that are truly cl nically-acceptable in terms of their spectrum of antimicrobial activity, avoidance of microbial resistance, and pharmacology.

SUMMARY OF THE INVENTION The present invention provides compounds of the general structure Q - L - B wherein Q, L and B are defined as follows: (I) Q is a structure according to Formula (I) wherein R 1 (A) (1) A1 is N or C(R7); where (i) is hydrogen, hydroxy, alkoxy, nitro, cyano, halogen, alkyl, or N(R8) (R9) , and (ii) R8 and R9 are, independently, R8A where R8A is hydrogen, alkyl, alkenyl, carbocyclic ring, or heterocyclic ring; or R8 and R9 together comprise a heterocyclic ring including the nitrogen to which they are bonded; (2) A2 is N or C(R2) ; where R is hydrogen or halogen; (3) A3 is N or C(R5) ; where R5 is hydrogen; (4) R1 is hydrogen or R*5, where R15 is alkyl, a carbocyclic ring, a heterocyclic ring, alkoxy, hydroxy, alkenyl, arylalkyl, or N(R8) (R9) ; (5) R3 is hydrogen, halogen, or R16, where R16 is alkyl, a carbocyclic ring, or a heterocyclic ring; (6) R4 is hydroxy; and (7) R6 is hydrogen, halogen, nitro, or N(R8) (R9) ; (B) and further that (1) when A1 is C(R7j, i and R7 may together comprise a heterocyclic ring including N' and A1; (2) when A2 is C(R2), R2 and R3 may together comprise -0-{CH2)N-0-, where n is an integer from 1 to 4; (3) when A3 is C(R5), R* and R5 may together comprise a heterocyclic ring including the carbon atoms to which R4 and R5 are bonded and the carbon atom of Formula (I) to which said carbon atoms are bonded; and (4) when A3 is C(R5), R1 and R5 may together comprise a heterocyclic ring including N' and the adjacent carbon to which R5 is bonded; and either R1 is R15 or R3 is R16 and said R13 or R16 is also part of the Q' or Q" of the moiety L thereby forming the linkage between the Q and L moieties; (II) B is a structure according to Formula (II): where L is bonded to R14 or if a, b and Rw are nil L is bonded direct to R12 or R13; wherein (A) R10 is hydrogen, halogen, alkyl, alkenyl, heteroalkyl , a carbocyclic ring, a heterocyclic ring, R8a-0-, RSaCH=N-, (R8)(R9)N-, Rl7-C(-NO-*19)-C(-0)NH-f or Rl8-(CH2)ffl-C(=0)NH-; where (1) m is an integer from 0 to 9} (2) Rl7 is hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, a carbocyclic ring, or a heterocyclic ring; (3) Rl8 is Rl7, -Yl, or -CH(Y2) (R*7) (4) R19 is Rl7, arylalkyl, heteroarylalkyl , -C(R 2)(R23)C0OH, -C(=0)0-Rl7, or -C(-0)NH-R17, where R22 and R23 are, independently, R17 or together comprise a carbocyclic ring or a heterocyclic ring including the carbon atom to which 22 ancj R23 are bonded; (5) R20 is R19, halogen, -γΐ, or -CH(Y2) (R17J ; (6) Yl is -C(-0)0R21, -C(-0)R21, -N(R24)R21, -S(0)pR29, or -0R29; and γ is γΐ or -OH, -SH, or -SO3H; (a) p is an integer from 0 to 2; (b) R24 is hydrogen; alkyl; alkenyl; heteroal kyl ; heteroal kenyl ; a carbocyclic ring; a heterocyclic ring; -SO3H; -C(=0)R25; 0r, when R*8 is , -CH(N(R24)R21)(R17)> R24 may comprise a moiety bonded to R21 to form a heterocyclic ring; and (c) R 5 is R17, NH( l7), N(R17)(R26)( 0(R26), or S( 26); where R26 is alkyl, alkenyl, a carbocyclic ring, a heterocyclic ring, or when R25 is N(R17)(R26)7 R26 may e a moiety bonded to Rl7 to form a heterocyclic ring; and (7) R21 is R 9 0r hydrogen; where R is alkyl; alkenyl; aryl alkyl; heteroal kyl; heteroal kenyl ; heteroaryl al kyl ; a carbocyclic ring; a heterocyclic ring; or, when Y is N(R24)R21 an(j R21 js R29? R21 and R 4 may together comprise a heterocyclic ring including the nitrogen atom to which 2 is bonded; (B) Rll is hydrogen, halogen, alkoxy, or R27c(=0)NH- , where R 7 is hydrogen or alkyl; (C) bond "a" is a single bond or is nil; and bond "b" is a single bond, a double bond, or is nil; except bond "a" and bond "b" are not both nil; (D) if (a) is nil and (b) is a single bond: R12 is C (R8*) ' or CH2R32 , wherein (i) X1 is -R2t; -OR30; -S(O) .R30, where r is an integer from 0 to 2, preferably 0; -OC=0)R: or N(R0)R3t; and 92032/5 (ii) R30 and R31 are, independently, alkyl, alkenyl, carbocyclic ring or heterocyclic ring substituents; or R30 and R3t together comprise a heterocyclic ring including the nitrogen atom to which R30 and R31 are bonded;- or R32 is —C (R8*) (R21) , -0-, or -NR8*, and R32 is directly bonded to N" in Formula (II) to form a 5- membered ring; R13 is C(0)NHS02; and R14 is nil; if (a) is nil and (b) is a double bond: R12 is C(R8*) X' or CHj 32 wherein (i) X1 is -R2t; -OR30; -S(0) .R30, where r is an integer from 0 to 2, preferably 0; -0C=0)R30; or N(R30)R31; and (ii) R30 and R31 are, independently, alkyl, alkenyl, carbocyclic ring or heterocyclic ring substituents; or R30 and R31 together comprise a heterocyclic ring including the nitrogen atom to which R30 and R31 are bonded; or R32 is -C(R8*) (R21) , -0-, or -NR8*, and R32 is directly bonded to N" in Formula (II) to form a 5- membered ring; R13 is -C(R33) ; R14 is nil if (a) is a single bond and (b) is nil: R12 is -C(RSa)-, or -CH,-R2¾-, preferably -C(R8*)-; where R28 is -C(R8t), -0-, or -N-, and R2s is directly bonded to N" in Formula (II) to form a~5-membered ring; R13 is hydrogen, -S03H, -POiOR^JOH, -C (0) NHS02N (R34) (R3S) , -0S03H, -CH(R33)COOH, or -OCH (R^COOH, preferably hydrogen, -S03H or —C (0) NHS02N (R34) (R35) ; where R34 is hydrogen, alkyl, alkenyl, a carbocyclic ring, or a heterocyclic ring; and R35 is hydrogen, alkyl, alkenyl, or -NHR8*; or, if R13 is -CiOJNHSOj f 34) (R35) , R3 and R35 may together comprise a heterocyclic ring including the nitrogen to which R34 and R33 are bonded; and R14 is nil j if (a) and (b) are both single bonds: R12 is -C(R8*)-, or -CH,-R28-, preferably -C(R«*)-; where R28 is -C(R**), -0-, or -N-, and R28 is directly bonded to N" in Formula (II") to form a ,5-membered ring5 R13 is -CH(R33)-; or -C"(R33)- if R14 contains a R36 moiety; where R33 is hydrogen or COOH, preferably COOH, and C" is linked to R3i to form a 3-membered ring; R14 is -W-C" ' =C (R8*) -R37-, or -W-C" ' (R36) -R37-; if (a) is a single bond and (b) is a double bond:- R12 is -C(RS*)-, or -CH,-R28-/ preferably -C(R8*)-; where R28 is -C(R8*), -0-, or -N-, and R¾ is directly bonded to N" in Formula (II) to form a 5-membered ringj R13 is C(R33)/ R14 is -C (R8*) R38,- -C" ' -R37-; -W-C (R8') (RM) -C" ^-R37-; or -W-C"'-R37; preferably -W-C (R8*) (R38) -C" ' -R37- or -W-C" ' -R37- ; where (a) W is O; S(0)s/ where s is an integer from 0 to 2, preferably 0; or C(R38), where R38 is hydrogen, alkyl or alkoxy; (b) R36 hydrogen; alkyl; alkenyl; -COOH;. or, if R13 is -c'(R32), R36 may be linked to C* to form a 3-membered carbocyclic ring; (c) R37 is nil, alkyl, alkenyl, a carbocyclic ring, or a heterocyclic ring; and (d) C" ' is directly bonded to R13 to form a 5- or 6-membered ring; (III) L links Q to B; and L is L', -X2t-R39.L' f or .X3t-R39.L', where L' is Q', -X2-Q", -X3-Q», -X4t-C(=Y3U) -Z-Q", -X5t-P0(Y4u8a).2'.Q»j or x5t.so2-Z'-Q»; (1) t and u are, independently, 0 or 1; (2) R39 is alkyl, alkenyl, heteroalkyl, heteroal kenyl , a carbocyclic ring, or a heterocyclic ring; (3) χ2 is oxygen, or S(0)v, where v is an integer from 0 to 2; (4) X3 is nitrogen; N(R0); N+(R*1) (R42) ; or R43-N(R 1); and is linked to R^4 b a single or double bond; or, if Rl4 is nil, X3 is linked to B by a single or double bond; where (a) 40 is Sa; .0R8a; or -c(=0)R8a; (b) R4^ and R42 are, independently, hydrogen; alkyl; alkenyl; carbocyclic rings; heterocyclic rings; or, together with Q", comprise a heterocyclic ring as l5 or Rl6; (c) R43 is N(R41), oxygen or sulfur; (5) X4 is oxygen, sulfur, NR0, or R43-NR41; (6) χ5 is oxygen or NR41; (7) Y3 is oxygen, sulfur, NR4& or N+(R4 ) (R42) ; (8) Y4 is oxygen or NR ^ ; (9) Z is nil, oxygen, sulfur, nitrogen, NR40, or N(R41).R43; (10) V is nil, oxygen, nitrogen, or N4^; (11) 0 is Rl5 or Rl6; and (12) Q" is Q'; or together with χ , X3, Z or Ζ', is an R15 or R16 group; and pharmaceutically-acceptable salts and bioh-ydrolyzable esters thereof, and hydrates thereof.

It has been found that the compounds of this invention, and compositions containing these compounds, are effective antimicrobial agents against a broad range of pathogenic microorganisms. These compounds provide advantages versus antimicrobial agents among those known in the art, including (for example) the spectrum of antimicrobial activity, potency, the avoidance of microbial resistance, reduced toxicity, and improved pharmacology.

DESCRIPTION OF THE INVENTION The present invention encompasses certain novel lactam-quinolones, methods for their manufacture, dosage forms, and methods of administering the 1 actam-quinolones to a human or other animal subject. Specific compounds and compositions to be used in the invention must, accordingly, be pharmaceutically acceptable. As used herein, such a "pharmaceutical ly-acceptable" component is one that is suitable for use with humans and/or animals without undue aaverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.

Lactam-Quinolones The compounds of this invention, herein referred to as "lactam-quinolones", encompass any of a variety of lactam moieties linked, by a linking moiety, to a quinolone moiety at positions other than the 3-carboxy position. These compounds include those having the general formula Q - L - 8 wherein Q, L and B are defined as "herein above, and pharmaceutically-acceptable salts and bioh-ydrolyzable esters thereof, and hydrates thereof.

Definitions and Usage of Terms: The following is a list of definitions for terms used herein.

"Heteroatom" is a nitrogen, sulfur or oxygen atom. Groups containing one or more heteroatoms may contain different heteroatoms.

"Alkyl" is an unsubstituted or substituted saturated hydrocarbon chain radical having from 1 to 8 carbon atoms, preferably from 1 to 4 carbon atoms. Preferred alkyl groups include (for example) methyl, ethyl, propyl, isopropyl, and butyl .

"Heteroalkyl" is an unsubstituted or substituted saturated chain radical having from 3 to 8 members comprising carbon atoms and one or two heteroatoms.

"Alkenyl" is an unsubstituted or substituted hydrocarbon chain radical having from 2 to 8 carbon atoms, preferably from 2 to 4 carbon atoms, and having at least one olefinic double bond.

"Carbocyclic ring" is an unsubstituted or substituted, saturated, unsaturated or aromatic, hydrocarbon ring radical. Carbocyclic rings are monocyclic or are fused, bridged or spiro polycyclic ring systems. Monocyclic rings contain from 3 to 9 atoms, preferably 3 to 6 atoms. Polycyclic rings contain from 7 to 17 atoms, preferably from 7 to 13 atoms.

"Cycloalkyl " is a saturated carbocyclic ring radical. Preferred cycloalkyl groups include (for example) cyclopropyl, cyclobutyl and cyclohexyl.

"Heterocyclic ring" is an unsubstituted or substituted, saturated, unsaturated or aromatic ring radical comprised of carbon atoms and one or more heteroatoms in the ring. Heterocyclic rings are monocyclic or are fused, bridged or spiro polycyclic ring systems. Monocyclic rings contain from 3 to 9 atoms, preferably 3 to 6 atoms. Polycyclic rings contain from 7 to 17 atoms, preferably from 7 to 13 atoms.

"Aryl" is an aromatic carbocyclic ring radical. Preferred aryl groups include (for example) phenyl, tolyl, xylyl, cumenyl and naphthyl .

"Heteroaryl" is an aromatic heterocyclic ring radical. Preferred heteroaryl groups include (for example) thienyl, furyl , -16- pyrrolyl, pyridinyl, pyrazinyl, thiazolyl, quinolinyl, pyrimidinyl and tetrazolyl .

"Alkoxy" is an oxygen radical having a hydrocarbon chain substituent, where the hydrocarbon chain is an alkyl or alkenyl (i.e., -0-alkyl or -0-alkenyl). Preferred alkoxy groups include (for example) methoxy, ethoxy, propoxy and allyloxy.

"Alkylamino" is an amino radical having one or two alkyl substituents (i.e., -N-alkyl).

"Arylalkyl" is an alkyl radical substituted with an aryl group. Preferred arylalkyl groups include benzyl and phenyl ethyl.

"Arylamino" is an amine radical substituted with an aryl group (i.e., -NH-aryl).

"Aryloxy" is an oxygen radical having a aryl substituent (i.e., -0-aryl).

"Acyl" or "carbonyl" is a radical formed by removal of the hydroxy from a carboxylic acid (i.e., R-C(=0)-). Preferred alkyl acyl groups include (for example) acetyl, formyl , and propionyl .

"Acyloxy" is an oxygen radical having an acyl substituent (i.e., -0-acyl); for example, -0-C(=0)-alkyl .

"Acyl ami no" is an amino radical having an acyl substituent (i.e., -N-acyl); for example, -NH-C(=0) -alkyl .

"Halo", "halogen", or "halide" is a chloro, bromo, fluoro or iodo atom radical. Chloro and fluoro are preferred halides.

Also, as referred to herein, a "lower" hydrocarbon moiety (e.g., "lower" alkyl) is a hydrocarbon chain comprised of from 1 to 6, preferably from 1 to 4, carbon atoms.

A "pharmaceutical ly-acceptable salt" is a cationic salt formed at any acidic (e.g., carboxyl) group, or an anionic salt formed at any basic (e.g., amino) group. Many such salts are known in the art, as described in World Patent Publication 87/05297, Johnston et al., published September 11, 1987 (incorporated by reference herein). Preferred cationic salts include the alkali metal salts (such as sodium and potassium), and alkaline earth metal salts (such as magnesium and calcium).

Preferred anionic salts include the halides (such as chloride salts) .

A "biohydrolyzable ester" is an ester of a lactam-quinolone that does not essentially interfere with the antimicrobial activity of the compounds, or that are readily metabolized by a human or lower animal subject to yield an antimicrobially-active lactam-quinolone. Such esters include those that do not^inter- fere with the biological activity of quinolone antimicrobials or beta-lactam antimicrobials (cephens, for example). Many such esters are known in the art, as described in World Patent Publication 87/05297, Johnston et al., published September 11, 1987, (incorporated by reference herein). Such esters include lower alkyl esters, lower acyloxy-alkyl esters (such as acetoxymethyl , acetoxyethyl , aminocarbonyloxymethyl , pivaloylox-ymethyl and pivaloyloxyethyl esters), lactonyl esters (such as phthalidyl and thiophthal idyl esters), lower alkoxyacyloxyalkyl esters (such as methoxycarbonyloxymethyl , ethoxycarbonyloxyethyl and isopropoxycarbonyloxyethyl esters), alkoxyalkyl esters, choline esters and alkyl acylamino alkyl esters (such as acetamidomethyl esters).

As defined above and as used herein, substituent groups may themselves be substituted. Such substitution may be with one or more substituents. Such substituents include (for example) those listed in C. Hansch and A. Leo, Substituent Constants for Correlation Analysis in Chemistry and Biology (1979), incorporated by reference herein. Preferred substituents include (for example) alkyl, alkehyl, alkoxy, hydroxy, oxo, nitro, amino, aminoalkyl (e.g., aminomethyl, etc.), cyano, halo, carboxy, alkoxyaceyl (e.g., carboethoxy, etc.), thiol, aryl, cycloalkyl, heteroaryl, heterocycloalkyl (e.g., piperrdinyl, morpholinyl, pyrrol idinyl, etc.), imino, thioxo, hydroxyal kyl , aryloxy, aryl alkyl, and combinations thereof.

Also, as used in defining the structure of the compounds of this invention, a particular radical may be defined for use as a substituent in multiple locations. For example, the R8a substituent is defined as a potential substituent of R7, but is -18- also incorporated into the definition of other substituents (such as R6, Rl2, R32 an(j L'). AS used herein, such a radical is independently selected each time it is used (e.g., R8a need not be alkyl in all occurrences in defining a given compound of this invention).

Lactam-containing moietv: Groups Rl2, l3f an(j R14, together with bonds "a" and "b" of formula (I), form any of a variety of lactam-containing moieties known in the art to have antimicrobial activity. Such moieties wherein either bond "a" or bond "b" are nil (i.e., do not exist) are mono-cyclic; if both bonds exist, the structures are bi -cyclic. Preferably, bond "a" is a single bond and bond "b" is a double bond.

Preferred lactam moieties include the cephems, oxacephems and carbacephems of the representative formula: COOH wherein, referring to formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl is -C(R8a)-, where R8a is hydrogen; Rl3 ]s -CH(R33), where R3 is COOH; and RH is -W-C(R8a)(R38)-C'"-R37, where R8a and R38 are hydrogen, R37 is methylene, and W is S (for cephems), 0 (for oxacephems) or C(R38) (for carbacephems).

Other preferred lactam moieties include the isocepheros and iso-oxacephems of the representative formula: -19- COOH wherein, referring to formula II, bond "a" is a single bond; bond "b" is a double bond; R12 is -C(R8A) where R8A is hydrogen; R13 is -C(R33)=, where R33 is COOH; and R is -C(R8 )(R38)-W-C'"-R37 where R8A and R38 are each hydrogen, R3? is methylene, and W is S (for isocephems) or 0 (for iso-oxacephems).

Other preferred lactam-containing moieties include the penems, carbapenems and clavems, of the representative formula: COOH wherein, referring to formula (II), bond "a" is a single bond; bond "b" is a double bond; R*2 1S -C(R8A), where R8A is hydrogen; R* Is -C(R3 )=, where R33 is COOH; and RU is -W-C"'-R3?, where R37 is methylene, and W is S (for penems), C(R38) (for carbapenems), or 0 (for clavems). Such lactam moieties are described in the following articles, all incorporated by reference herein: R. Wise, "In Vitro and Pharmacokinetic Properties of the Carbapenems", 30 Antimicrobial Agents and Chemotherapy 343 (1986); and S. McCombie et al., "Synthesis and -20- In Vitro Activity of the Penem Antibiotics", 8 Medicinal Research Re iews 393 (1988).

Other preferred lactam-containing moieties of this invention include the penicillins of the representative formuVaT wherein, referring to formula II, bond "a" is a single bond, bond "b" is a single bond; R12 is -C(R8a)-, where is hydrogen; R13 is -CH(R33)- where R33 is C00H; and R** 1s -W-C"' (R36)-R37- where R36 is methyl, R37 is methylene, and W is S.

Other preferred lactam-containing moieties include the monocyclic beta- lactams, of the representative formula: wherein, referring to formula (II), bond "a" is a single bond; bond "b" is nil; Rl2 is -C(R8a)-, where R * is hydrogen; Rl* is nil; and R*3 is -SO3H (for a monobactam), -P0(0R3*)0H (for a monophospham) ; -C(0)NHS02N(R34)(R35) (for a monocarbam), -OSO3H (for a monosulfactam), -CH(R35)C00H (for nocardicins), or -0CH(R34)C00H. Such lactam moieties are described in C. Cimarusti et al., "Monocyclic 8-lactam Antibiotics", -21- 4 Medicinal Research Reviews 1 (1984), Incorporated by reference herein.

Other preferred lactam moieties include the monocyclic beta-lactams of the representative formula: wherein referring to formula II, bond "a" is nil, bond "b" is a single bond; Rl2 is -C(R8a)(R29). where both R8a and R29 are hydrogen; and R14 is ni .

Other preferred lactam moieties include the clavams of the representative formula: wherein, referring to formula (II), bond "a" is a single bond; bond "b" is a single bond; Rl2 is -C(R8a)-, where R8a is hydrogen; Rl3 is -CH(R33)-, where R33 is COOH; and Rl* is W-C"'-C-(R8a)-R37, where R8a is hydrogen and R37 is methylene, and W Is 0.

Other preferred lactam moieties include the 2,3-methyleno-penams and -carbapenams of the representative formula: -22- wherein, referring to formul a (II), bond "a" is a single bond; bond "b" is a single bond; R12 is -C(R8A)-, where R8A is hydrogen; Rl3 is -C*(R33)> where R33 is COOH; and is W-C"'(R36).R37, Where 37 Is nil, R36 is linked to C* to form a 3-membered carbocyclic ring, and W is C(R38) or sulfur.

Lactam moieties of this invention also include the lactivicin analogs of the representative .formula: wherein, referring to formula (II), bond "a" is nil; bond "b" is a single bond; Rl2 iS -CH2-R32, where R32 is 0; Rl3 is -CH(R33)-, where R33 is COOH; and Rl4 is nil.

Other lactam moieties include the pyrazolidinones of the representative formula: -23- wherein, referring to formula (I), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -c^-R28-, where R28 is -N-; Rl3 is -C(R33)-, where R33 iS COOH; and R*4 is W-C"'-R37-, where R37 is methylene, and W is C(R38).

Other lactam moieties include the gamma- lactams of the representative formula: wherein, referring to formula (II), bond "a" is a single bond; bond "b" is nil; R*2 is -CH2-R28-, where R28 is -C(R8a) and R8a is hydrogen; Rl3 iS -SO3H, -P0(0R34)0H, -C(0)NHS02N(R34) (R35) , -OSO3H, -CH(R35)C00H, or -OCH(R34)COOH; and R*4 is nil.

Preferred lactam-containing moieties , include cephems, isocephems, iso-oxacephems, oxacephems, carbacephems, penicillins, penems, carbapenems, and monocyclic beta-lactams. Particularly preferred are cephems, penems, carbapenems and monocyclic beta-lactams.

RIO, in formula (II), Is any radical that may be substituted at the active stereoisomeric position of the carbon adjacent to the lactam carbonyl of an antimicrobially-active lactam. (As -24-used herein, the term "antimicrobially-active lactam" refers to a lactam-containing compound, without a quinolonyl substituent moiety, which has antimicrobial activity.) This "active" position is beta (i.e., 7-beta) for cephems, oxacephems and carbacephems (for example). The active position is alpha for penems, carbapenems, clavems and clavams.

Appropriate R° groups will be apparent to one of ordinary skill in the art. Many such R10 groups are known in the art, as described in the following documents (all of which are incorporated by reference herein): Cephalosporins and Penicillins: Chemistry and Bioloov (E. Flynn, editor, 1972); Chemistry and Biology of b-Lactam Antibiotics (R. Morin et al., editors, 1987); "The Cephalosporin Antibiotics: Seminar-in-Print", 34 Drugs (Supp. 2) 1 (J. Williams, editor, 1987); New Beta-Lactam Antibiotics: A Review from Chemistry of Clinical Efficacy of the New Cephalosporins (H. Neu, editor, 1982); M. Sassiver et al., in Structure Activity Relationships among the Semi -synthetic Antibiotics (D. Perlman, editor, 1977). W. Ourckheimer et al., "Recent Developments in the Field of Beta-Lactam Antibiotics", 24 Anoew. Chem. Int. Ed. Engl. 180 (1985); G. Rolinson, "Beta-Lactam Antibiotics", 17 jh Antimicrobial Chemotherapy 5 (1986); European Patent Publication 187,456, Jung, published July 16, 1986; and World Patent Publication 87/05297, Johnston et al., published September 11, 1987.

For penems, carbapenems, clavems and clavams, R*0 is preferably lower alkyl, or hydroxy-substituted lower alkyl. Particularly preferred RlO groups include hydrogen, hydroxymethyl , ethyl, [l(R)-hydroxyethyl], £l(R)-[(nydroxysul . fonyl)oxyethyl]], and [1-methyl-l-hydroxyethyl].

Except for penems, carbapenems, clavems and clavams, preferred R10 groups are amides, such as: acetylamino, preferably substituted with aryl, heteroaryl, aryloxy, heteroarylthio and lower alkylthio substituents; arylglycyiamino, preferably N-substituted with heteroarylcarbonyl and cycloheteroalkylcarbonyl substituents; arylcarbonylamino; -25-heteroarylcarbonylamino; and lower alkoximinoacetylamino, preferably substituted with aryl and heteroaryl substituents. Particularly preferred R0 groups Include amides of the general formula and Rl8 1S Rl7. Examples of such preferred RlO groups nclude: [(2-amino-5-hal0-4-thlazolyl)acetyl]am no; [(4-am1nopyr1d1n-2-yl)acetyl]am1no; [[(3,5-dichloro-4-oxo-l(4H)-pyridinyl)acetyl]amino]; [[[2-(aminomethy1)phenyl]acetyl]amino]; [(lH-tetrazol-l-ylacetyl )amino]; [(cyanoacetyl )amino] ; [(2-thienylacetyl )amino]; [[(2-amino-4-thiazoyl)acetyl]amino]; and sydnone, 3-[-2-amino]-2-oxoethyl .

The following are other such preferred RlO groups.

HCONH- When lO is Rl8-(CH2)m-C(O0)NH-, and R*8 is -γΐ, preferred roups include the following: [sul famo hen lacetyl ]amino; [[(4-pyridinylthio)acetyl]amino] ; [[[(cyanomethyl )thio]acetyl ]amino] ; (S)-[[[(2-amino-2-carboxyethyl)thio]acetyl]amino]; [[[(trifluoromethyl)thio]acetyl Jamino]; and (E)-[[[(2-aminocarbony1-2-fluoroethenyl )thio]acetyl ]amino] .

When RlO is , and Rl8 is -CH(Y2) ( l7) , preferred R10 groups include the following: [carboxyphenylacetyl ]amino; [(phenoxycarbonyl )phenylacetyl ]amino; [4-methyl-2,3-dioxo-l-piperazinecarbonyl -D-phenylglycyl ]- amino; -30- [[[3-(2-furylmethyleneamino)-2-oxo-l-imidazol idinyl]- carbonyl]amino]phenyl ]acetyl ]amino; (R)-[(aminophenylacetyl)amino]; (R)-[[amino(4-hydroxyphenyl )acetyl]amino] ; (R)-[(amino-1,4-cyclohexadien-1-ylacetyl )amino] ; [(hydroxyphenylacetyl)amino] ; (R)-[[[[(4-ethyl-2,3-dioxo-l-piperazinyl)carbonyl Jamino]- (4-hydroxyphenyl)acetyl]amino]; (R)-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenyl acetyl]amino]; (R)-[[[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4 hydroxyphenyl)acetyl]amino] ; (R)-[(phenylsulfoacetyl)amino] ; (2R,3S)-[[2-[[(4-ethyl-2,3-dioxo-l-piperazinyl)carbonylJ- amino]-3-hydroxy-l-oxobutyl Jamino] ; [[carboxy(4-hydroxyphenyl)acetyl]amino]; (R)-[[amino[3-[(ethylsulfonyl)amino]phenyl]acetyl]amino]; (R)-[[amino(benzo[b]thien-3-y1)acetyl]amino]; (R)-[[amino(2-naphthyl )acetyl]amino]; .(R)-[[amino(2-amino-4-thiazolyl)acetylJaminoJ ; [[[[(6,7-dihydroxy-4-oxo-4H-l-benzopyran-3-yl)carbonylJ- amino](4-hydroxyphenyl )acetyl]amino] ; (R,R)-[[2-[4-[2-amino-2-carboxyethyloxycarbonyl]aminophen yl]-2-hydroxyacetylJamino]; and (S)-[[(5-hydroxy-4-oxo-l(4H)-pyridin-2-yl)carbonylamino(2 amino-4-thiazolyl )acetyl ]amino] .

The following are other such preferred R*° groups.

Another preferred RlO group is Such groups include (for example) the following structures. -36- , Another class of preferred RlO groups (for lactam-containing moieties other than penems, carbapenems, clavems and clavams) Include those of the formula: Rl7-C(=N0-Rl9)-C(-0)NH-.

Examples of this preferred class of Rl° groups include: 2-phenyl -2-hydroxyiminoacetyl ; 2-thienyl -2-methoxyiminoacetyl ; and 2- [4- (gamma-D-gl utamyl oxy)phenyl ] -2-hydroxyiminoacetyl .

(Z)[[(2-amino-4-thiazo1yl ) (methoxyimi no) acetyl ] amino] ; [[(2-furanyl (methoxyimino)acetyl ]amino] ; (Z)-[[(2-amino-4-thiazolyl)[(l-carboxy-l-methyl)ethoxyim- i no] acetyl] ami no]; (Z) - [ [ (2-amino-4-thiazolyl ) ( 1 -carboxymethoxy iml no) acetyl ] amino]; [[(2-amino-4-thiazolyl)[(lH-imidazol-4-ylmethoxy)imino]acet- yl ] ami no] ; (Z) -[[(2-amino-4-thiazolyl-3-oxide) (methoxyimi no) acetyl ] amino]; and (S, Z) - [ [ (2-amino-4-thi azolyl ) [carboxy(3, 4-dihydroxyphen- yl )methoxyimino]acetyl ]amino] .

Other preferred R10 groups include the following structures (where "SS" is HC0NH-). -¾0- The following are other preferred R1^ groups.

Suitable RH groups are among those well-known in the art, including those defined in the following documents (all incorporated by reference herein). W. Ourckheimer et al., "Recent Developments in the Field of Beta-Lactam Antibiotics", 24 Anoew. Chem. Int. Ed. Engl. 180 (1985); 6. Rolinson, "Beta-Lactam Antibiotics", 17 J. Antimicrobial Chemotherapy 5 (1986); and European Patent Publication 187,456, Jung, published July 16, 1986. Preferred R11 groups include hydrogen, methoxy, -41-ethoxy, propoxy, thiomethyl, halogen, cyano, formyl and formylamino. Particularly preferred R*1 groups include hydrogen, methoxy, halogen, and formylamino.

Quinolone Moieties: Groups A1, A2, A3, R*, R3, * and R6 of formula I form any of a variety of quinolone, naphthyridine or related heterocyclic moieties known in the art to have antimicrobial activity. Such moieties are well known in the art, as described in the following articles, all incorporated by reference herein: J. Wolfson et al., "The Fluoroquinolones: Structures, Mechanisms of Action and Resistance, and Spectra of Activity In Vitro", 28 Antimicrobial Agents and Chemotherapy 581 (1985); and T. Rosen et al., 31 j Med Chem. 1586 (1988); T. Rosen et al., 31 J. Med. Chem. 1598 (1988); G. Klopman et al., 31 Antimicrob. Agents Chemother. 1831 (1987) ; 31:1831-1840; J. P. Sanchez et al., 31 J. Med. Chem.983 (1988) ; J. M. Domagala et al., 31 J. Med. Chem.991 (1988); M. P. Wentland et al., in 20 Ann. Rep. Med. Chem. 145 (D. M. Baily, editor, 1986); J. B. Cornett et al., in 21 Ann. Rep. Med. Chem. 139 (D. M. Bailey, editor, 1986); P. B. Fernandes et al., in 22 Ann. Rep. Med. Chem. 117 (D. M. Bailey, editor, 1987); R. Albrecht, 21 Proo. Drug Research 9 (1977); and P. B. Fernandes et al., in 23 Ann. Reo. Med. Chem. (R. C. Allen, editor, 1987).

Preferred quinolone moieties include those where A* is C(R7), A2 is C(R2), and A3 is C(R5) (i.e., quinolones); A* is nitrogen, A2 is C(R2), and A3 is C(R5) (i.e., naphthyridines) ; A1 is C(R7), A2 is C(R2), and A3 is nitrogen (i.e., cinnoline acid derivatives); and where A1 is nitrogen, A2 is nitrogen, and A3 is C(R5) (i.e., pyridopyrimidine derivatives). More preferred quinolone moieties are those where A* is C(7>, A2 is C(R2), and A3 is C(R5) (i.e., quinolones); and where A1 is nitrogen, A2 is C(R2), and A3 is C(R5) (i.e., naphthyridines). Particularly preferred quinolone moieties are where A^ is C(R7), A2 is C(R2), and A3 is C(R5) (i.e., quinolones).

R1 is preferably alkyl, aryl , cycloalkyl and alkylamino. More preferably, R1 is ethyl, 2-fluoroethyl , 2-hydroxyethyl , t-butyl, 4-fluorophenyl , 2,4-difluorophenyl , methylamino and -42-cyclopropyl. Cyclopropyl is a particularly preferred Rl group. Preferred quinolone moieties also include those where A1 is C(R7) and Rl and R? together comprise a 6-membered heterocyclic ring containing an oxygen or sulfur atom.

R2 is preferably hydrogen or halo. More preferably R2 is chlorine or fluorine. Fluorine is a particularly preferred R2 group.

Preferred R3 groups include nitrogen-containing heterocyclic rings. Particularly preferred are nitrogen-containing heterocyclic rings having from 5 to 8 members. The heterocyclic ring may contain additional heteroatoms, such as oxygen, sulfur, or nitrogen, preferably nitrogen. Such heterocyclic groups are described in U.S. Patent 4,599,334, Petersen et al., issued July 8, 1986; and U.S. Patent 4,670,444, Grohe et al., issued June 2, 1987 (both incorporated by reference herein). Preferred R3 groups include unsubstituted or substituted pyridine, piperi -dine, morpholine, diazabicyclo[3.1.1]heptane, diazabicy-clo[2.2.1]heptane, diazabicyclo[3.2.1]octane, diazabicyclo[2.2.2] octane, thiazolidine, imidazol idine, pyrrole and thiamorphol ine, as well as the following particularly preferred R3 groups include piperazine, 3-methylpiperazine, 3-aminopyrrol idine, 3-aminomethylpyrrol idine, Ν,Ν-dimethylaminomethylpyrrol idine, N-methylaminomethylpyrrol idine, N-ethylaminomethylpyrrol idine, pyridine, 4-dithiocarbamoylpiperazine, 3-dithiocarbamoylaminopyrrol idine, N-methylpiperazine, 3,5-dimethylpiperazine, and 3-(dithiocarbamoylamino)pyrrol idine.

Preferred lactam-quinolones include those having a 6-fluoroquinolone moiety or an 8-halo-6-fluoroquinolone moiety, of formula: -43- wherein, referring to formula (I) , A is C(R2) and R2 jS F; A3 is C(R5) ; and Al is C(R7) where R7 is hydrogen, fluorine or chlorine. Preferred examples of such quinolone moieties include: 1 -cycl opropyl -6- fl uoro-l ,4-dihydro-4-oxo-7- ( l-piperazinyl ) -- 3- quinol inecarboxyl ic acid; 7- (3- ami nopyrrol idinyl ) -l-cyclopropyl -6-fl uoro-l , 4-dihydro- 4- oxo-3-quinol inecarboxyl ic acid; 7- [(3- ami nomethyl )pyrrol idinyl ]-l -cycl opropyl -6-fluoro-l ,4- dihydro-4-oxo-3-quinol inecarboxyl ic acid; 7- (3-ami nopyrrol idinyl ) -8-chloro-l -cycl opropyl -6-fluoro-l , 4- dihydro-4-oxo-3-quinol inecarboxyl ic acid; 7 - ( 3 -ami nopyrrol i d i n 1 ) - 1 -cycl oprop l -6, 8-di f 1 uoro- 1 , 4 - dihydro-4-oxo-3-quinol inecarboxyl ic acid; 7- [ (3-ami nomethyl ) pyrrol idinyl ] - 1 -cycl opropyl -6 , 8-di f 1 uoro- l ,4-dihydro-4-oxo-3-quinol inecarboxyl ic acid ; 6,8-difluoro-l-(2-fluoroethyl )-l,4-dihydro-7- (4-methyl -l- piperazinyl ) -4-oxo-3-quinol inecarboxyl ic acid; 1 -ethyl -6-fluoro-l , 4-dihydro-4-oxo-7-(l -pi perazi nyl ) -3- quinol inecarboxyl ic acid; 1 -ethyl -6-fluoro-l ,4-dihydro-7-(4-methyl - 1 -pi perazi nyl ) -4- oxo-3-quinol inecarboxyl ic acid; 6- fl uoro- 1 , 4-di hydro- 1 -methyl amino-7- (4-methyl - 1 - piperazinyl )-4-oxo-3-quinol inecarboxyl ic acid; and 1 -cycl opropyl -7- [3- (dimethyl ami nomethyl ) - l -pyrrol idinyl ] - 6,8-difluoro- 1 ,4-dihydro-4-oxo-3-quinol inecarboxyl ic acid; -45- -51- -53- Also preferred are lactam-quinolones having 1,8-naphthyridine moiety, of formula: wherein, referring to formula (I), A* is N; A is C(R2) and A^ is C(R5). Preferred examples of such quinolone moieties include: 7-(3-aminopyrrol idin 1)-1-(2,4-dif1uoropheny1 )-6-fluoro-1 ,4- dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid; and l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7-(l-piperazinyl )-l,8- naphthyridine-3-carboxyl ic acid. -57- Also preferred are lactam-qulnolones having a pyridobenzoxa zine or pyridobenzthiazine moiety, of formula: wherein, referring to formula (I), A* is C(R7); A2 is C(R2); A3 is C(R5); and R7 and R1 together comprise a linking moiety between N' and A to form a 6-membered, oxygen-containing, heterocyclic ring where X (in this formula) is oxygen, sulfur or carbon. Preferred examples of such quinolone moieties include 9-fluoro-4,7-dihydro-3-methyl -10-(4-methyl-l-piperazinyl )-7-oxo-2H-pyrido[l,2,3-de]-l,4-benzoxazine-6-carboxylic acid; and the following structures.  -59- -60- Also preferred are lactam-quinolones having an isothia-zoloquinol inedione or isoxazoloquinol inedione moiety, of formula: wherein, referring to formula (I), wherein A is C(R7); A2 is C(R2); A3 is C(R5); and R4 and R$ together comprise a moiety forming a 5-membered, substituted, heterocyclic ring.

Preferred examples of such quinolone moieties include 9-cyclopropyl-6-fluoro-2,3,4,9-tetrahydro-7-(l-piperazinyl)iso-thiazolo[5,4-b]quinol ine-3,4-dione; and: -61- -62- Linkino Moieties: Group L, together with the Rl5 or R16 substituents of the quinolone moiety, form a variety of linking moieties between the lactam-containing structure (B) and the quinolone structure (Q) of the lactam-quinolones. Representative structures for linking groups are set forth below. (In these structures, Rl2, 13, R14, and bonds "a" and "b" comprise a cephem structure, for purposes of exemplification only. The linking moieties depicted may be used with any of the actam-containing moieties of this invention. Also, in these structures, each linking moiety is depicted as a substituent of either Rl or R3, for exemplification purposes only. Each linking moiety may also be substituted at the alternative position.) Carbamate linking moieties: wherein, referring to formulas (I) and (II), L is -X4t-C(-Y2u)-Z-Q"; t is 1 and u is 1; X4 is oxygen; γ2 is oxygen; Z is nitrogen; and Q" is 0/ which is (for example) a pyrollidinyl R16 group. -63- Another example of a carbamate linking moiety is: wherein, referring to formulas (I) and (II), L is -X2-R39-L'; X2 is -S(0)m where m is 0; R39 is ethyl; and L' is -X4t-C(-Y2u)-Z-Q", where t is 1 and u is 1, X* is oxygen, Y2 is oxygen, Z is nitrogen, and Q" is, together with Z, an R16 group which is (for example) a piperazinyl group.

Dithiocarbamate linking moieties: wherein, referring to formulas (I) and (II), L is -X4t-C(-Y2u)-Z-Q"; t is 1 and u is 1; X* is sulfur; Y2 is sulfur; Z is NR41, where R41 is hydrogen; and Q" is Q' which is (for example) a pyrrol idinyl R*6 group.

Urea linking moieties: wherein, referring to formulas (I) and (II), L is -X4t-C(-Y2u)-Z-QH; t is 1 and u is 1; X4 is NR40, where R40 is hydrogen; Y2 is oxygen; Z is nitrogen; and Q" is, together with Z, an Rl6 group which is (for example) a piperazinyl group.

Thiourea linking moieties: wherein, referring to formulas (I) and (II), L is -Xt-C(-Y2u)-Z-Q"; t is 1 and u is 1; X4 is NR4(>, where R40 is hydrogen; Y2 is sulfur; Z is nitrogen; and Q" is, together with Z, an Rl6 group which is (for example) a piperazinyl group. ■65- Isouronium linking moieties: wherein, referring to formulas (I) and (II), L is -X4t-C(«Y2U)-Z-Q"; is 1 and u is 1; X4 is oxygen; Y2 is N+(R41)(R42), where R*l and R42 are hydrogen; Z is nitrogen; and Q" is, together with Z, an R16 group which is (for example) a piperazinyl group.

Isothiouronium linking moieties: wherein, referring to formulas (I) and (II), L is -Xt-C(-Yu)-Z-Q"; t is 1 and u is 1; X4 is sulfur; Y2 is N+(R41)(R42), where R* and R42 are hydrogen; Z is nitrogen; and Q" is, together with Z, an R16 group which is (for example) a piperazinyl group. -66- Guanidinium linking moieties: wherein, referring to formulas (I) and (II), L is -Xt-C(»Y2U)-Z-Q"; is 1 and u is 1; X* is NR40, where R40 is hydrogen; γ2 is N+(R41)(R42), where R41 and R42 are hydrogen; Z is nitrogen; and Q" is, together with Z, an R^ group which is (for example) a piperazinyl group.

Carbonate linking moieties: wherein, referring to formulas (I) and (II), L is -Xt-C(-Y2u)-Z-(r; t is 1 and u is 1; X4 is oxygen; Y2 is oxygen; Z is oxygen; and Q" is Q' which is (for example) an ethyl R^ group.

Trithiocarbonate linking moities wherein, referring to formulas (I) and (II), L is t is 1 and u is 1; χ4 is sulfur5 γ2 is sulfur; Z is sulfur; and Q" is Q' which is (for example) an N-propionylpyrrol idinyl Rl6 group.

Reversed carbamate linking moieties: wherein, referring to formulas (I) and (II), L i -xVC(-Y2u)-Z-Q"; t is 1 and u is 1; X* is NR*0, R40 i hydrogen; is oxygen; Z is oxygen; and QH is Q', which is (fo example) an ethyl R^ group.

Xanthate linking moieties wherein, referring to formulas (I) and (II) L is -X t- C(«Y2u)-Z-Q"; t is 1 and u is 1; X* is sulfur; Y2 is sulfur; Z is oxygen; and Q" is Q' which is (for example) an N-ethy piperazinyl group.

Reversed isouronium linking moieties: wherein, referring to formulas (I) and (II), L is -XVC(-Y2u)-Z-Q"; t is 1 and u is 1; X* is NR40, where R40 is hydrogen; Y2 is N+(R41)(R42), where R42 and R42 are hydrogen; Z is oxygen; and Q" is Q' which is (for example) an N-ethyl piperazinyl R 6 group. -69- Reversed dithiocarbamate linking moieties: wherein, referring to formulas (I) and (II), L is -XVC(«Y2u)-Z-Q"; T IS 1 AND U IS L'> Χ4 1S NR40> WHERE R4° 1S hydrogen; γ2 is sulfur; Z is sulfur; and Q" is Q' which is (for example) an N-acetylpiperazinyl R16 group.

Reversed isothiouronium linking moieties: wherein, referring to formulas (I) and (II), L is 1 is 1 and u is 1; χ4 is Nr 0, where r4° is hydrogen; γ2 is N+(R4 )(R42)» where R * and R* are both hydrogen; Z is sulfur; and Q" is Q' which is (for example) an N-acetylpiperazinyl R*6 group.

Amine linking moieties wherein, referring to formulas (1) and (II), L is -X3-Q"; X3 is nitrogen: and Q" is, together with X3, an R16 group which is (for example) a piperazinyl group.

Imine 1 inking moieties wherein, referring to formulas (I) and (II), L is -X3-Q"; X3 is nitrogen, and is linked to R1* by a double bond; and Q" is Q' which is (for example) a pyrrol idinyl Rl6 group.

Ammonium linking moieties wherein, referring to formulas (I) and (II), L is -X^-Q"; χ3 is N+(R41)(R42), R41 is methyl and R<2 is part of Rl6; and Q" is, together with X^, an R 6 group which is (for example) a piperazinyl group.

Heteroaryl ium linking moieties: wherein L is -X^-Q"; χ3 is nitrogen; and Q" is, together with X^, an Rl6 group which is (for example) a pyridinium group. -72- Ether linking moieties; wherein, referring to formulas (I) and (II), L is -X2-QM; X2 is oxygen; and Q" is Q' which is (for example) an ethyl Rl5 group.

Thioether, sulfoxide and suifone linking moieties: wherein, referring to formulas (I) and (II), L is -X2-Q"; X2 is S(0)t, where t»0 (thioether), t=l (sulfoxide) or t=2 (suifone); and Q" is Q' which is (for example) an N-ethylpiperazinyl group. -73- Phosphono linking moieties: wherein, referring to formulas (I) and (II), L is -X5t-P0(Y3UR8)-Z-Q"; t is 0 and u is 1 (for example); γ3 is oxygen; R** is methyl; Z' is oxygen; and Q" is Q' which is (for example) an N-ethylpiperazinyl Rl6 group.

Phosphoramide linking moieties: wherein, referring to formulas (I) and (II) , L is -X5t-P0(Y3UR8)-Z-Q"; t is 1 and u is 1; X* is oxygen; γ3 is oxygen; R8 is methyl; V is nitrogen and Q" is, together with Z, an R16 group which is (for example) a piperazinyl group. -74- Phosphate linking moieties: wherein, referring to formulas (I) and (II), L is -X5t-P0(Y3U8)-Z-Q"; t is 1 and u is 1; X5 is oxygen; Y3 is oxygen; R8 is methyl; Z' is oxygen; and Q" is Q' which is (for example) an ethyl R15 group.

Other sulfoxide-containing linkages (a sulfonamide, for example): wherein, referring to formulas (I) and (II), L is -X5t-S02-Z' -Q" ; where t is 0; V is nitrogen; and Q" is, together with Z', an R16 group which is (for example) a piperazinyl group. -75- Ester or thioester linking moiety: wherein, referring to formulas (I) and (II), L is -X4t-C(»Y2U)-Z-Q"; t is 1 and u is 1; X* is oxygen (for an ester) or sulfur (for a thioester); Y2 is oxygen; Z is nil; and Q" is Q' which is (for example) an N-propionylpiperazinyl R16 group.

Amide or hydrazide linking moiety: wherein, referring to formulas (I) and (II), -Xt-C(-Yu)-Z-Q'*; t is 1 and u is 1; X4 is N(R40), where R40 is hydrogen (for an amide), or X2 is R«-NR41 (for a hydrazide), where R41 is hydrogen and R43 is NR41, and R41 is hydrogen; Y2 is oxygen; Z is nil; and Q" is Q' which is (for example) an N-propionylpiperazinyl R*6 group.

Preferred linking moieties include carbamate, dithiocar-bamate, urea, thiourea, isothiouronium, amine, ammonium, and heteroarylium containing moieties." Particularly preferred linking moieties include carbamate and dithiocarbamate linking moieties. -76- The specific physical, chemical, and pharmacological properties of the lactam-quinolones of this invention may depend upon the particular combination of the integral lactam-containing moiety, quinolone moiety and linking moiety comprising the compound. For example, selection of particular integral moieties may affect the relative susceptibility of the lactam-quinolone to bacterial resistance mechanisms (e.g., beta-lactamase activity).

Preferred lactam-quinolones include compounds having the following specific combinations of lactam-containing moieties, quinolone moieties and linking moieties. 1) Carbamate-! inked cephem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R*2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -S-CH2-C"'-CH2-; where the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and where the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group (b) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R2 is -CH-; R3 is -C(COOH)-; and Rl* is -S-CH2-C" -CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R15 and is a substituent moiety of L; and -77-the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R5 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R2 is -CH-; l3 is -C(COOH)-; and R^ is -S-CH2-C"' -CH2- ; the quinolone moiety is a 6-fluoroquinolone, wherein referring to Formula (I), is -C(R7)-J A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(=0)-Z-Q" ; Z is nitrogen and Q", together with Z, is a substituted Rl6 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a sing'ie bond; bond "b" is a double bond; Rl2 iS -CH-; Rl3 is -C(COOH)-; and Rl* is -S-CH2-C" -CH2- ; the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A^ is -N-; A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R*6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(«0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R11 is -H or -OMe; Rl2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -S-CH2-C"'-CH2-; and R10 is [[(2-thienyl )acetyl ]amino] , [[(2-amino-4-thiazolyl ) ( ethoxyimino)acetyl ] amino] , [[(4-pyridylthio)acetyl ]amino] , -78- [(phenoxy)acetyl ]amino] , [[(2-amino-4-thiazolyl )acetyl ]amino] , or [[(2-amino-4-thiazolyl)[[(3,4-dihydroxyphenyl) carbonyl ] amino]acetyl ]amino] ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and . R3 is R16, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Carbamate-1 inked cephem quinolones of classes (c), (d) and (e) are preferred; compounds of class (e) are particularly preferred. (2) Carbamate-1 inked penem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; 2 is -CH-; R^3 is -C(COOH)-; and Rl* is -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R is -OH; and R3 is R16 and is a substituent moiety of L; and -79-the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R16 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 iS -CH-; Rl3 is -C(COOH)-; and Rl* is -S-C"' -CH2- ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R15 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted Rl5 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); R^ is -H; R*2 is -CH-; R3 is -C(COOH)-; and is -S-C"'-CH2-; the quinolone moiety is a 6-fluoroquinolone, wherein referring to Formula (I), A* is -C(R7)-; A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is and is a substituent moiety of L; the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R*2 is -CH-; R3 is -C(COOH)-; and l* is -S-CW'-CH2-; the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A^ is -N-; A2 is -CF-; -80- A3 is -CH-; R* is -OH; and R3 is l6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -O- -OJ-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; l2 IS -CH-; R13 is -C(COOH)-; and R^ is -S-CW,-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; A3 is -CH-; R* is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R^, being either a 3-amino-1-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a carbamate, where L is -0-C(-0)-Z-Q"; Z is nitrogen and Q", together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R*2 is -CH-; R*3 is -C(COOH)-; and R^ is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and -81-the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(-0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R16 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 iS -CH-; Rl is -C(COOH)-; and Rl* is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is RiS and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(-0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R5 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; Rl is -C(COOH)-; and Rl* is -S-C"'-; the quinolone moiety is a 6-fluoroquinolone, wherein referring to Formula (I), is -C(R^)- ; A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is Rl6 and is a substituent moiety of L; the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(=0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; l* is -CH-; R3 is -C(COOH)-; and Rl* is -S-C"'-; the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A* is -N-; A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R*6 and is a substituent moiety of L; and -82- the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(-0)-Z-Q"; Z is nitrogen and— together with Z, is a substituted^6 group (j) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); RH is -H; Rl2 iS -CH-; R*3 IS -C(COOH)-; and Rl* is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R^6, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the I moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(=0)-Z-Q"; Z is nitrogen and Q\ together with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Carbamate-1 inked penem quinolones of classes (c), (d), (e), (h), (i) and (j) are preferred; compounds of classes (e) and (j) are more preferred. 3. Carbamate-1 inked carbacephem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -83- -CH-5 Rl3 is -C(COOH)-; and R is the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF- A3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(*0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R^ group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and Rl* is the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A is -CH-; R4 is -OH; and R3 is R15 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(-0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R15 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; Rl3 is -C(COOH)-; and R*4 is the quinolone moiety is a 6-fluoroquinolone, wherein referring to Formula (I), A1 is -C(R7)-; A2 is -CF-; A is -CH-; R4 is -OH; and R is Rl6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R15 group -84-the lactam-containing moiety is a carbapenem,- -wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R1* is -CH-; Rl3. is -C(COOH)-; and Rl* is the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A1 is -N-; A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(-0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted Rl6 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); RH is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and R^ is -CH(R38)-C"' -CH2-; 38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; A3 is -CH-; R* is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl , 4-fluorophenyl , or t-butyl ; and R3 is R16, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a carbamate, where L is -0-C(-0)-Z-QM; Z is nitrogen and Q", together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group -85-the lactam-containing moiety 1s a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 iS -CH-; Rl3 is -C(COOH)-; and is -CH(R38)-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 IS -CF-; A3 is -CH-; R4 is -OH; and R3 is R 6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(»0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R^ group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl is -C(COOH)-; and R* is -CH(R38) -C" - ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R15 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(-0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R15 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond Nb" is a double bond; R12 is -CH-; Rl is -C(COOH)-; and R^ is -CH(R38)-C"'-; the quinolone moiety is a 6- fluoroquinolone, wherein referring to Formula (I), Al is -C(R7)-; A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; -86-the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(-0)-Z-q"; Z is nitrogen and Q", together with Z, is a substituted R6 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R2 is -CH-; Rl3 is -C(COOH)-; and l* is -CH(R38)-C"'-; the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A1 is -N-; A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R*6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(-0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R^6 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); RH is -H; Rl2 is -CH-; R is -C(COOH)-; and R^ is -CH(R38)-C"-; R38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl , 4-fluorophenyl , or t-butyl ; and R3 is R16, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-amino position by the L moiety), or a l-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a carbamate, where L is -S-CH2CH2-0-C(-0)-Z-QM; Z is nitrogen and Q", together with Z, is R16, either a 3-amino -87- substituted 1-pyrrol idinyl group, or a 4-substituted l-piperaz1nyl group Carbamate-1 inked carbacephem quinolones of classes (c), (d), (e), (h), (i), and (j) are preferred; compounds of classes (e) and (j) are more preferred. 4. Carbamate-1 inked oxacephem quinolones, such as compounds of the class where the l ctam-containing moiety is a oxacephem, wherein referring to Formula (II), bond "a" is a single bond; bond Mb" is a double bond; Rl2 is -CH-; Rl s -C(COOH)-; and R** is -0-CH2-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R 6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group. 5. Carbamate-1 inked isocephem quinolones, such as compounds of the class where the lactam-containing moiety is a isocephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 iS -C(COOH)-; and Rl* is -CH2-S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group. -88- 6. Carbamate- 1 inked iso-oxacephem quinolones, such as compounds of the class where the 1 actam-containing moiety is a iso-oxacephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; l3 is -C(COOH)-; and Rl* is -CH2-0-Cn'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; is -OH; and R3 is R*6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(«0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted Rl6 group. 7. Carbamate- 1 inked carbacephem quinolones, such as compounds of the class where the lactam-containing moiety is a carbacephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and Rl* is -CH2-CH2-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(*0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R*6 group. 8. Carbamate- 1 inked penicillin quinolones, such as compounds of the class where the lactam-containing moiety is a penicillin, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a single bond; R12 is -89- -CH-; Rl3 is -C(COOH)-; and RH IS -S-C*"(Me)-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R*6 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -0-C(-0)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R6 group. 9. Carbamate-1 inked monobactam quinolones, such as compounds of the class where the lactam-containing moiety is a monobactam, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is nil; R12 is -CH- and is bonded directly to L; and R is nil; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a carbamate, where L is -CH2-0-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R6 group. 10. Dithiocarbamate-linked cephem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R*2 is -CH-; Rl3 is -C(COOH)-; and R* is -S-O^-C'-CHe- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and -90-the linking moiety is a dithiocarbamate, where L is -S-C(-S)-Z-Qw; Z is nitrogen and Q\ together with Z, is a substituted Rl6 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 ,S -CH-; R!3 is -C(COOH)-; and Rl* is -S-CH2-C" -CH2- ; the quino!one moiety is a structure, wherein referring to Formula (I), A is -CF-; A3 is -CH-; R* is -OH; and R3 is R15 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(-S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R5 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 1S -CH-; Rl3 is -C(COOH)-; and Rl* is -S-CH2-C"'-CH2-; the quinolone moiety is a 6-fluoroquinolone, wherein referring to Formula (I), A* is -C(R7)-; A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is Rl6 and is a substituent moiety of L; the linking moiety is a dithiocarbamate, where L is -S-C(-S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -S-CH2-C"' -CH2- ; -91-the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A1 is -N-; A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(-S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rll is -H or -OMe; Rl2 is -CH-; R*3 is -C(COOH)-; and R*4 is -S-CH2-C"'-CH2-; and R*0 is [[(2-thienyl )acetyl]-amino] , [[(2-amino-4-thiazolyl )(methoxyimino)-acetyl] amino], [[(4-pyridylthio)acetyl]amino], [(phenoxy)acetyl]amino], [[(2-amino-4-thiazolyl)-acetyljamino], or [[(2-amino-4-thiazolyl)-[[(3,4-dihydroxyphenyl )carbonyl] amino]acetyl ]-amino] ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl, 4-fluorophenyl , or t-butyl ; and R3 is R16, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a dithiocarbamate, where L is -S-C(=S)-Z-Q"; Z is nitrogen and Q\ together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group -92- Dithiocarbamate-1 inked cephem quinolones of classes (c), (d) and (ej are preferred; compounds of class (e) are more preferred. 11. Dithiocarbamate-1 inked penem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 iS -CH-; Rl3 is -C(COOH)-; and is -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(-S)-2-Q" ; Z is nitrogen and Q", together with Z, is a substituted R*6 group (b) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxy- ethyl); RH is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and R^ is -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; 6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro- phenyl, 4-fluorophenyl , or t-butyl ; and R3 is R16, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a dithiocarbamate, where L is -S-C(«S)-Z-Q"; Z is nitrogen and Q", together with Z, is Rl6, either a 3-amino substituted -93- 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; Rl is -C(COOH)-; and R4 is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and 3 is R*6 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(-S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R6 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 iS -CH-; Rl3 is -C(COOH)-; and Rl* is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R is R15 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(»S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted l5 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; Rl3 is -C(COOH)-; and RI is -S-C"'-; the quinolone moiety is a 6-fluoroquinolone, wherein referring to Formula (I), A1 is -C(R7)-; A2 is -CF-; A is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; -94-the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(-S)-Z-QH; Z is nitrogen and Q", together with Z, is a substituted R16 grou _ the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R*2 \s -CH-; R3 is -C(COOH)-; and R1* is -S-C"'-; the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A* is -N-; A2 is -CF-; -3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(=S)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R*6 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxy-ethyl); RH is -H; Rl2 is -CH-; R3 is -C(COOH)-; and R^ is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; A is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R16, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(-S)-Z-QM; Z is nitrogen and Q\ together with Z, is l6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group -95- Dithiocarbamate-1 inked penem quinolones of classes (b), (e), (f) and (g) are preferred; compounds of class (g) are more preferred. 12. Dithiocarbamate-1 inked carbapenem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 iS -CH-; Rl3 is -C(COOH)-; and Rl* is the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(»S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted l6 group (b) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl° is (1-hydroxyethyl); RH is -H; R*2 is -CH-; R 3 is -C(COOH)-; and Rl* is -CH(R38)-C*" -CH2-; R38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A∑ is -CF-; A3 is -CH-; 4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro- phenyl, 4-fluorophenyl , or t-butyl; and R3 is R16, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-amino position by the I moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and -96-the linking moiety is a dithiocarbamate, where L is -S-C(»S)-Z-Q"; Z is nitrogen and Q\ together with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R is -CH-; Rl3 is -C(COOH)-; and R is -CH(R38)-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(=S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R6 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R1 is -CH-; Rl3 is -C(COOH)-; and R*4 is -CH(R38)-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R15 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(»S)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R15 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and R*4 is -CH(R38)-CM' - ; -97- the quinolone moiety is a 6- fluoroquinolone, wherein referring to Formula (I), is -C(R7)-; A2 is -CF- A3 is -CH- R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the J inking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(-S)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R16 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 iS -CH-; Rl3 is -C(COOH)-; and R** is -CH(R38)-C"' -; the quinolone moiety is a naphthyridinone, wherein referring to Formula (I), A* is -N-; A is -CF-; A3 is -CH-; R4 is -OH; and R is Rl6 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(-S)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R e group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; RlO is (1-hydroxyethyl); R^ is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -CH(R38)-C"'-; R38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro- phenyl, 4- fluorophenyl , or t-butyl; and 3 is R 6, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L 35 -98- moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a dithiocarbamate, where L is -S-CH2CH2-S-C(-S)-Z-Q"; Z is nitrogen and Q", together with Z, is R6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Oithiocarbamate-1inked carbapenem quinolones of classes (b), (e), (f) and (g) are preferred; compounds of class (g) are more preferred. 13. Oithiocarbamate-1 inked oxacephem quinolones, such as compounds of the class where the lactam-containing moiety is a oxacephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -0-CH2-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(=S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group. 14. Dithiocarbamate-1 inked isocephem quinolones, such as compounds of the class where the lactam-containing moiety is a isocephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-: Rl3 is -C(COOH)-; and l* is -CH2-S-C"'-CH2-; -99- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(»S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted group. 15. Dithiocarbamate-1 inked iso-oxacephem quinolones, such as compounds of the class where the lactam-containing moiety is a iso-oxacephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and R^ is -CH2-0-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(=S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group. 16. Dithiocarbamate-1 inked carbacephem quinolones, such as compounds of the class where the lactam-containing moiety is a carbacephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl is -C(COOH)-; and R1* is -CH2-CH2-C'"-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and -100- the linking moiety is a dithiocarbamate, where L is -S-C(-S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted group. 17. Dithiocarbamate-1 inked monobactam quinolones, such as compounds of the class where the lactam-containing moiety is a monobactam, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is nil; R 2 is -CH- and is bonded directly to L; and R^ is nil; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a dithiocarbamate, where L is -S-C(»S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group. 18. Urea-linked cephem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 Is -CH-; R*3 is -C(COOH)-; and RU is -S-CH2-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a urea, where L is -NH-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group (b) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R11 is -H or -101- -O e; Rl2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -S-CH2-C"'-CH2-; and R is [[ (2-thienyl) acetyl ]- amino], [[(2-amino-4-thiazolyl)(methoxyimino)- acetyl] amino], [[(4-pyridylthio)acetyl ]amino] , [ (phenoxy) acetyl ] ami no], [[(2-amino-4-thiazolyl )- acetyl] mi no], or [[(2-amino-4-thiazolyl )- [ [ ( 3 , 4 -d i hydroxypheny 1 ) carbonyl ] ami no] acetyl ] - amino] ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; 4 is -OH; 6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro- phenyl, 4-fluorophenyl, or t-butyl; and R3 is R 6, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a l-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a urea, where L is -NH-C(=0)-Z-Q"; Z is nitrogen and Q", together with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted l-piperazinyl group Urea-linked cephem quinolones of class (b) are preferred. 19. Urea-linked penem quinolones, such as compounds of the following classes. the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R is -CH-; R^ is -C(COOH)-; and R*4 is -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; -102- R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a urea, where L is -NH-C(=0)-Z-q"; Z is nitrogen and Q\ together with Z, is a substituted R16 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxy-ethyl); Rll is -H; Rl2 iS -CH-; l3 is -C(COOH)-; and R4 is -S-CM'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl, or t-butyl; and R3 is R^, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a l-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a urea, where L is -NH-C(=0)-Z-Q"; Z is nitrogen and Q", togethe with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted l-piperazinyl group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; Rl3 is -C(COOH)-; and R* is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and -103- the linking moiety is a urea, where L is -S-CH2CH2-NH-C(-0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R*6 group (d) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R° is (1-hydroxy- ethyl); Rll is -H; l2 iS -CH-; Rl3 is -C(COOH)-; and Rl4 is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and R^ is Rl6, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a urea, where L is -S-CH2CH2-NH-C(»0)-Z-Q"; Z is nitrogen and Q\ together with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Urea-linked penem quinolones of classes (b) and (d) are preferred. 20. Urea-linked carbapenem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and ■ Rl* is -CH(R37)-CH,-CH2-; -104- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R 6 and is a substituent moiety of L; and - the linking moiety is a urea, where L is -NH-C(»0)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group (b) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl° is (1-hydroxyethyl); RH is -H; Rl2 is -CH-; l3 1S -C(COOH)-; and RH is -CH(R38)-C"'-CH2-; R38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -di fluorophenyl , 4- fluorophenyl , or t-butyl; and R3 is Rl6, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a urea, where L is -NH-C(-0)-Z-Q"; Z is nitrogen and Q\ together with Z, is l6» either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group (c) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and Rl4 is -CH(R 8) -C"' - ; -105- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a urea, where I is -S-CH2CH2-NH-C(-0)-Z-Q"; Z is nitrogen and Q", together with Z, 1s a substituted R16 group (d) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R° is (1-hydroxyethyl); Rll is -H; Rl2 is -CH-; Rl3 IS -C(COOH)-; and R* is -CH(R38)-Cn'-; R38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; Al is -CH-, -CF-, -CC1-, or -N-; and R is cyclopropyl, ethyl, 2,4-difluoro- phenyl , 4-fluorophenyl, or t-butyl; and R is R^6, being either a 3-amino-1-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a urea, where L is -S-CH2CH2-NH-C(-0)-Z-Q"; Z is nitrogen and Q", together with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Urea-linked carbapenem quinolones of classes (b) and (d) are preferred. 21. Thiourea-1 inked cephem quinolones, such as compounds of the following classes. -106-the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; R*3 is -C(COOH)-; and is -S-CH2-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R*6 and is a substituent moiety of L; and the linking moiety is a thiourea, where L is -NH-C(=S)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R6 group the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R11 is -H or -OMe; Rl2 is -CH-; Rl3 is -C(COOH)-; and R1* is -S-CH2-C'"-CH2-; and RlO is [[(2-thienyl)acetyl]-amino] , [[(2-amino-4-thiazolyl )(methoxyimino)-acetyl] amino], [[(4-pyridylthio)acetyl ]amino] , [(phenoxy)acetyl]amino] , [[(2-amino-4-thiazolyl )-acetyl ]amino], or [[(2-amino-4-thiazolyl )-[[(3,4-dihydroxyphenyl )carbonyl ] amino]acetyl]-amino] ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A1 is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R16, being either a 3-amino-1-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and -107- the linking moiety is a thiourea, where L is -NH-C(-S)-Z-Q"; Z is nitrogen and Q", together with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Thiourea-1inked cephem quinolones of class (b) are preferred. 22. Thiourea-1 inked penem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 IS -CH-; Rl3 is -C(COOH)-; and is -$-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a thiourea, where L is -NH-C(»S)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R16 group (b) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxy- ethyl); Rll is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and RH iS -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R16, being either a 3-amino-1-pyrrol idinyl group (substituted at the 3-amino position by the L -108-moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a thiourea, where L is -NH-C(-S)-Z-Q"; Z is nitrogen and Q\ together with Z, is Rl6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 Is -CH-; Rl3 is -C(COOH)-; and Rl* is -S-C'"-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a thiourea, where L is -S-CH2CH2-NH-C(»S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R 6 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; ° is (1-hydroxy-ethyl); RH is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and Rl4 is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl, or t-butyl; and R3 is Rl6, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L -109- moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a thiourea, where L is -S-CH2CH2-NH-C(-S)-Z-QH; Z is nitrogen and Q\ together with Z, is R 6, either a 3-amino substituted 1-pyrro idinyl group, or a 4-substituted 1-piperazinyl group Thiourea-1 inked penem quinolones of classes (b) and (d) are preferred. 23. Thiourea-1 inked carbapenem quinolones, such as compounds of the following classes. (a) where the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R2 is -CH-; Rl3 is -C(COOH)-; and is the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a thiourea, where L is -NH-C(=S)-Z-Q"; Z is nitrogen and Q\ together with Z, is a substituted R16 group (b) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); R^ is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and R^ is -CH(R38)-C"'-CH2-; R38 is -H or -Me; -110-the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; 6 is -H; A1 is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is Rl6, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-am o position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a thiourea, where L is -NH-C(»S)-Z-Q"; Z is nitrogen and Q\ together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond Mb" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and R*4 is -CH(R38)-C'"-; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a thiourea, where L is -S-CH2CH2-NH-C(=S)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); RU is -H; Rl2 is -CH-; Rl is -C(COOH)-; and R*4 is -CH(R38) -C"' - ; R38 is -H or -Me; -111- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH- ≠ is -OH; R6 is -H; A* is -CH-, ^CF_-,.^CC ,-or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , -fluorophenyl , or t-butyl; and R3 is R16, being either a 3-amino-1-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a l-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a thiourea, where L is -S-CH2CH2-NH-C(-S)-Z-Q"; Z is nitrogen and Q\ together with Z, is R6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted l-piperazinyl group Thiourea-1 inked carbapenem quinolones of classes (b) and (d) are preferred. 24. Isothiouronium-1 inked cephem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; R3 is -C(COOH)-; and R* is -S-CH2-C"' -CH2- ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a isothiouronium, where L is -S-C(-NH2+)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R16 group -112- the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is" a single bond; bond "b" is a double bond R11 is -H or -OMe; Rl2 iS -CH-; Rl3 is -C(COOH)-; and Rl4 is -S-CH2-C"'-CH2-; and RlO [[(2-thieny )- acetyl ]amino] , [[(2-amino-4-thiazolyl )- (methoxyimino)acetyl ] amino], [[(4-pyridylthio)- acetyl ]amino] , [(phenoxy)acety ] mino] , [[(2-amino-4-thiazolyl)acetyl]amino], or [[(2-amino-4-thiazolyl)[[(3,4-dihydroxyphenyl)car- bonyl] amino]acetyl]amino]; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro- phenyl, 4-fluorophenyl, or t-butyl; and R3 is Rl6, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-posi_tion by the L moiety); and the linking moiety is a isothiouronium, where L is -S-C(-NH2+)-Z-Q"; Z is nitrogen and Q", together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Isothiouronium-1 inked cephem quinolones of class (b) are preferred. 30. Isothiouronium-1 inked penem quinolones, such as compounds of the following classes. -113-the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R2 is -CH- Rl3 is -C(COOH)-; and R4 IS -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a isothiouronium, where L is -S-C(=NH2+)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R6 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); fill is -H; R*2 is -CH-; R*3 IS -C(COOH)-; and R^ is -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; ≠ is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl, 4-fluorophenyl, or t-butyl; and R3 is R16, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a isothiouronium, where L is -S-C(-NH2+)-Z-Q"; Z is nitrogen and Q", together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group -114-the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "aH is a single bond; bond "b" is a double bond; Rl2 is -CH-; l3 is -C(COOH)-; and R^ is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R6 and is a substituent moiety of L; and the linking moiety is a isothiouronium, where L is -S-CH2CH2-S-C(=NH2+)-Z-Q"; Z is nitrogen and Q", together with Z, is a substituted R6 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxy-ethyl); R^ is -H; Rl2 is -CH-; R*3 is -C(COOH)-; and Rl4 is -S-C'"-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; R6 is -H; A1 is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R*6, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a l-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a isothiouronium, where L is -S-CH2CH2-S-C(-NH2+)-Z-Q"; Z is nitrogen and Q\ together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted l-piperazinyl group -115- Isothiouronium-1 inked penem quinolones of classes (b) and (d) are preferred. 31. Isothiouronium-1 inked carbapenem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond nb" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and l4 iS the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R*6 and is a substituent moiety of L; and the inking moiety is a sothiouronium, where I is -S-C(»NH2+)-Z-Q"; 2 is nitrogen and Q", together with Z, is a substituted group (b) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); Rll is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and R^ is -CH(R38)-C"'-CH2-; 38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A1 is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl, 4-fluorophenyl , or t-butyl ; and R3 is R16, being either a 3-amino-l-pyrrol dinyl group (substituted at the 3-am no position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and -116-the linking moiety is a isothiouronium, where L is -S-C(-NH2+)-Z-Q"; Z is nitrogen and Q", together with Z, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted l-piperazinyl group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; 12 1S -CH-; l is -C(COOH)-; and R1* is -CH(R38)-C"-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a isothiouronium, where L is -S-CH2CH2-S-C(=NH2+)-Z-QM; Z is nitrogen and Q\ together with Z, is a substituted Rl6 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R ° is (1-hydroxyethyl); RH is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -CH(R38)-C"'--; R38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro-phenyl, 4-fluorophenyl, or t-butyl; and R3 is R16, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a l-piperazinyl group (substituted at the 4-position by the L moiety); and -117- the linking moiety is a isothlouronium, where L is S-CH2CH2-S-C(-NH2+)-Z-Q"; Z is nitrogen and Q\ together with Z, is R16, either a 3-amino substituted 1-pyrrol dinyl group, or a 4-substituted 1-piperazinyl group Isothiouronium-1 inked carbapenems of classes (b) and (d) are preferred. 32. Quaternary ammonium-linked cephem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond ¥ is a double bond; R*2 is -CH-; R*3 is -C(COOH)-; and Rl* is -S-CH2-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a quaternary amine moiety, where L is -X -Q"; X3 is N+(R41)(R42), and Q\ together with X3, is a substituted R16 group (b) where the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R11 is -H or -OMe; Rl2 iS -CH-; R*3 is -C(COOH)-; and Rl* is -S-CH2-Cn'-CH2-; and R*° is [[(2-thienyl)acetyl ]- amino], ([(2-amino-4-thiazolyl )(methoxyimino)- acetyl] amino], [[(4-pyridylthio)acetyl]amino], [(phenoxy)acetyl]amino] , [[(2-amino-4-thiazolyl )- acetyl]amino], or -118- [[(2-amino-4-thiazolyl)[[(3,4-dihydroxyphenyl)car- bonyl ]amino]acetyl ]amino] ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; ≠ is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl, 4-fluorophenyl, or t-butyl; and R3 is R6, being a 1-substituted 1-methyl-piperazinio-4-yl moiety; and the linking moiety is a quaternary amine moiety, where L is -X3-QH; X3 is N+(R41)(R42) , and Q", together with X3, is R16, a 1-substituted 1-methyl - l-piperazinio-4-yl group Quaternary ammmoniurn-linked cephem quinolones of class (b) are preferred. 33. Quaternary ammonium-linked penem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R2 is -CH-; R*3 is -C(COOH)-; and Rl4 is -S-C"'-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a quaternary amine moiety, where L is -X3-Q"; X3 is N+(R41)(R42) , and Q\ together with X3, is a substituted R6 group (b) where - the lactam-containing moiety is a penem, wherein rferring to Formula (II), bond "a" is a single -119- bond bond "b" is a double bond; Rl2 IS -CH-; l3 is -C(COOH)-; and Rl* is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a quaternary amine moiety, where L is -S-CH2CH2-X3-Q"; X3 is N+(R41)(R42), and Q\ together with X3, is a substituted Rl6 group the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxy ethyl); Rll is -H; Rl2 is -CH-; R* is -C(COOH)-; and Rl4 is -S-C'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R16, being a 1-substituted l-methyl-piperazinio-4-yl moiety; and the linking moiety is a quaternary amine moiety, where L is -S-CH2CH2-X3-Q"; X3 is N+(R41)(R42), and Q", together with X3, is Rl6, a 1-substituted l-methyl-l-piperazinio-4-yl group Quaternary ammonium-linked penem quinoiones of class (c) are preferred. 34. Quaternary ammoniurn-1 inked carbapenem quinol compounds of the following classes. ■120- the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and l* is the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R is Rl* and is a substituent moiety of L; and the linking moiety is a quaternary amine moiety, where L is -X3-Q"; χ3 is N+(R41)(R42), and Q", together with X3, is a substituted R^ group (b) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and Rl* is -CH(R38)-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a quaternary amine moiety, where L is -S-CH2CH2-X3-Q"; χ is N+(R41)(R42), and Q", together with χ3, is a substituted R6 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; 10 is (1-hydroxyethyl); RH is -H; R*2 is -CH-; Rl3 is -C(COOH)-; and Rl* is -CH(R38)-C"'-; R38 Is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; 6 is -H; A* is -CH-, -CF-, -CC1-, or -121- -N-; and R3 is cyclopropyl, ethyl, 2,*-di luorophenyl , 4-fluorophenyl , or t-butyl; and R3 is R*6, being a 1-substituted 1-methyl -piperazinio-4-yl moiety; and the linking moiety is a quaternary amine moiety, where L is -S-CH2CH2-X3-Q"; X3 is N+(R41)(R42), and Q\ together with X3, is Rl6, a 1-substituted 1-methyl -l-piperazinio-4-yl group Quaternary arnmoniurn-1 inked carbapenem quinolones of class (c) are preferred. 35. Amine-1 inked cephem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; R13 is -C(COOH)-; and Rl* is -S-CH2-C'"-CH2-; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; A is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is an amine, where L is -X3-Q"; X3 is nitrogen and Q", together with X3, is a substituted R16 group (b) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R^ is -H or -OMe; l2 1S -CH-; R*3 is -C(COOH)-; and R4 is -S-CH2-C"'-CH2-; and R10 [[(2-thienyl )acetyl ]- amino] , [[ (2-amino-4-thiazolyl ) (methoxyimino)- -122- acetyl] amino], [[(4-pyridylthio)acetyl]amino], [(phenoxy)acetyl]am no], [[(2-amino-4-thiazo1yl)acetyl]amirio], or [[(2-amino-4-th azoly1 )[[(3,4-dihydroxyphenyl)car- bony1] amino]acetyl]amino]; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; 4 is -OH; R6 is -H; A1 is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-di luorophenyl, 4-fluorophenyl , or t-butyl; and R3 is R6, being either a 3-amino-l-pyrrol idinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a amine, where L is -X3-QM; X3 is nitrogen and Q", together with X3, is R16, either a 3-amino substituted 1-pyrrolidinyl group, or a 4-substituted 1-piperazinyl group Amine-1 inked cephem quinolones of class (b) are preferred. 36. Amine-1inked penem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R*2 is -CH-; R3 is -C(COOH)-; and Rl* is -S-C"'-CH2S the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R* is -OH; and R3 is R16 and is a substituent moiety of L; and -123- the Unking moiety is an amine, where L is - X3 is nitrogen and Q", together with X3, substituted R 6 group (b) where - where the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); RH is -H; Rl2 is -CH-; Rl3 iS -C(COOH)-; and R*4 is -S-C"'-CH2-; the quinolone moiety 1s a structure, wherein referring to Formula (I), A2 1s -CF-; A3 is -CH-; R4 1s -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, 4-di fluorophenyl, 4- fluorophenyl , or t - butyl ; and R3 is R16, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3 -ami no position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a amine, where L is -X3-Q"; X3 is nitrogen and Q", together with X3, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group (c) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl2 is -CH-; R*3 is -C(COOH)-; and R^ is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R*6 and Is a substituent moiety of L; and -124- the linking moiety is a amine, where L is -S-CH2CH2-X3-Q"; X3 is nitrogen and Q\ together with X3, is a substituted R6 group (d) where - the lactam-containing moiety is a penem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R1^ is (1-hydroxy- ethyl); RH is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and Rl4 is -S-C*"-; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A1 is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2, -difluorophenyl , 4-fluorophenyl , or t-butyl; and R3 is Rl6, being either a 3-amino-l-pyrroidinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is a amine, where L is -S-CH2CH2-X3-Q"; X3 is nitrogen and QM, together with X3, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Amine-1 inked penem quinolones of classes (b) and (d) are preferred. 37. Amine-1inked carbapenem quinolones, such as compounds of the following classes. (a) where - the lactam-containing moiety is a carbapenem, werein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl is -C(COOH)-; and R** is -CH(R37)-C"'-CH2-; -125-and, where the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substi-tuent moiety of L; and the linking moiety is an amine, where L is -X3-Q"; X3 is nitrogen and Q", together with X3, is a substituted Rl6 group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" 1s a double bond; R*° is (1-hydroxyethyl); Rll is -H; *2 1S -CH-; Rl3 is -C(COOH)-; and Rl* is -CH(R8)-C"'-CH2 R38 is -H or -Me; the quinolone moiety 1s a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; 6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl, 4-fluorophenyl , or t-butyl; and R3 is R16, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is an amine, where L is -X3-Q"; X3 is nitrogen and Q", together with X3, is R6, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" 1s a double bond; R12 is -CH-; Rl3 is -C(COOH)-; and Rl* is -CH(R38)-C"'-; -126- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is an amine, where L is -S-CH2CH2-X3-Q"; X3 is nitrogen and Q", together with X3, is a substituted R*6 group (d) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); RH is -H; Rl2 1S -CH-; R*3 is -C(COOH)-; and R* is -CH(R38)-C"'-; R3^ is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl , 4-fluorophenyl, or t-butyl; and R3 is Rl6, being either a 3-amino-l-pyrrolidinyl group (substituted at the 3-amino position by the L moiety), or a 1-piperazinyl group (substituted at the 4-position by the L moiety); and the linking moiety is an amine, where L is -S-CH2CH2-X3-Q"; X3 is nitrogen and Q", together with X3, is R16, either a 3-amino substituted 1-pyrrol idinyl group, or a 4-substituted 1-piperazinyl group Amine-1 inked carbapenem quinolones of classes (b) and (d) are preferred. 38. Pyridinium-1 inked cephem quinolones, such as compounds of the following classes. -127- (a) where - the lactam-containlng moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; Rl21S -CH-; R13 is -C(COOH)-; and Rl* is -S-CH2-C"'-CH2-; the quino!one moiety is a structure, wherein referring to Formula (I), A is -CF-; A3 is -CH-; R* is -OH; and R3 is Rl6 and is a substituent moiety of L; and the linking moiety is a pyridinium moiety, where L is -X3-Q"; X3 is nitrogen, and Q", together with X3, is a substituted R16 group (b) where - the lactam-containing moiety is a cephem, wherein referring to Formula (II), bond "a" is a single bond; bond nb" is a double bond; 11 is -H or -OMe; Rl2 iS -CH-; l3 1S -C(COOH)-; and R^ is -S-CH2-C"'-CH2-; and R*0 [[(2-thienyl)acetyl]- amino], [[(2-amino-4-thiazolyl)(methoxyimino)- acetyl] amino], [[(4-pyridylthio)acetyl]amino], [(phenoxy)acetylJamino], [[(2-amino-4-thiazolyl )- acetyl]amino], or [[(2-amino-4-thiazolyl )[[(3,4- diydroxyphenyl)carbonyl] amino]acetyl]amino] ; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro- phenyl, 4-fluorophenyl , or t-butyl; and R3 is R16, being a 1-substituted pyridinio-4-yl moiety; and the linking moiety is a pyridinium moiety, where L is -X3-Q"; X3 is nitrogen, and Q", together with X3, is R16, a 1-substituted pyridinio-4-yl group Pyridinium-1inked cephem quinolones of class (b) are preferred. -128- 39. Pyrldlnlum- linked penem qulnolones, such as compounds of the following classes. (a) where the lactam-containlng moiety 1s a penem, wherein referring to Formula (II), bond "a" 1s a single bond; bond "b* 1s a double bond; l2 jS -CH-; Rl is -C(COOH)-; and Rl* is -S-C"'-CH2-; the quinolone moiety Is a structure, wherein referring to Formula (I), A2 1s -CF-; A3 is -CH-; R4 Is -OH; and R3 1s R16 and Is a substHuent moiety of L; and the linking moiety is a pyrldlnlum moiety, where L is -X3-Q"; X3 is nitrogen, and Q", together with X3, is a substituted R16 group (b) where the lactam-containlng moiety 1s a penem, wherein referring to Formula (II), bond "a" 1s a single bond; bond "b" is a double bond; Rl2 iS -CH-; R*3 is -C(COOH)-; and Rl* is -S-C"'-; the quinolone moiety is a structure, wherein referring to Formula (I), A* is -CF-; A3 1s -CH-; R* is -OH; and R3 is l6 and 1s a substituent moiety of L; and the Unking moiety 1s a pyridinium moiety, where L Is -S-CH2CH2-X3-Q"; X3 1s nitrogen, and Q", together with X3, is a substituted R16 group (c) where - the lactam-contalning moiety is a penem, wherein referring to Formula (II), bond "a" 1s a single bond; bond "b" is a double bond; R*0 1s (1-hydroxy- ethyl); R^ is -H; Rl2 iS -CH-; R* Is -C(COOH)-; and Rl* is -S-C"'-; -129- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH- R* is -OH; ≠ is -H; Al is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluorophenyl, 4-fluorophenyl , or t-butyl; and R3 is R16, being a 1-substituted pyridinio-4-yl moiety; and the linking moiety is a pyridinium moiety, where L is -S-CH2CH2-X3-Q"; X3 Is nitrogen, and Q", together with X3, is Rl6, a 1-substituted pyridinio-4-yl group Pyridinium-1 inked penem quinolones of class (c) are preferred. 40. Pyridinium-1inked carbapenem quinolones, such as compounds of the following classes. the lactam-containing moiety is a carbapenem, werein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R12 is -CH-; Rl3 iS -C(COOH)-; and R^ is the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 1s -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a pyridinium moiety, where L is -X3-Q"; X3 is nitrogen, and Q", together with X3, is a substituted R16 group (b) where the lactam-containing moiety 1s a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; 12 is -CH-; Rl3 is -C(COOH)-; and RH is -CH(R38)-C"' -; -130- the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; and R3 is R16 and is a substituent moiety of L; and the linking moiety is a pyridinium moiety, where L is -S-CH2CH2-X3-Q"; X3 is nitrogen, and Q", together with X3, is a substituted R16 group (c) where - the lactam-containing moiety is a carbapenem, wherein referring to Formula (II), bond "a" is a single bond; bond "b" is a double bond; R10 is (1-hydroxyethyl); R1* is -H; Rl2 is -CH-; Rl3 is -C(COOH)-; and R^ is -CH(R8)-C"'-; R38 is -H or -Me; the quinolone moiety is a structure, wherein referring to Formula (I), A2 is -CF-; A3 is -CH-; R4 is -OH; R6 is -H; A* is -CH-, -CF-, -CC1-, or -N-; and R3 is cyclopropyl, ethyl, 2,4-difluoro- phenyl, 4-fluorophenyl , or t-butyl; and R3 is Rl6, being a 1-substituted pyridinio-4-yl moiety; and the linking moiety is a pyridinium moiety, where L is -S-CH2CH2-X3-Q"; X3 is nitrogen, and Q", together with X3, is R16, a 1-substituted pyridinio-4-yl group Pyridinium-iinked carbapenem quinolones of class (c) are preferred.

Preferred lactam-quinolones also include compounds wherein: (1) if bond "a" or bond "b" is nil, then Rl -L is L; (2) if bond "a" and "b" are single bonds, Rl -L is -W-C'"=C(R8a)-R7-L, or -W-CM (R36)-R37-L; or (3) if bond "a" is a single bond and bond "b" is a double bond, R14-L is -C(R8a)(R38)-W-C"'-R37-L; or (preferably) -W -C(R8a) (R38)-C" .R37.l, or -W-C" -R37-L; where (a) W is 0, or C(R38); and -131- (b) L" is Q\ -X2-Q", -N.Q-, N( 40).Q-, R43.N(R41).Q", -X4t-C(-Y3u)-Z-Q", -X5t-P0(Y*uR8a)-Z'-Q\ or X5t-S02-Z'-Q" (preferably -X2-Q\ or -X4t-C(-Y3u)-Z-Q").

Preferred lactam-quinolones Include (for example) the fo owing compounds. [5R-[5a,6a]]-3-[[[4-[3-Carboxy-l-(2,4-difluorophenyl)-6- fluoro-l,4-dihydro-4-oxo-l,8-naphthyridin-7-yl]-l-pipera- zi nyl ] t i oxomethy 1 ] th i omethy 1 ] -6- [ ( R) - 1 - hydroxyethyl ] -4 - methyl -7-oxo- l-azabicyclo[3.2.0]hept-2-ene-2-carboxyl 1c add di sodium salt [5R- [5a , 6a] ] -3- [ [ [4 - (3 -Carboxy- 1 -cycl opropyl -6- f 1 uoro- 1,4- d1hydro-4-oxo-7-quinol1nyl)-l-piperazinyl]th1oxomethyl]thio- methyl ] -6- [ (R) - 1 -hydroxyethyl ] -7-oxo-4-thi a- 1 -azabi cy- clo[3.2.0]hept-2-ene-2-carboxyl1c acid di sodium salt -132- [6R-[6a,7b]]-3-[[[4-[6-Carboxy-8-ethyl-5,8-dihydro-5-oxo- pyrido[2,3-d]pyrimidin-2-yl]-l-piperazinyl]thioxomethyl ] thi omethyl ]-7-[[[[[3-[(3, -dihydroxyphenyl ) methyl eneami no] -2- oxo- 1-imidazol idinyl ]carbonyl ami no] phenyl ]acetyl ]amino]-5- thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid di sodium salt [5R-[5a,6b]J-3-[[[4-[3-Carboxy-l-ethyl-6-fluoro-l,4- dihydro-4-oxo-7-quinolinyl]-l-piperazinyl]carbonyloxy] methyl ]-6-[(R)-l-hydroxyethyl]-7-oxo-l-azabicyclo[3.2.0] hept-2-ene-2-carboxyl ic acid disodium salt -133- [5R-[5a,6a]]-3-[[[4-(3-Carboxy-cyclopropyl-6-fluoro- l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]iminomethyl] thiomethyl]-6-[(R)-l-hydroxyethyl]-7-oxo-l-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid disodium salt [5R-[5a,6a]]-3-[[[4-[3-Carboxy-l-(2,4-dif1uorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridin-7-y1]-l-pipera-ziny1]iminomethy1]thiomethyl J-6-[(R)-1-hydroxyethy1 ]-7-oxo-4-thia-l-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt •134- [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-7-quinolinyl )-l-piperazinyl ]iminomethyl ]thi - omethyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-l-azabicy- clo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt [6R-[6a,7b(Z)]]-7-[[(2-Amino-4-t iazolyl)(methoxyimino) acetyl ]amino]-3-[[[4-[3-carboxy-l-(2,4-difluorophenyl )-6- fluoro-l,4-dihydro-4-oxo-l,8-naphthyridin-7-yl ]-l-pipera- zinyl]iminomethyl]thiomethyl]-5-thia-l-azabicyclo[4.2.0] oct-2-ene-2-carboxyl ic acid sodium salt -135- [6R-[6af7b]]-3-[[[l-(3-Carboxy-8-c loro-l-cyclopropyl-6- fluoro-4-dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino] iminomethyl Jthiomethyl ]-7-[[(R)-hydroxy(phenyl )acetyl ] amino]-7-methoxy-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2- ene-2-carboxyl ic acid sodium salt (3S)-2-[[[4-[3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4- oxo-7-quinol inyl] -1-piperazinyl] iminomethyl ] thio] -3- [[phen- oxyacetyl]amino]-4-oxo-l-azetidinesulfonic acid sodium salt -136- [6R-[6a,7b]]-3-[[[[4-[3-Carboxy-l-cyclopropyl-l,4-dihydro-4- oxo-7-qui ol i nyl]-l-piperazinyl]thioxomethy1]amino]methyl ]- 7- (2-thienyl acetyl) amino] -5-thia-l-azabicyclo[4.2. OJoct-2- ene-2-carboxyl ic acid disodium salt [6R-[6a,7b]]-3-[[[[l-[3-Carboxy-8-chloro-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-7-quinolinyl]-3-pyrrol idinyl amino] thioxomethyl]amino]methyl] -7- [(2-thienyl acetyl )amino] -5- thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt -137- [5R-[4b,5a,6a]]-3-[[[l-[3-Carboxy-l-(2,4-difluorophenyl)-6- fluoro-l,4-dihydro-4-oxo-l,8-naphthyridin-7-ylJ-3-pyrrol idinyl ]amino]thioxomethylamino}metyl-]-6-(-(-R)-1-hydroxyethyl ]-4-methyl -7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2-carboxyl ic acid disodum salt [5R-[5a,6a]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl )-l-piperazinyl Jthioxomethylamino] methyl ]-6-[(R)-l-hydroxyethyl]-7-oxo-4-thia-l-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid disodium salt -138- [5R-[5a,6a]]-3-[[[4-(3-Carboxy-l-cyclopropyl -6-fluoro-l ,4 dihydro-4-oxo-7-quinol inyl )-l-piperazinyl]carbonylamino] methyl ] -6- [ (R) -1 -hydroxyethyl ] -7-oxo-4-thi a- 1 -azabi cycl o- [3.2.0]hept-2-ene-2-carboxyl ic acid disbdium salt [6R- [6a, 7b]]-3-[[[2- [4- (3-Carboxy-l -ethyl -6-fluoro-l, 4- dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]ethoxy] thioxomethyl thio]methyl ] -7- [ [carboxy(4-hydroxyphenyl ) acetyl ]amino]-8-oxo-5-oxa-l-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid tri sodium salt -139- [6R-[6a,7b]]-7-([(R)-amino(4-hydroxyphenyl ) acetyl Jaraino] - 3- [[[2- [4- (3-carboxy- 1 -cycl opropyl -6-fl uoro-l,4-dihydro-4- oxo - 7 - qu i nol i ny 1 ) - 1 - p i peraz i ny 1 ] ethyl th i o] th i ox meIbylami.noJ, methyl 1-8-oxo- 5-thi a- 1-azabi cycl o[4.2.0]oct-2-ene- 2- carboxylic acid di sodium salt [5b-[5a,6a]]-3-[[[[l-(3-Carboxy-8-chloro-6-fluoro-l,4- dihydro-4-oxo-7-quinolinyl)-3-pyrrolidinylamino]carbonyl methyl th io] thioxomethyl ami nojmethyl ] -6- [ (R) - 1 -hydroxyethyl ] 7-oxo-4-thia-l-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid disodium salt -140- [6R-[6a,7b]]-3-[[[4-(3-carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-7-quinol inyl )-l-piperazinyl liminomethyl Jamino- methyl]-8-oxo-7-[(2-thienylacetyl)am no]-5-thi -l-azabicy- clo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt [5R-[5a,6a]]-3-[[[[l-(3-Carboxy-2-cyclopropyl-6,8-dif1uoro- l,4-dihydro-4-oxo-7-quinol inyl)-3-pyrrol idinyl]methylamino]- iminomethyl ]aminomethyl] -6- [(R)-l-hydroxyethyl ] -7-ΟΧΟ-4- thia-l-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt -141- (3)-3-[[(2-Amino-4-thiazoyl)(l-carboxymethoxyimino)- acetyl ]amino]-2-[[2-[3-carboxy-6-fluoro-l,4-dihydro-4- oxo-7-(4-methyl -1-piperazinyl)-1-quinol inyl ]ethoxy]thiox omethylthio]-4-oxo-l-azetidinesulfonic acid trisodium salt [6R-[6a,7b]]-7-[[(R)-amino(phenyl)acetyl]amino]-3-[[[l-(3-carboxy-8-chloro-l-cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-7 quinol inyl )-3-pyrrol idinylamino]carbonylamino]methyl]-8-oxo 5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt -142- [5R- [5a, 6a] ]-3-[[l-[3-Carboxy-l- (2, 4-di fluorophenyl )-6- fluoro-1 ,4-dihydro-4-oxo-l ,8-naphthyridin-7-yl ] -3 -pyrrol i- dinyl ] ami nomethylene] -6- [(R)-l -hydroxyethyl 1-7-0X0-4- thi - l-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt [5R-[5a,6a]]-3-[[[l-[3-Carboxy-l-(2,4-difluorophenyl)-6- fl uoro-l,4-dihydro-4-oxo-l,8-naphthyridin-7-yl]-3-pyrroli dinyl amino]hydroxyphosphinyl ]oxymethyl ]-6-[(R) -1- hydroxyethyl]-7-oxo-4-th a-l-azabicyclo[3.2.0]hept-2-ene- carboxylic acid tri sodium salt -143- [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl -6-fluoro-1 ,4- dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]hydroxyphos- phinyl ]oxymethyl ]-8-oxo-7-[(2-thienylacetyl )amino]-5-thia- l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid trisodium (3S)-2-[2-[3-Carboxy-6-fluoro-l,4-dihydro-7-(4-methyl-l-piperazinyl )-4-oxo-l-quinol inyl]ethyloxy]-4-0X0-3- [phenylacetyl]amino]-l-azetidinesulfonic acid disodium salt -144- (3S)-2-[4-[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro- 4-oxo-7-quinol inyl )-3-piperazinyl ]phenoxy]-3-[[[[(2-oxo-l- imidazolidinyl )carbonyl]amino](phenyl )]acetyl]amino]-4-oxo- 1-azetidinesulfonic acid sodium salt [6R-[6a,7b]]-3-[[2-[4-(3-Carboxy-l-cyclopropyl-6-fluoro- l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]ethyl] sulfinylmethyl]-8-0X0-7-[(2-thienylacetyl)amino]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt CO,Na -145- [5R-[5a,6a]]-3-[[[2-(3-carboxy-6-fluoro-l,4-dihydro-4-oxo-7-(4-methyl-l-piperazinyl)-l-quinolinyl ]ethoxy]carbonyl aminojmethyl ]-6-[(R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid disodium salt [5R-[4b,5a,6a]]-3-[[[4-(3-Carboxy-1-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]methylimi-nomethyl ]methylthio]-6-[(R)-1-hydroxyethyl ]-4-methyl-7-oxo-4-thia-l-azabicyclo[3.2.0]hept-l-ene-2-carboxylic acid disodium salt -146- [5R-[5a,6a]]-3-[2-[[l-(3-carboxy-8-chloro-l-cyclopropyl-6- fl uoro-l,4-dihydro-4-oxo-7-quinolinyl )-3-pyrrol idinylamino] iminomethyl ] amino]ethyl thio] -6- (R) - 1 -hydroxyethyl -7-oxo- 1 - azabicyclo[3.2.0] hept-2-ene-2-carboxyl ic acid mono sodium salt [5R-[4b,5a,6a]]-l-[2-[[2-Carboxy-6-[(R)-l-hydroxyethyl]-4- methoxy-7-oxo-l-azabicyclo[3.2.0]hept-2-en-3-yl]thio]ethyl]- 4-(3-carboxy-l-ethyl -1 ,4-dihydro-4-oxo-7-quinol inyl )pyridi- nium sodium salt -147- [6R-[6a,7b]]-7-[[(2-Amino-4-thiazolyl )(methoxyimi no)] acetyl am no]-3-[[[4-(3-carboxy-l-cyclopropyl -6-fluoro-l,4- dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]carbonyloxy] methyl]-8-oxo-5-thia-l-azabicyc1o[4.2.0]oct-2-ene-2- carboxylic acid di sodium salt [6R- [6a , 7b] ] -3- [ [ [ 1 - (3-Carboxy-8-chl oro- 1 -cycl opropyl -6- fluoro-1 , 4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinyl - amino]carbonyloxy]methyl]-8-oxo-7-[2-thienylacetyl)amino] 5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid di sodium salt -148- [5R-[5a,6a]]-3-[[[l-[3-Carboxy-l-(2,4-difluoropenyl)-6- fluoro-l,4-d1hydro-4-oxo-l,8-naphthyrid1n-7-yl]-3- pyrrol idinylamino]carbonyloxy]methyl]-6-[(R)-1- hydroxymethyl]-7-oxo-4-thia-l-azabicyclo[3.2.01hept-2-ene- 2-carboxylic acid disodium salt [6R-(6a,7b)]-7-[[[(2-Aminocarbonyl -2-f1uoro)ethenyl- thio]acetyl)amino]-3-[[[l-(3-carboxy-8-chloro-l- cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl)-3- pyrrol idinylamino]carbonyloxy]methyl]-8-oxo-5-oxa-l- azabicyclo[4.2.0]oct-2-ene-2-carboxyl 1c acid disodium salt -149- [6R-(6a,7b)]-3-[[[4-(3-carboxy-l-ethy1-6-fluoro-l,4- dihydro-4-oxo-7-quinol inyl)-l-piperazinyl Jcarbonyloxy]- methyl ] -7- [[carboxy (phenyl ) acetyl ] ami no] -7-methoxy-8- oxo-5-oxa-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic- acid di sodium salt [6R-[6a,7b]]-7-[[(2-amino-4-th1azoyl)(l- carboxyethoxy)imino)acetyl]amino]-3-[[[[4-(3- carboxy- 1 -cyclopropyl -6,8-di f luoro- 1 ,4-dihydro- 4-oxo-7-quinol inyl )-l-piperazinyl ]carbonyloxy]- methyl]-8-oxo-5-oxa-l-azabicyclo[4.2.0]oct-2-ene- 2-carboxylic acid disodium salt -150- [6R-[6a,7b]]-3-[[[[3-carboxy-6-fluoro-l,4-dihydro-4- oxo-7-(4-methyl -1-piperazlnyl)-l-quinol inyl ]methyl- amino]carbonyloxy]methyl]-7-[[[(S)(5-hydroxy-4-oxo-l(4H) pyridin-2-yl )carbonylamino](2-amino-4-thiazoyl )acetyl]- amino]-8-oxo-l-azabicyclo[4.2.0] oct-2-ene-2-carboxyl 1c disodium salt [6R-(6a,7b)]-7-[[[(R)-4-ethyl-2,3-dioxo-l- piperazinyl)carbonyl]amino](hydroxyphenyl)acetyl- ]amino]-3-[[[4-[6-carboxy-8-ethyl-5,8-dihydro-5-oxopyrido- [2,3-d]pyrimidin-2-yl]l-piperazinyl] carbonyloxy]- methyl]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid disodium salt -151 [6R-(6a,7b)]-7-[[(2-Amino-4-thiazoyl )acetyl ]amino]-3- [[[1-[3-carboxy-1-(2, -dif1uorophenyl)-6-f1uoro-1,4- dihydro-4-oxo-l,8-naphthyridin-7-yl]-3-pyrrol idinylamino] carbonyloxy]methyl]-8-oxo-5-t ia-l-azabicyclo[4.2.0]Oct-_ [3S]-3-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]- 2-[[[1-(3-carboxy-l-cyclopropyl-8-chloro-6-fluoro-1,4- dihydro-4-oxo-7-quinol inyl)-3-pyrrolidinylamino]thiox- omethyl]thio]-4-oxo-l-azetidinesulfonic acid disodium salt -152- [3S]-2-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-7-qu1nolinyl)-l-piperazinyl]t ioxofflethyl]- thio]-4-oxo-3-[(phenoxyacetyl )amino]-1-azetidinesu]fonic acid disodium salt [6R-(6a,7b)]-7-[[(2-Amino-4-thiazolyl)acetyl]amino]-3- [[[[[l-(3-carboxy-l-cyclopropyl-6,8-difluoro-l,4-dihydro- 4-oxo-7-quinolinyl)-3-pyrrol idinyl]methyl]methylamino]- thioxomethyl]thiomethyl]-8-oxo-5-thia-l-azabicyclo[4.2.0] oct-2-ene-2-carboxyl ic acid disodium salt -153- [6R-(6a,7b)]-7-[[[(2-Am1no-4-thiazolyl}[(l-carboxy-l- methyl )ethoxyimino] acetyl ] ami no] -3- [ [ [4- (3-carboxy- 1 - cyclopropy1-6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-l- piperazinyl]thioxomethyl]thiomethyl]-5,8-dioxo-5-thia- l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, disodium salt [6R-(6a,7b)]-3-[[[4-(3-Carboxy-l-ethy1-6-fluoro-l,4- d i hydro - 4 - oxo - 7 -qu i no i ny 1 ) - 1 -p i peraz i ny 1 ] t h i oxomet hy 1 ] - thiomethyl ] -7- [ [ (2-furanyl (methoxyimi no) acetyl ]amino] - 8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt -154- [6R-(6a,7b)]-7-[[Amino[benzo[b]thien-3-yl]acetyl ] amino] - 3- [[[4- [3-carboxy-6-f1uoro-l- (2, 4-d1 fluorophenyl ) - l,4-dihydro-4-oxo-7-(l,8-naphthyridinyl)]-l-piperazinyl]- thioxomethyl]thiomethyl] -8-0X0-5- thi a- l-azabicyclo[4.2.0] oct-2-ene-2-carboxyl ic acid d1 sodium salt [5R-(5a,6b)]-3-[[l-(3-Carboxy-l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-3-pyrrolidinylamino]methyl]-6-[(R)-l-hydroxyethyl]-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2-carbox-yl ic acid di sodium salt -155- [6R- (6a, 7b) ] -3- [ [4- (3-Carboxy- 1 -cycl opropyl -6- f 1 uoro- 1 ,4-dihydro-4-oxo-7-quinol 1nyl J-l-piperazinyl Jmethyl ]- 8-0X0-7- [ (2- thi enyl acetyl ) ami no] -5- thi a- 1 -azabicycl o- [4.2.0]oct-2-ene-2-carboxylic acid di sodium salt [6R-[6a,7b](Z)]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)- acetyl ] ami no] -3- [ [ [ [ 1 - (3-carboxy-8-chl oro- 1 -cycl opropyl -6- fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-3-pyrrolidinyl] methyl ]methyl ami no]methyl J-8-OXO-5- thi a- 1-azabi cycl o[4.2.0] oct-2-ene-2-carboxy1ic acid di sodium salt -156- [6R-(6a,7b)]-[7-[[(2-Amino-4-thiazolyl )(methoxyimino)- acetyl]amino]-2-carboxy-8-oxo-5-th a-l-azabicyclo- [4.2.0]oct-2-en-3-yl]methyl]-[[l-[3-carboxy-8-ch1oro-l- cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl]-3- pyrrolidinyl]met yl]di methyl anvnonium sodium salt [6R-(6a,7b)]-3-[[4-(3-Carboxy-l-cyclopropyl-6,8-difluoro- l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]methyl]-7- [[2(R)-[[(4-ethyl-2,3-dioxo-l-piperazinyl )carbonyl]amino] 3(S) -hydroxy- l-oxobutyl]amino]-8-oxo-5-thia-l-azabicyc1o [4.2.0]oct-2-ene-2-carboxylic acid di sodium salt Other preferred lactam-quinolones are exemplified by the following structures. -158- -159- -162- -163- -165- -167- -168- 35 -169- 35 -170- -171-  -176- Methods of Manufacture The lactam-quinolones of this invention may be made using any of a variety of synthetic techniques known in the art. Manufacture of lactam-quinolone generally involves_the_prepaa-tion of a lactam-containing moiety, a quinolone moiety and a procedure or set of procedures for linking the lactam-containing and quinolone moieties. Procedures for making a broad variety of lactam-containing moieties and quinolone moieties are well known in the art. For example, procedures for preparing lactam-containing moieties are described in the following references, all incorporated by reference herein (including articles cited within these references): Cephalosporins and Penicillins; Chemistry and Biology (E. H. Flynn, ed, 1972) Chapters 2, 3, 4, 5, 6, 7, 15 and Appendix I; Recent Advances in the Chemistry of fl-Lactam Antibiotics (A.G. Brown and S. M. Roberts, ed., 1985); Topics in Antibiotic Chemistry. Vol. 3, (P.art B) and Vol. 4, (P. Sommes, ed., 1980); Recent Advances in the Chemistry of d-lactam Antibiotics (J. Elks, ed., 1976); Structure-Activity Relationships Among the Semisynthetic Antibiotics (D. Perlman, ed, 1977); Chapts. 1, 2, 3, 4; Antibiotics. Chemotherapeutics and Antibacterial Agents for Disease Control (M. Grayson, ed, 1982); Chemistry and Biology of ^-Lactam Antibiotics, Vols 1-3 (K. B. Morin and M. Gorman, eds, 1982); 4 Medicinal Research Reviews 1-24 (1984); 8 Medicinal Research Review 393-440 (1988); 24 Anoew. Chem. Int. Ed. Engl. 180-202 (1985); 40 J. Antibiotics 182-189 (1987); European Patent Publication 266,060; 42 JL Antibiotics 993 (1989); U.S. Patent 4,742,053; 35 Chem. Pharm. Bull. 1903-1909 (1987); 32 J. Med. Chem.. 601-604 (1989); U.S. Patent 4,791,106; Japanese Patent Publication 62/158291; 31 «L Med. Chem. 1987-1993 (1988); 30 J. Med. Chem.. 514-522 (1987); 28 Tet. Let. 285-288 (1987); 28 Tet. Let. 289-292 (1987); 52 J. Org. Chem.. 4007-4013 (1987); 40 J. Antibiotics. 370-384 (1987); 40 vh Antibiotics. 1636-1639 (1987); 37 J. Antibiotics. 685-688 (1984); 23 Heterocvcles. 2255-2270; 27 Heterocvcles. 49-55; 33 Chem. Pharm. Bull. 4371-4381 (1985); 28 Tet. Let. 5103-5106 (1987); 53 J. Org. Chem.. 4154-4156 (1988); 39 J. Antibiotics. 1351-1355 -177- (1986); 59 Pure and ADD!. Chem.. 467-474 (1987); 1987 J.C.S. Chem. Comm.; 44 Tetrahedron. 3231-3240 (1988); 28 Tet. Let.. 2883-2886, (1987); 40 J. Antibiotics. 1563-1571 (1987); 33 Chem. Pharm. Bull.. 4382-4394 (1985); 37 J. Antibiotics. 57-62 (1984); U.S. Patent 4,631,150; 34 Chem. Pharm. Bull.. 999-1014 (1986) ; 52 J. Org. Chem.. 4401-4403 (1987); 39 Tetrahedron. 2505-2513 (1983); 38 J. Antibiotics. 1382-1400 (1985); European Patent Application 053,815; 40 J. Antibiotics. 1563-1571 (1987); 40 JL. Antibiotics. 1716-1732 (2987); 47 J. Org. Chem.. 5160-5167 (1981); U.S. Patent 4,777,252; U.S. Patent 4,762,922; European Patent Publication 287,734; U.S. Patent 4,762,827; European Patent Publication 282,895; European Patent Publication 282,365; U.S. Patent 4,777,673; Also, for example, procedures for preparing quinolones useful in the methods of this invention are described in the following references, all incorporated by reference herein (including articles listed within these references); 21 Progress in Drug Research. 9-104 (1977); 31 J. Med. Chem.. 503-506 (1988); 32 J. Med: Chem.. 1313-1318 (1989); 1987 Liebios Ann. Chem.. 871-879 (1987); 14 Drugs Exotl . Clin. Res.. 379-383 (1988); 31 jh Med. Chem.. 983-991 (1988); 32 J. Med. Chem.. 537-542 (1989); 78 J. Pharm. Sci.. 585-588 (1989); 26 J. Het. Chem.. (1989); 24 vL Het. Chem.. 181-185 (1987); U.S. Patent 4,599,334, 35 Chem. Pharm. Bull.. 2281-2285 (1987); 29 J. Med. Chem.. 2363-2369 (1986); 31 J. Med. Chem.. 991-1001 (1988); 25 J. Het. Chem.. 479-485 (1988); European Patent Publication 266,576; European Patent Publication 251,308, 36 Chem. Pharm. Bull.. 1223-1228 (1988); European Patent Publication 227,088; European Patent Publication 227,039; European Patent Publication 228,661; 31 «L Med. Chem.. 1586-1590 (1988); 31 J. Med. Chem.. 1598-1611 (1988); and 23 J. Med. Chem.. 1358-1363 (1980); Procedures for linking the lactam-containing moiety and quinolone moieties may vary according to the type of linking group desired. For example, the lactam-quinolones having a carbamate linking moiety may be made by the following general reaction sequence: -178- Lact-CH20H ---> Lact-CH20C(-0)-X + HN-Quin ---> Lact-CH2-0C(-0)N-Quin where X is a reactive leaving group (such as alkoxy, halo,-or N-heteroaryl ) , "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, -monocyclic beta-lactam, oxacephem, or carbacephem) and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as formation of the intermediate lactam carbonate derivative, followed by acylation of a quinolone amino functionality to form a carbamate coupled conjugate of the lactam and quinolone.

Alternatively, "reversed" dithiocarbamate conjugates can be prepared by the following sequence.

Quin-CH20H Quin-CH20C(=0)-X + H2N-C.H2-I.act ---> Lact-CH2-NHC(=0)0-CH2-Quin where X is a reactive leaving group (such as alkoxy, halo, or N-heteroaryl), "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, oxacephem, or carbacephem) and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as formation of the intermediate quinolone carbonate derivative, followed by acylation of a lactam amino functionality to form a carbamate coupled conjugate of the lactam and quinolone.

Lactam-Quinolones having a dithiocarbamate linking moiety may be made by the following general reaction sequence: CS2 + HN-Quin ---> M+-SC(=S)N-Quin + Lact-CH2-X — > Lact-CH2-SC(-S)N-Quin where X is a reactive leaving group (such as halo, a sulfonate ester, acetate, thiobenzoate or other activated hydroxy! functionality), "Lact" represents an appropriately protected -179-lactam-containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or carbacephem) , and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as formation of the intermediate quinolone dithiocarbamate salt, followed by nucleophilic displacement of the lactam X substituent to form a dithiocarbamate coupled conjugate of the lactam and quinolone.

Alternatively, "reversed" dithiocarbamate conjugates can be prepared by the following sequence.

Lact-CH2-NH2 + CS2 —► Lact-CH2-NHC(-S)S"M+ + X-CH2-Quin ---> Lact-CH2-NHC(»S)S-CH2-Quin where X is a reactive leaving group (such as halo, a sulfonate ester, or other activated hydroxyl functionality), "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, oxacephem, or carbacephem), and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as formation of the intermediate lactam, dithiocarbamate salt, followed by nucleophilic displacement of the suitable quinolone X substituent to form a "reversed" dithiocarbamate coupled conjugate of the lactam and quinolone.

Lactam-quinolones having a thiourea or urea linking moiety may be made by the following general reaction sequence: Lact-CH2-X + M+'YCN ---> HN-Quin + Lact-CH2-N»OY ---> Lact-CH2-NHC(»Y)N-Quin (thiourea: Y is sulfur; urea: Y is oxygen) where X is a reactive leaving group (such as halo, a sulfonate ester, dichloroacetate, thiobenzoate or other activated hydroxyl functionality), and Y is either 0 or S. "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or -180-carbacephem) , and "Quin" represents an appropri tely protected quinolone. The sequence can be envisioned as formation of the intermediate lactam isothiocyanate (Y » S) or isocyanate ..(Ύ-- 0), followed by reaction with the quinolone amino substituent to form a thiourea (Y = , S) or urea (Y - 0} coupled conjugate of the lactam and quinolone.

Alternatively, the thiourea or urea conjugates can be prepared by the following sequence.

Quin-NH + XC(»Y)X ---> Quin-NC(=Y)X + Lact-CH2NH2 Lact-CH2NHC(=Y)N-Quin (thiourea: Y is sulfur; urea: Y is oxygen) where X is a reactive leaving group such as halo, N-heteroaryl or activated hydroxyl functionality, and Y is either S or 0. "Lact" represents an appropriately protected lactam-containing structure (such as penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or carbacephem) , and "Quin" represents an appropri-ately protected quinolone. The sequence can be envisioned as formation of the intermediate quinolone activated thio carbamate (Y»S) or carbamate (Y=0), followed by reaction with the lactam amino substituent to form a thiourea (Y*S) or urea (Y»0) coupled conjugate of the lactam and quinolone.

Lactam-quinolones having an imine, amine or ammonium linking moiety may be made by the following general reaction sequence: Lact-CHO + HN-Quin ---> Lact-CH=N-Quin (an imine) Lact-CH2-N-Quin (an amine) ---> Lact-CH2-N+(R)-Quin (an ammonium) "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, oxacephem, or carbacephem), and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as -181-the condensation of the quinolone amine with the lactam aldehyde to form the imine coupled lactam-quinolone conjugate. Reduction of the imine yields the corresponding amine coupled lactam-quinolone conjugate. Alkylation yields the corresponding quaternary ammonium-coupled lactam-quinolone conjugate.

Alternatively, the quaternary ammonium and amine (R is H) conjugates can be prepared by the following general sequence.

Lact-CH2-X + (R)N-Quin Lact-CH2-N+(R)-Quin where X is a reactive leaving group (such as halo, a sulfonate ester, or other activated hydroxyl functionality, etc.) This sequence can be envisioned as an alkylation of a quinolone amino group with the lactam starting material to obtain the amine or quaternary ammonium coupled conjugate between the lactam and quinolone.

Lactam-quinolones having an amide linking moiety may be made by the following general reaction sequence: Lact-CH2-NH2 + X-C(=0)-Quin ---> Lact-CH2-NHC(=0)-Quin where X is a reactive leaving group (such as halo, an HOBt ester, mixed anhydride or other activated carboxyl functionality), "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, oxacephe , or carbacephem) , , and "Quin" represents an appropriately protected quinolone. The reaction can be envisioned as an acylation of the lactam amino substituent with the activated quinolone carboxyl group, to form an amide coupled conjugate of the lactam and quinolone.

Alternatively, "reversed" amide conjungates can be prepared by the following sequence.

Lact-COOH LactC(=0)-X + HN-Quin Lact-C(=0)N-Quin -182-where X is a reactive leaving group (such as halo, an HOBT ester, mixed anhydride or another activated carboxyl functionality), "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, oxacephem or carbacephem) , and "Quin" represents an appropriately protected quinolone. The reaction can be envisioned as an acylation of the quinolone amino substituent with the activated lactam carboxyl group to form a "reversed" amide coupled conjungate of the lactam and quinolone.

Lactam-quinolones having a guanidinium linking moiety may be made by the following general reaction sequence: R'C(-0)N-C-S + HN-Quin ---> H2NC(*S)N-Quin ---V RSC(-NH2+X-)N-Quin + Lct-CH2-NH2 ----> Lact-CH2-NHC(-NH2+X-)N-Quin where "Lact" represents an appropriately protected lactam-containing structure (such as penem, carbapenem, cephem, oxacephem, or carbacephem) and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as formation of the intermediate quinolone isothiouronium salt, followed by reaction with the lactam amino substituent to form a guanidinium coupled conjugate of the lactam and quinolone.

Lactam-quinolones having a heteroaryl ium linking moiety may be made by the following general reaction sequence: Lact-CH2-X + NHefQuin --- Lact-CH2-N+HefQ^n where X is a reactive leaving group (such as halo, a sulfonate ester, acetate, thiobenzoate or other activated hydroxyl functionality), "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or carbacephem) and "Quin" represents an appropriately protected quinolone that contains a -183-heteroaromatic nitrogen-containing substituent (for example, pyridine). The sequence can be envisioned as an alkylation of the quinolone heteroaromatic nitrogen containing substituent by the lactam to form the pyridini urn- type conjugate.

Lactam-quinolones having a xanthate linking moiety may be made by the following general reaction sequence: CS2 + HO-Quin M+"SC(-S)0-Quin + Lact-CH2-X ---> Lact-CH2-SC(-S)0-Quin where X is a reactive leaving group (such as halo, a sulfonate ester, acetate, thiobenzoate or other activated hydroxyl functionality), "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lacta , oxacephem, or carbacephem) , and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as formation of the intermediate quinolone xanthate salt, followed by nucleophilic displacement of the lactam X substituent to form a xanthate coupled conjugate of the lactam and quinolone.

Lactam-quinolones having a thioether, sulfoxide or sulfone linking moiety may be made by the following general reaction sequence: Lact-CH2-X + HS-Quin ---> Lact-CH2-S-Quin (a thioether) ---> Lact-CH2-S0-Quin (a sulfoxide) ---> Lact-CH2-S02-Quin (a sulfone) where X is a reactive leaving group (such as halo, a sulfonate ester, acetate, thiobenzoate or other activated hydroxyl functionality, etc.). "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or carbacephem), and "Quin" represents an appropriately protected -184- quinolone. The sequence can be envisioned as nucleophilic displacement of the lactam X group with a thio-containing quinolone to form the thioether coupled conjugate of the lactam and the quinolone. Oxidation of the thioether yields the corresponding sulfoxide conjugate. Further oxidation produces the sulfone lactam-quinolone conjugate.

Lactam-quinolones having a vinyl -thioether linking moiety may be made by the following general reaction sequence: where X is a reactive vinyl ic leaving group (such as halo, sulfonate ester, phosphate ester or other activated enolic functionality, etc.) The lactam-containing structure may be a penem, as represented above, or more may be another appropriately protected lactam-containing structure (such as carbapenem, cephenf, oxacephem, or carbacephem), and "Quin" represents an appropriately protected quinolone possessing a thiol substituent. The sequence can be envisioned as the displacement of the vinyl ic lactam X substituent to form the corresponding vinyl -thioether coupled conjugate of the lactam and quinolone.

Lactam-quinolones having a phosphonate or phosphonamide linking moiety may be made by the following general reaction sequence: (R0)3P + Lact-CH2-X ---> Lact-CH2-P0(0R)2 + HY-Quin Lact-CH2-PO(OR)-Y-Quin (phosphonate: Y is oxygen; phosphonamide: Y is nitrogen) "Lact" represents an appropriately protected lactam- containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or carbacephem) as described -185-within this invention, and "Quin" represents an appropriately protected quinolone possessing an amino or hydroxyl substituent. The sequence can be envisioned as Arbusov formation of the intermediate dialkyl quinolone phosphonate followed by an exchange with the quinolone hydroxyl group to form the corresponding phosphonate (Y - 0) coupled conjugate, or the quinolone amino group forming the phosphonamide (Y - N) coupled conjugate of the lactam and quinolone.

Lactam-quinolones having a phosphate or phosphoramide linking moiety may be made by the following general reaction sequence: (R0)2P0-C1 + HY-Quin --> (R0)2P0-Y-Quin + Lact-CH2-0H Lact-CH2-0-P0(0R)-Y-Quin (phosphate: Y is oxygen; phosphoramide: Y is nitrogen) "Lact" represents an appropriately protected lactam-containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or carbacephem) , and "Quin" represents an appropriately protected quinolone possessing an amino or hydroxyl substituent. The sequence can be envisioned as formation of the intermediate dialkyl quinolone phosphate (Y = 0) or phosphoramide (Y » N) followed by an ester exchange with the lactam hydroxyl group to form the corresponding phosphate (Y = 0) and phosphoramide (Y = N) coupled conjugates of the lactam and quinolone.

Lactam-quinolones having an isothiouronium linking group may be made by the following general reaction sequence: RC(«0)N»OS + HN-Quin H2NC(»S)N-Quin + Lact-CH2-X ---> Lact-CH2-SC(»NH2+X-)N-Quin where X is a reactive leaving group (such as halo, a sulfonate ester, acetate, thiobenzoate or other activated hydroxyl functionality), Lact represents an appropriately protected -186-lactam-containing structure (such as a penem, carbapenem, cephem, monocyclic beta-lactam, oxacephem, or carbacephem, and "Quin" represents an appropriately protected quinolone. The sequence can be envisioned as formation of the intermediate quinolone thiourea, followed by nucleophilic displacement of the lactam X substituent to form a isothiouronium coupled conjugate of the lactam and quinolone.

In the reaction sequences described herein, certain functional groups contained in the Lact and Quin structures, (such as carboxyl, hydroxy1, and amino groups) may need to be blocked in order to prevent undesired competing side reactions from occurring with X. Suitable protecting groups for carboxyl substituents include esters. Protecting groups for hydroxyl substituents include ethers, esters, and carbonates; and protecting groups for amino substituents include carbamates, and amides. If various protecting groups are employed, then appropriate deprotecting chemistry, that will not decompose the coupled conjugate, may be required to obtain antibacterially active products.

Compositions The compositions of this invention comprise: (a) a safe and effective amount of a lactam-quinolone; and (b) a pharmaceutically-acceptable carrier.

A "safe and effective amount" of a lactam-quinolone is an amount that is effective, to inhibit microbial growth at the site of an infection to be treated in a human or lower animal subject, without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the duration of treatment, the nature of concurrent therapy (if any), the specific dosage form to be used, the carrier employed, the solubility of the lactam-quinolone therein, and the dosage regimen desired for the composition. -187- The compositions of this invention are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition of this invention containing an amount of a lactam-quinolone that is suitable for administration to a human or lower animal subject, in a single dose, according to good medical practice. These compositions preferably contain fom ~ about 30 mg to about 20,000 mg, more preferably from about 50 mg (milligrams) to about 7000 mg, more preferably from about 500 mg to about 3500 mg, of a lactam-quinolone.

The compositions of this invention may be in any of a variety of forms, suitable (for example) for oral, rectal, topical or parenteral administration. Depending upon the particular route of administration desired, a variety of pharmaceutically-acceptable carriers well-known in the art may be used. These include solid or liquid fillers, diluents, hydrotropes, surface-active agents, and encapsulating substances. Optional pharmaceutically-active materials may be included, which do not substantially interfere with the antimicrobial activity of the lactam-quinolone. The amount of carrier employed in conjunction with the lactam-quinolone is sufficient to provide a practical quantity of material for administration per unit dose of the lactam-quinolone. Techniques and compositions for making dosage forms useful in the methods of this invention are described in the following references, all incorporated by reference herein: 7 Modern Pharmaceutics. Chapters 9 and 10 (Banker & Rhodes, editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms 2d Edition (1976).

In particular, pharmaceutically-acceptable carriers for systemic administration include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffer solutions, emulsifiers, isotonic saline, and pyrogen-free water. Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil. Preferably, the pharmaceutically-acceptable carrier, in -188-compositions for parenteral administration, comprises at least about 90% by weight by the total composition.

Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. These oral forms comprise a safe and effective amount, usually at least about 5%, and preferably from about 25% to about 50%, of the lactam-quinolone. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow- inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents. Preferred carriers for oral administration include gelatin, propylene glycol, cottonseed oil and sesame oil.

The compositions of this invention can also be administered topically to a subject, i.e., by the direct laying on or spreading of the composition on the epidermal or epithelial tissue of the subject. Such compositions include, for example, lotions, creams, solutions, gels and solids. These topical compositions preferably comprise a safe and effective amount, usually at least about 0.1%, and preferably from about 1% to about 5%, of the lactam-quinolone. Suitable carriers for topical administration preferably remain in place on the skin as a continuous film, and resist being removed by perspiration or immersion in water. Generally, the carrier is organic in nature and capable of having dispersed or dissolved therein the lactam-quinolone. The carrier may include pharmaceutically-acceptable emolients, emulsifiers, thickening agents, and solvents. -189- Methods of Administration This invention also provides methods of treating or preventing an infectious disorder in a human or other animal subject, by administering a safe and effective IrniourfT of a lactam-quinolone to said subject. As used herein, an "infectious^ disorder" is any disorder characterized by the presence of a microbial infection. Preferred methods of this invention are for the treatment of bacterial infections. Such infectious disorders include (for example) central nervous system infections, external ear infections, infections of the middle ear (such as acute otitis media), infections of the cranial sinuses, eye infections, infections of the oral cavity (such as infections of the teeth, gums and mucosa), upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients (such as patients receiving cancer chemotherapy, or organ transplant patients).

The lactam-quinolones and compositions of this invention can be administered topically or systemically. Systemic application includes any method of introducing the lactam-quinolone into the tissues of the body, e.g., intrathecal, epidural, intramuscular, transdermal, intravenous, intraperitoneal, subcutaneous, sublingual, rectal, and oral administration. The specific dosage of antimicrobial to be administered, as well as the duration of treatment, are mutually dependent. The dosage and treatment regimen will also depend upon such factors as the specific lactam-quinolone used, the resistance pattern of the infecting organism to the lactam-quinolone used, the ability of the l ctam-quinolone to reach minimum inhibitory concentrations at the site of the infection, the nature and extent of other infections (if any), the personal attributes of the subject (such as weight), compliance with the treatment regimen, and the presence and severity of any side effects of the treatment. -190- Typically, for a human adult (weighing approximately 70 kilograms), from about 75 mg to about 30,000 mg, more preferably from about 100 mg to about 20,000 mg, more preferably from about 500 mg to about 3500 mg, of lactam-quinolone are administered per day. Treatment regimens preferably extend from about 1 to about 56 days, preferably from about 7 to about 28 days, in duration. Prophylactic regimens (such as avoidance of opportunistic infections in immunocompromised patients) may extend 6 months, or longer, according to good medical practice.

A preferred method of parenteral administration is through intramuscu r injection. As is known and practiced in the art, all formulations for parenteral administration must be sterile. For mammals, especially humans, (assuming an approximate body weight of 70 kilograms) individual doses of from about 100 mg to about 7000 mg, preferably from about 500 mg to about 3500 mg, are acceptable.

A preferred method of systemic administration is oral. Individual doses of from about 100 mg to about 2500 mg, preferably from about 250 mg to about 1000 mg are preferred.

Topical administration can be used to deliver the lactam-quinolone systemical , or to treat a local infection. The amounts of lactam-quinolone to be topically administered depends upon such factors as skin sensitivity, type and location of the tissue to be treated, the composition and carrier (if any) to be administered, the particular lactam-quinolone to be administered, as well as the particular disorder to be treated and the extent to which systemic (as distinguished from local) effects are desired.

The following non-limiting examples illustrate the compounds, compositions, processes, and uses of the present invention.

EXAMPLE 1 [6R-[6a,7b]]-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl)-l-piperazinyl]carbonyloxy]methyl ]-8- -191- oxo-7-[(2-thienylacety1)amino]-5-thia-l-azabicyclo[4.2.0]oct-2- ene-2-carboxyl ic acid disodium salt, according to this invention, is made by the following general reaction sequence.

Approximately 28 ml (milliliters) of IN NaOH is slowly added, with stirring, to a suspension of approximately 7.5 g (grams) of 7-aminocephalosporanic acid in methanol, while maintaining the temperature at approximately -5°C (23*F). An additional portion of approximately 28 ml IN NaOH is added dropwise over 7 minutes at approximately 4*C (40*F) and the -192-solutlon stirred for 30 minutes. Acetone is added to the reaction mixture. Approximately 4.4 g of 2-thiopheneacetyl chloride is then added dropwise over 30 minutes. The reaction mixture is washed with ethyl acetate and the aqueous phase acidified with concentrated HCl. The reaction product is extracted with ethyl acetate, and filtered.

Approximately 0.63 g of this product (I) is dissolved in ethyl acetate and THF (tetrahydrofuran) . A solution of approximately 0.38 g of diphenyldiazomethane in ethyl acetate is then added, maintaining the temperature at approximately 5*C (41*F). The mixture is stirred for approximately 4 hours. The mixture is then concentrated to dryness, and THF is added, with removal of some insoluble material by filtration. The filtrate is concentrated to a small volume to yield crystals, and ethyl acetate added. The mixture is cooled in an ice bath for approximately 1.5 hours and the product (II) collected by filtration.

A solution of approximately 0.4 g of Product (II), in dichloromethane, is cooled in an ice bath and approximately 0.112 ml 1,2,2,2,-tetrachloroethyl chloroformate is added, followed by the dropwise addition of approximately 0.067 ml pyridine. The reaction is stirred for 35 minutes, then diluted with dichloromethane and washed with ice cold 0.5N HCl and cold water. The organic phase is dried over Na2S04, filtered, and concentrated to dryness, yielding product (III).

A mixture of approximately 0.24 g ciprofloxacin (IV) in water and NaHC03 is heated to approximately 45'C (113*F), and stirred for approximately 30 minutes. To this mixture, in a water bath at approximately 19'C (66'F), is added a solution of approximately 0.52 g of product (III) in dioxane. The mixture is stirred at approximately 22*C (44*F) for approximately 1.5 hours, diluted with ether and water and separated. The aqueous phase i cooled to approximately 5'C (41'F), chloroform is added, and the mixture is acidified with HCl. The chloroform extract is washed with 0.5 N HCl and water, then dried over a2S04, filtered and concentrated to dryness, yielding product (V). -193- To a solution of approximately 0.31 g of Product (VI), in anlsole, 1s added approximately 7 ml of trifluoroacetic acid, dropwise at approximately -15*C (5*F). The solution is stirred at ambient temperature for approximately 20 minutes, and concentrated to dryness in vacuo. The residue is stirred for approximately 2 hours in ether, and the product is collected by filtration. This free acid is dissolved in water, followed by addition of NaHC03, with stirring, for approximately 40 minutes. The solution is filtered, and washed with a small amount of OMF to dissolve some solid. The filtrate is then concentrated In vacuo and the solid dissolved in water. The solution is diluted with about 2.5 volumes of acetone and the final product (V) collected by filtration.

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-an»inopyrro11d1nyl)-l-cyclopropyl-6,8-d1fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al . , 31 J. Med. Chem. 983 (1988)) -194- uslng the qulnolone 7-(3-aminopyrrolid1nyl)-8-chloro-l-cyclopropy1-6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) using the qulnolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) -195- using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) except using the quinolone l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7- (l-piperazinyl)-3-quinoline carboxylic acid (prepared according to H. Koga, et al?, 23 J. Med. Chem. 1358 (1980)) using the naphthyridinone 7-(3-aminopyrrolidiny1)-l-(2,4- di fluorophenyl )-6-fluoro-l, 4-dihydro-4-oxo-l,8-naphthyridine-3- carboxylic acid (prepared according to D.T.W. Chu, et al., 29 J. Med. Chem. 2363 (1986)) -196- using the quinolone 6-fluoro-l,4-dihydro-l-methylamino-7-(4-methyl-l-piperazinyl)-4-oxo-3-quinoline carboxylic acid (prepared according to M.P. Wentland, et al., 27 J. Med. Chem. 1103 (1984)) using the quinolone 6-fluoro-l-(4-fluorophenyl )-l ,4-dihydro-4-oxo-7-(l-piperazinyl)-3-quinoline carboxylic acid (prepared according to D.T.W. Chu, et al., 28 J. Med. Chem. 1558 (1985)) -197- using the quinolone 9-fluoro-4,7-dihydro-3-methyl-10-(l- piperazinyl)-7-oxo-2H-pyrido[l,2,3-de]-l,4-benzoxazine-6- carboxylic acid (prepared according to I. Haakawa, et al., 32 Chem. Pharm. Bull.4907 (1984)) using the quinolone 9-cyclopropyl-6-fluoro-2,3,4,9-tetrahydro-7- (l-piperazinyl)isothiazolo[5,4-b]quinol ine-3,4-dione (prepared according to D.T.W. Chu, European Patent Application 227,088) using the naphthyridinone 7-(2,5-diazabicyc1o[2.2. l]heptan-2-yl )- l-(l,l-dimethylethyl)-6-fluoro-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid (prepared according to A. Weber, et al., European Patent Application 266576) -198- using the beta-lactam alpha-(4-hydroxyphenyl)-2-oxo-3-[(phenoxyacetyl)aminoj-l-azetidineacetic acid (prepared according to M. Hashimoto, et al., U.S. Patent 4,207,234) using the beta-lactam 3-(2-hydroxyethylidene)-7-oxo-4-oxa azabicyclo[3.2.0] heptane-2-carboxyl ic acid (prepared accord to P.H. Bentley, et al., Tet. Let. 1889 (1979)) -199- using the beta-lactam 3-(hydroxymethyl )-8-oxo-7-[[(2-thiophene) acetyl] amino]-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (prepared according to B.G. Christensen, et al., German Offen. 235S209) using the beta-lactam 3-(hydroxymethyl)-8-oxo-7-[(phenoxyacetyl) amino]-4-oxa-l-azabicyclo(4.2.0]oct-2-ene-2-carboxylic acid (prepared according to M. Menard, German Offen. 2615693) using the beta-lactam 3-(hydroxymethyl)-7-methoxy-8-oxo-7-[[(2-thlophene) acetyl ]amino]-5-oxa-l -azabicyclo(4.2.0]oct-2-ene-2-carboxylic acid (prepared according to B.G. Christensen, German Offen. 2355209).

EXAMPLE 2 According to the general procedure of Example 1, the following lactam-quinolone is made: except using the beta-lactam 3-(hydroxymethyl)-8-oxo-5-thia-7-[[[[[(2-triphenylmethyl )aminoj-4-thiazolyl]methoximino]acetyl] amino]-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (prepared according to S. Kishimoto, et al., European Patent Application 249,170) The following other 1actam-quinolones are made by the general procedure of this Example with substantially similar results. using the quinolone 6-fluoro-l-(4-fluorophenyl)-l,4-dihydro-4-oxo-7-(l-piperazinyl)-3-quinoline carboxylic acid (prepared according to O.T. . Chu, et al., 28 J. Med. Chem. 1558 (1985)) using the quinolone 9-fluoro-4,7-dihydro-3-methy]-10-(l-piperazinyl)-7-oxo-2H-pyrido[l,2,3-de]-l,4-benzoxaz1ne-6-carboxylic acid (prepared according to I. Hayakawa, et a!., 32 Chem. Pharm. Bull.4907 (1984)) using the naphthyridinone 7-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-l-(l,l-dimethylethyl)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyri-dine-3-carboxylic acid (prepared according to A. Weber, et al., European Patent Application 266576) using the quinolone 9-cyclopropyl-6-fluoro-2,3,4,9-tetrahydro-7-(1-piperazinyl )isothiazolo[5,4-b]quinol1ne-3,4-dione (prepared according to O.T.W. Chu, European Patent Application 227,088) using the quinolone l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7-(l-piperazinyl)-3-quino!ine carboxylic acid (prepared according to H. Koga, et al., 23 J. Med. Chem. 1358 (1980)) -203- using the quinolone 6-f)uoro-l,4-dihydro-l-raethylamino-7-(4- methyl-l-piperazinyl)-4-oxo-3-quinoline carboxylic acid (prepared according to M.P. Wentland, et al., 27 J. Med. Chem. 1103 (1984)) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-{2,4-dif1uorophenyl)-6-f1uoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (prepared according to O.T.W. Chu, et al., 29 J. Med. Chem.2363 (1986)) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-dif1uoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) using the quinolone 7-(3-aminopyrrolidinyl)-8-chloro-l- cyclopropy1-6-fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. CjejL.983 (1988)) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinoline carboxyl ic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) using the quinolone 7-(3-aminopyrrolid1nyl)-8-chloro-l-cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxyl ic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) ■219- using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-f1uoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) -220- using the quinolone l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7-(l- p1perazinyl)-3-quinoline carboxylic acid (prepared according to H. oga, et al., 23 J. Med. Chem. 1358 (1980)) using the naphthyridinone 7-(3-aminopyrrolid1nyl)-l-(2,4 dif1uorophenyl)-6-f1uoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxyl c acid (prepared according to D.T.W. Chu, et al. 29 J. Med. Chem.2363 (1986)) using the quinolone 6-fluoro-l,4-dihydro-l-methylamino-7-(4-methyl-l-piperazinyl)-4-oxo-3-quino1ine carboxylic acid (prepared according to M.P. Wentland, et al., 27 J. Med. Chem. 1103 (1984)) -221- using the quinolone 6-fluoro-l-(4-fluorophenyl)-l,4-dihydro-4- oxo-7-(l-piperazinyl)-3-quinoline carboxylic acid (prepared according to D.T.W. Chu, et al., 28 J. Med. Chem. 1558 (1985)) using the quinolone 9-fluoro-4»7-dihydro-3-methyl-10-(l-piperazinyl)-7-oxo-2H-pyrido[l,2,3-de]-l,4-benzoxazine-6-carboxylic acid (prepared according to I. Hayakawa, et al., 32 Chem. Pharm. Bull.4907 (1984)) -222- using the quinoione 9-cyclopropyl-6-fluoro-2,3,4,9-tetrahydro-7- (l-piperazinyl)isotbiazolo[5,4-b]quinol ine-3,4-dione (prepared according to O.T.W. Chu, European Patent Application 227,088) using the naphthyridinone 7-(2,5-diazabicyclo[2.2.1]heptan-2-yl)- 1-(1,1-dimethylethyl)-6-fluoro-1, -dihydro-4-oxo-1,8-naphthyri- dine-3- carboxylic acid (prepared according to A. Weber, et al., European Patent Application 266576) EXAMLE 9 According to the general procedure of Example 8, the following lactam-quinolone is made: using the beta-lactam ally! 6- (1,1-dimethylethyl )dimethyl silyl]oxy] ethyl]-3-[(2-hydroxyethyl)thio]-7-oxo-4-thia-l- azab1cydo[3.2.0]hept-2-ene-2-carboxylate (prepared according to E. Pe rone, et al., European Patent Application 199,490) The following other lactam-quinolones are made by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) using the quinolone 7-(3-aminopyrrol dinyl)-8-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) -224- using the quinolone 7-(3-aminopyrrolidinyl-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-fluoro-l ,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxyl ic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chew. 983 (1988)) EXAM LE \0 According to the general procedure of Example 8, the following lactam-quinolone is made: using the beta- lactam allyl 6-[l-[[(l,l-dimethylethyl)dimethyl s i 1 yl ] oxy ] ethyl ] -3 - ( hydroxymethy 1 ) -4 -methyl - 7 - oxo - 1 - azab i cycl o [3.2.0]hept-2-ene-2-carboxylate (prepared according to T.N. Salzmann, et al., European Patent Application 184,844) The following other lactam-quinolones are made by the general procedure of this Example, with substantially similar results. -225- uslng the quinolone 7- (3- ami nopyrrol Idinyl) -1-cycl opropyl -6,8- difluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chern. 983 (1988)) using the quinolone 7- (3- ami nopyrrol idinyl )-8-chloro-l- cycl opropyl -6- f 1 uoro- 1 , 4-di hydro-4-oxo-3-qui nol i ne carboxyl i c acid (prepared according to J. P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) -226- using the quinolone 7-(3-aminopyrrolid1nyl-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) using the naphthyrldlnone 7-(3-am1nopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyrid1ne-3-carboxyl1c acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem.983 (1988)) EXAHPE U [4 ,5S,6S]-3-[2-[4-(3-Carboxy-1-cyclopropyl-6-f1 oro-l,4-dihydro-4-oxo-7-quinol1yl)-1-piperazinyljcarbonyloxy]ethyl thio]-6[(R)-l-hydroxyethyl]-4-methyl-7-oxo-l-azabicyclo[3.2.0] hept-2-ene-2-carboxyl ic acid sodium salts according to this Approximately 7.2 g of 2-(t-butyldimethylsilyloxy)-l-methylcarbaceph-2-em (prepared according to 53 J. Org. Chem., 4154 (1988)), 1.6 g NaHC03, 36 ml of 2-(trimethylsilyl)ethanol , and 1 ml of a 0.1% solution of Sudan III in CH2CI2 are combined in approximately 300 ml of -228- CH2CI2. A stream of argon is bubbled through the solution while cooling to approximately -784C. Ozone is bubbled through the solution until the red color disappears, then argon is bubbled through the solution as it is allowed to warm to room temperature. Approximately 7.1 ml of triethylamine and 9.6 ml of acetic anhydride are added to the solution and it is allowed to stir for approximately 16 hours at room temperature. The mixture is diluted with approximately 400 ml of saturated aqueous ammonium chloride and the aqueous phase is extracted twice with approximately 400 ml of ether. The combined organic layers are washed with approximately 400 ml of saturated aqueous sodium chloride then dried over gS04. After filtration and concentration most of the 2-(trimethylsilyl )ethanol is removed by short path distillation at approximately 60*C/0.1 mmHg. The resulting residue is dissolved in approximately 600 ml of CH2CI2 under an argon atmosphere and approximately 8.2 g of 2,2'-dipyridyl disulfide and 9.8 g of triphenylphosphine are added. After approximately 5 hours at room temperature the solution is concentrated and purified by chromatography on silica gel to give the product II as a mixture of isomers at the position alpha to the thioester carbonyl .

A solution containing approximately 3.0 g of product II in approximately 120 ml of tetrahydrofuran is cooled to approximately -75'C under an argon atmosphere. Approximately 10.0 ml of a 1.0 M solution of sodium bis(trimethylsilyl )amide in tetrahydrofuran is added dropwise over approximately 7 minutes while maintaining the reaction temperature below approximately -70*C. Approximately 3 minutes after completion of the addition approximately 30 ml of 1 M HC1 is added, the mixture is further diluted with approximately 180 ml of water, and extracted with approximately 40 ml of 1:1 ether:petroleum ether six times. The combined organic layers are washed with approximately 100 ml of water, then approximately 100 ml of saturated aqueous sodium chloride, and dried over MgS0 . Concentration of the solution provides product III as a mixture of isomers at the 4-position. -229- Approximately 0.90 ml of diphenyl chlorophosphate and 0.80 ml of Ν,Ν-diisopropylethylamine are added simultaneously in a dropwlse fashion to a cold solution (ice bath) of approximately 2.8 g of product III dissolved in approximately 30 ml of dry acetonitrile under an argon atmosphere. The ice bath is removed and the mixture is allowed to stir approximately 30 minutes at room temperature before concentrating and purifying by chromatography on silica gel to provide product IV as a single isomer.

A solution containing approximately 1.3 g of product IV in approximately 4.5 ml of dry acetonitrile is cooled in an ice bath under an argon atmosphere. Approximately 0.53 ml of Ν,Ν-diisopropylethylamine is added followed by the dropwise addition of approximately 0.20 ml of 2-mercaptoethanol . After stirring for approximately 10 minutes the ice bath is removed and the solution is stirred approximately 3 hours longer at room temperature. Concentration of the solution, followed by chromatography on silica gel, provides product V.

A solution containing approximately 0.15 g of product V in approximately 1.8 ml of dry tetrahydrofuran is cooled in an ice bath under an argon atmosphere. Approximately 0.061 ml of 1,2,2,2-tetrachloroethyl chloroformate is added, followed by the dropwise addition of approximately 0.028 ml of pyridine. After stirring approximately 1 hour the mixture is transferred into a mixture containing approximately 0.126 g of ciprofloxacin (VI) and 0.159 g of NaHC03 in approximately 2.5 ml of water which had been stirred approximately 1 hour at room temperature. After stirring approximately 2.5 hours at room temperature the mixture is poured into approximately 15 ml of chloroform and 15 ml of cold 0.1 M HC1. The aqueous phase is extracted with chloroform again, and the combined chloroform layers are washed successively with cold 0.1 H HC1 , water, and saturated aqueous sodium chloride. After drying over a2S0 and concentrating the resulting residue is treated with approximately 10 ml of ether. -230- The resulting precipitate is washed twice with approximately 5 ml of ether and dried in vacuo to provide product VII.

Approximately 0.11 g of product VIII and 0..41— g tetra-n-butylammonium fluoride trihydrate are stirred together in approximately 0.35 ml of dimethylformamide at room temperature for approximately 16 hours. Approximately 0.20 g of NaHC.03 is added and the mixture is eiuted through a OowexR 50X4 (Na cycle) column with deionized water. The appropriate fractions are partially concentrated in vacuo, then lyophilized to give the final product (VIII).

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar resuts. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-d1hydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) -231- using the quinolone 7-(3-aminopyrrol idinyl)-8-chloro-l- cyclopropy1 -6-f1uoro-1 ,4-dihydro-4-oxo-3-qu1noline carboxy1ic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Hed. Chem. 983 (1988)) using the naphthyridinone 7-(3-aminopyrrol1dinyl)-l-cyclopropyl-6.-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J.P. Sanchez, et al., 31 J. Med. Chem. 983 (1988)) -232- EXAMPLE 12 [2S-(2a,3^,5e,6^)]-3-([[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl )-l-piperazinyl IcarbonyloxyJmethylJ - methyl -7-oxo-6-[(phenoxyacetyl )amino]-4-thia-l-azabicyclo [3.2,0]heptane-2-carboxyl ic Acid 01 sodium Salt -233- A mixture of approximately 3.8 g of [2S- (2a, 30,5a, 60) ] -3- (hydroxymethyl ) -3-methyl -7-oxo-6- [ (phenoxy acetyl )am1no] -4- thi a- 1 - azab1cyclo[3.2.0]heptane-2-carboxyl 1c add 4-n1trobenzyl ester I (prepared according to J. Org. Chem. 1979, 44(17) , 3084) and 20 ml of CH2CI2 is cooled n an Ice bath and approximately 1.1 ml of 1 ,2,2,2-tetrachloroethyl chloroformate 1s added, followed by the dropwi se addition of approximately 0.67 ml of pyridine. The reaction 1s stirred for approximately 40 minutes, then diluted with CH2CI 2 and washed with Ice cold 0.5N HC1 and cold water. The organic phase 1s dried over a2S04, fi l tered and Is concentrated to dryness to give I I . To a mixture of approxi mately 1.2 g of ciprofloxacin II I and 1.8 g of NaHC.03 In 50 ml of water s added a solution of approximately 2.5 g of II in 75 ml of dloxane. The mixture 1s stirred at room temperature for approximately 1.5 hours, diluted wi th ether and water and separated. The aqueous phase is cooled to approximately 5*C, CHCI3 is added and the mixture 1s acidi fied with IN HC1 . The CHCI3 extract is washed with 0.5N HC1 and water, then 1s dried over a2S0 , fi l tered and I s concentrated to dryness to give IV. A mixture of approximately 2.2 g of IV, 200 ml of 80% THF/H20 and 2.2 g of 10% Pd/C 1 s subjected to hydrogenation for approximately one hour. A solution of approximately 0.51 g of NaHC.03 in 125 ml of water is added and the catalyst is removed by fi ltration. The filtrate i s concentrated to dryness and the residue is puri fied by C-18 reverse phase chromatography to afford the title compound V.

The fol lowing other l actam-quinolones are al so prepared by the general procedure of thi s Example and Examples 2-12, with substantial ly simil ar resul ts .

EXAMPLE 13 [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]thioxomethylthio]meth-yl3-8-0X0-7-[(2-thienylacetyl )amino]-5-thia-l-azabicyclo[4.2.0]-oct-2-ene-2-carboxyl1c acid disodium salt, according to this invention, is made by the following general reaction sequence. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-i[4-(roercapto)thioxo- methyl]-l-piperazinyl]-4-oxo-3-quinoline carboxylic acid disodium salt is first made by suspending approximately 5.0 g of ciprofloxacin in approximately 7.5 ml of 4N sodium hydroxide and water, and cooling to approximately 4*C (40*F). Approximately 0.9 ml of carbon disulfide is added dropwise. The reaction is then stirred for approximately 140 minutes. A second equivalent of carbon disulfide (approximately 0.9 ml) is added dropwise. The reaction is then allowed to slowly warm to room temperature (approximately 68*F, 20*C), as it Is stirred for approximately 12 hours. Acetone Is added to precipitate a solid product (I), which is collected by filtration, washed with acetone, and dried.

Approximately 1.5 g of this product is then mixed with approximately 1.4 g of cephalothin sodium salt, in water, and stirred at approximately 42*C (107*F) for 24 hours. A small volume of acetone Is added and the precipitate isolated by filtration. The solid is washed with acetone and air dried, to yield product (II).

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. -241- using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8- difluoro-l,4-d1hydro-4-oxo-3-quinoline carboxylic add (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-l-chloro-l-cyclopropyl-6-fluoro-l,4-d1hydro-4-oxo-3-qu1noline carboxyl ic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolid1nyl)-l-cyclopropyl-6-f1uoro-l,4-d1hydro-4-oxo-3-quinol1ne carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -242- using the naphthyridinone 7-(3-aminopyrrol1dinyl)-l-cyc1opropyl- 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxy1ic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7-(l- piperazinyl)-3- quinoline carboxylic acid (prepared according to H. Koga, et. al., J. Med. Chem., 1980, 23, 1358) -243- using the naphthyridinone 7-(3-aminopyrrolid1nyl)-l-(2,4 dtfl uorophenyl ) -6-f 1 uoro- 1 , 4-dihydro-4-oxo- 1 ,8-naphthyridi ne-3- carboxylic acid (prepared according to D.T.W. Chu, et. al,, J Med. Chem., 1986, 29, 2363) " ----- - using the quinolone 6-fluoro-l,4-dihydro-l-methylamino-7-(4- methyl-l-piperazinyl)-4-oxo-3-quinoline carboxylic acid (prepared according to M.P. Wentland, et. al., J. Med. Chem., 1984, 27, 1103) using the quinolone 6-fluoro-l-(4-fluorophenyl)-l,4-dihydro-4- oxo-7-(l-piperaziny1)-3-quinoline carboxylic acid (prepared according to D.T.W. Chu, et. al., J. Med. Chem., 1985, 28, 1558) -244- using the quinolone 9-fluoro-4,7-dihydro-3-methyl-10-(l-piperazinyl)-7-oxo-2H-pyr1do[l,2,3-de]-l,4-benzoxazine-6-carboxylic acid (prepared according to I. Hayakawa, et. al., Chem. Pharm. Bull., 1984, 32, 4907) using the quinolone 9-cyclopropyl-6-fluoro-2,3,4,9-tetrahydro-7-(l-piperazinyl)isothiazolo[5,4-b]quinoline-3,4-dione (prepared according to D.T.W. Chu, EP 227,088) -245- uslng the naphthyridinone 7-(2,5-d1azabicyclo[2.2. l]heptan- 2-yl)-l-(l,l-d1methylethyl)-6-fluoro-l,4-dihydro-4-oxo-l,8- naphthyridine-3- carboxylic acid (prepared according to A. Weber, et. al., EP 266576) using the beta-lactam 3-(acety1oxymethyl)-7-[[(2-amino-4-thiazo1yl)[[(3,4-dihydroxyphenyl)carbonyl]amino]acetyl]amino]-8-oxo-5-thia-l-azabicyclo [4.2.0]oct-2-ene-2-carboxy1 ic acid (prepared according to T. Naito, EP 115,820) using the beta-lactam 3-(acetyloxymethyl )-7-[[(2-amino-4-th1azoly1)[carboxy (3,4-dihydroxypheny1)methoxyimino]acety ] amino]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl1c acid (prepared according to H. Ohnishi, et. al., PCT Int. Appl. WO 86/5786) -246- EXAMPLE 14 According to the general procedure of Example 13, the following lactam-quinolone is made: using the beta-lactam 3-(acetyloxymethyl)-8-oxo-7-[(4-pyridylthioacetyl ) amino]-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (prepared according to S. Crast, et. al . , J. Med. Chem., 1973, 16, 1413).

The following other lactam-quinolones are made by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrol idinyl )-l-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quino1 ine carboxyl ic acid (prepared according to J. . Sanchez, et. al., J. Med. Chent., 1988, 31, 983) using the quinolone 7-(3-aminopyrrol idinyl)-l-cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxyl ic acid (prepared according to J. . Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -248- using the naphthyridinone 7-(3-aminopyrrol idinyl)-l-cyclopropyl - 6-fluoro-l ,4-dihydro-4-oxo-l ,8-naphthyridine-3-carboxyl ic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) EXAMPLE 15 According to the general procedure of Example 13, the following lactam-quinolone is made: using the beta-lactam 3-(acetyloxymethyl )-7-[[[[[(R)-4-ethyl -2,3-dioxo-l-piperazinyl Jcarbonyl ]amino] (4-hydroxyphenyl )acetyl ] amino]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (prepared according to I. Saikawa, et. al . , Ger. Offen. OE 2600880) The following other lactam-quinolones are made by the general procedure of this Example, with substantially similar results. -249- using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8- difluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-l-chloro-l- cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -250- using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) EXAMPLE 16 According to the general procedure of Example 13, the following lactam-quinolone is made: using the beta-lactam 3- ( acetyl oxymethyl )-7-[[(2-amino-4-thiazo1yl)acetyl] amino]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (prepared according to J. Org. Chem., 1970, 35, 2430) The following other lactam-quinolones are made by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrol idinyl )-l-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -252- using the quinolone 7-(3-aminopyrrol idinyl)-! -cyclopropyl -6- fluoro-l,4-dihydro-4-oxo-3-quino1ine carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrol idinyl )-l -cyclopropyl - 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxyl7c acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) EXAMPLE 17 According to the general procedure of Example 13, the following lactam-quinolone is made: using the beta-lactam 3- (acetyl oxymethyl )-8-oxo-7- [(phenoxyacetyl)aminoJ-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid (prepared according to R.B. Morin, et. al., J. Am. Chem. Soc, 1969, 91, 1401) The following other lactam-quinolones are made by the general procedure of this Example, with substantially similar results. -253- using the quinolone 7-(3-aminopyrrol idinyl )-l-cyclopropyl -6,8-difluoro-1 ,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrol idinyl )-l-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J. P. Sanchez, et. al . , J. Med. Chem., 1988, 31, 983) -254- using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) EXAMPLE 18 [6R-[6a,79(Z)]]-7-[[[(2-Amino-4-thiazolyl)methoxyimino]acetyl ]araino]-3-[[[[4-(3-carboxy-l-cyclopropyl -6-fluoro-l ,4-dihydro- 4-oxo-7-quinolinyl )-l-piperazinyl ]thioxomethyl ]thio]methyl ]-8- oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodi- um salt, according to this invention, is made by the following general reaction sequence. -255- Approximately 11.4 g of 1-hydroxybenzotriazole hydrate is dissolved in approximately 90 ml of Ν,Ν-dimethylacetamide (DMAC). Approximately 12.6 ml of triethylamine is added and the solution cooled in an ice/acetone bath. Approximately 6.3 ml of methanesulfonyl chloride in DMAC is added dropwise at approximately 0*C (32*F) over approximately 25 minutes. The reaction is stirred for an additional 90 minutes. Approximately 15 g of 2-amino-2-(methoxyimino)-4-thiazoleacetic acid is then added. After the addition is complete, approximately 11.3 ml of triethylamine is added dropwise, at approximately 5*C (41 *F) over approximately 30 minutes. The reaction is then stirred for an additional 105 minutes. Water is added dropwise over 20 minutes and the temperature increased to approximately 20*C (68'F). The suspension is stirred for 10 minutes, then a precipitate collected by filtration, washed with large volumes of water, and dried to yield product (I).

Approximately 8 g of 7-aminocephalosporanic acid is suspended in 50% aqueous acetone and cooled in an ice bath. Approximately 3.7 ml of triethylamine is added slowly. Approximately 11 g of product (I) is added, at approximately 2'C (35*F). Solutions of saturated aqueous potassium phosphate monobasic (pH 4.5) and 45% aqueous potassium phosphate dibasic -256- (pH 10) are added as necessary to maintain a pH of approximately 7.5. After the addition of product (I) is complete, the mixture is stirred at approximately 2*C (35*F) approximately 2 hours, and stirred at room temperature for approximately 3 hours. The acetone is removed by evaporation and the aqueous solution cooled in ice. The solution is then layered with ethyl acetate and adjusted to approximately pH 2.3 with concentrated hydrochloric acid. The layers are separated and the aqueous phase extracted with ethyl acetate. The organic extracts are combined and evaporated. The residue is stirred in ether and collected by filtration yielding product (II).

Approximately 1.5 g of product (II) is suspended in water (24 ml), and approximately 0.27 g of sodium bicarbonate is added, followed by approximately 1.2 g of product (I) from Example II. The solution is stirred at approximately 42'C (107'F) for 24 hours. The solvent is removed under vacuum, and the residue is stirred in acetone for 20 minutes and collected by filtration, yielding the final product (II).

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 6-fluoro-l-(4-fluorophenyl)-l,4-dihydro-4-oxo-7-(l-piperazinyl )-3-quinol ine carboxylic acid (prepared according to D.T.W. Chu, et. al., J. Med. Chem., 1985, 28, 1558) -257- using the quinolone 9-fluoro-4,7-dihydro-3-methyl -10 piperazinyl )-7-oxo-2H-pyrido[1,2,3-de]-l,4-benzoxazine-6-carboxylic acid (prepared according to I. Hayakawa, et. Chem. Pharm. Bull., 1984, 32, 4907) using the naphthyridinone 7-(2,5-diazabicyclo[2.2. l]heptan-2-yl ) 1-(1 , 1-dimethylethyl )-6-f1uoro-1 ,4-dihydro-4-oxo-1 ,8-naphthyri -dine-3- carboxylic acid (prepared according to A. Weber, et. al . EP 266576) using the quinolone 9-cyclopropyl -6-fluoro-2,3,4,9-tetrahydro-7-(1-piperazinyl )isothiazolo[5,4-bJquinoline-3,4-dione (prepared according to D.T.W. Chu, EP 227,088) using the quinolone l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7-(l-piperazinyl)-3- quinoline carboxylic acid (prepared according to H. oga, et. al., J. Med. Chem., 1980, 23, 1358) -259- using the quinolone 6-fluoro-l,4-dihydro-l-methylamino-7-(4- methyl -1-piperazinyl )-4-oxo-3-quinoline carboxyiic acid (prepared according to M.P. Wentland, et. al., J. Med. Chem. , 1984, 27, 1103) using the naphthyridinone 7-(3-aminopyrrol idinyl )-l-(2,4-difluorophenyl )-6-fluoro-l ,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to O.T.W. Chu, et. al., J. Med. Chem., 1986, 29, 2363) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyiic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -260- using the quinolone 7-(3-aminopyrrol idinyl)-l-chloro-l-cyc1opropy1 -6-f1uoro-1,4-dihydro- -oxo-3-quinol1ne carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrro1idinyl}-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -261- using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-fluoro-l ,4-dihydro-4-oxo-1 ,8-naphthyridine-3-carboxyl c acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983).

EXAMPLE 19 [6R-[6a,70]]-3-[[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-7-quinol inyl )-l-piperazinyl ]thioxomethyl ]thio]- methyl ]-7-methoxy-8-oxo-7-[(2-thienylacetyl )amino]-S-thia-1- azabicyc1o[4.2.0]-oct-2-ene-2-carboxyl ic Acid, Disodium Salt Approximately 5.0 g of cefoxitin sodium salt I (prepared according to U.S. Patent No. 4,297,488) and II (5.0 g) is stirred in water (50ml) at 90-95* (for 45 minutes). The reaction is cooled to room temperature, then refrigerated overnight. Acetone is added and the mixture is stirred for 1 hour. The solid is then collected by filtration and is dried. The crude material was purified by reverse phase chromatography to give III as the disodium salt.

Similarly, the following lactam-quinolones are prepared by the general procedure of this example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-1 ,4-dihydro-4-oxo-3-quino ine carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrol idinyl)-l-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem. , 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidiny¾-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Ned. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) ξΧΑΜΡΙ,ξ 20 According to the general procedure of Example 19, the following lactam-quinolone is made: -264- using the beta-lactam 3-[[(aminocarbonyl)oxy]methyl]-7-[[2- furanyl methoxyimino)acetyl ]amino]-8-oxo-5-thia-l-azabicyclo [4.2.0]oct-2-ene- carboxylic acid (prepared according to M.C. Cook, et. al., US 3,974,153) The following other lactam-quinolones are made by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrol idinyl )-l-cyclopropyl -6,8-difluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -265- using the quinolone 7-(3-am nopyrrol idinyl )-l-chloro-l- cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrol idinyl )-l -cyclopropyl - 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxyl ic acid -266- (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983).

EXAMPLE 21 [5R-[5a,6a(R*)]]-3-([[[4-(3-Carboxy-l-cyclopropyl- 6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-l-pipera- zinyl]thioxomethyUhio]acetyl]aminomethyl]-7-oxo-4-thia-l- azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid Oi sodium Salt To a solution of sodium bicarbonate (0.086 g) in water (2 ml) at O'C is added [5R«[5a,6a]]-3-(aminomethyl)-6-[(R)-l-hydrox-yethyl)]-7-oxo-4-thia-l-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid I (0.1 g) followed by acetone (1.5 ml). To the resulting solution is added bromoacetyl chloride (approximately 0.049 ml) in acetone (0.5 ml) dropwise over 7 minutes. The reaction is stirred in the cold for approximately 1.5 hours, then diluted with water and washed with ether. The aqueous phase is cooled to 5*C, adjusted to pH 2 with IN HC1 and the product is extracted with ethyl acetate. The organic phase is dried over sodium sulfate, filtered and the filtrate is concentrated to dryness to give II. To a solution of II (0.09 g) in dry OMF (4 ml) at O'C -267-is added triethylamine (0.034 ml) followed by III (0.11 g). The mixture is stirred at approximately 2*C for one hour and at ambient temperature for one hour. The mixture is concentrated to dryness in vacuo. The residue is stirred in water, cooled and adjusted to pH 2 with IN HC1. The product is collected by filtration and is added to a solution of sodium bicarbonate (0.032 g) in water (5 ml). After the mixture is stirred for one hour and is diluted with acetone, the product IV as the di sodium salt is collected by filtration.

SXAMP C II 2- (Acetyl oxy)-4-oxo-3S-[(phenoxyacetyl ) amino] -1-azetidine sulfonic acid sodium is prepared as an intermediate for use in Example 23. 0 -268- Mercury II acetate (15.9 g, 0.050 mole) is added to a solution of Penicillin V benzyl ester in 35.2 ml of acetic acid and heated to 90'C for 1.5 hours. The mercury salts are then filtered off over Celite. The filtrate is diluted with water and neutralized with solid sodium carbonate. The layers are separated and the organic layer washed with water, dried over sodium sulfate and concentrated to yield 11.3 g of crude I. This is chromatographed (silcia) to yield 5.6 g of pure I.

I (5.6 g, 0.012 mole) is dissolved in 125 ml of acetone with 2.57 ml of acetic acid and cooled to O'C. Potassium permanganate (2.47 g, 0.016 mole) is dissolved in 88 ml of water and added dropwise through a dropping funnel keeping the temperature between 0-5'C. When the addition is complete, the reaction is warmed to room temperature and allowed to stir for 3 hours. The manganese dioxide is filtered off over Celite, washing with methylene chloride. The layers are separated and the organic layer washed with saturated sodium bicarbonate solution and water, dried and concentrated. The oil formed is recrystall ized from petroleum ether and ethyl acetate to yield 0.78 g of pure II. -269- EXAMPLE 23 l-Cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-[4-[[[(2S-trans) 3-[(phenoxyacetyl )amino]-2-azetidinyl ]th o]thioxomethyl ]- 1-piperazinyl ]-3-quinol inecarboxyl ic Acid, Sodium Salt 2-(Acetyloxy)-4-oxo-3S-[(phenoxyacetyl )amino]-l-azetidine (I) (2.06 g, 7.4 mmol), as prepared in Example 22, is dissolved In approximately 6 ml of acetone with 2.7 ml of water. A solution of 5.01 g of (II), as prepared in Example 13, in approximately 12.4 ml of water is added to the mixture above and a yellow precipitate forms immediately. The mixture is allowed to stir for 30 minutes and the precipitate filtered off and washed with water and ether to yield 2 g of III. -270- EXAMPLE 24 1-Cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-7-[4-[[[(2S-trans)- 3-[(phenoxyacetyl )amino]-l-sulfo-2-azetidinyl ]thio]thioxomethyl ]- 1-piperazinyl ]-3-quinol inecarboxyl ic Acid, Di sodium Salt The product of Example 23 (I) (0.5 g, 0.772 mmol) is dissolved in approximately 5 ml of OMF at room temperature under a nitrogen atmosphere. DMF-S03 complex (1.04 g, 3.86 mmol) was added and the mixture is allowed to stir overnight. Approximately 70 ml of methylene chloride and 70 ml of 0.5N potassium hydrogen phosphate solution is added and the pH is adjusted to pH=8 with IN NaOH. Tetrabutyl ammonium hydrogen sulfate (0.52 g, 1.54 mmol) is added with stirring and the layers -271- separated. The organic layer is washed with water, dried and concentrated. The tetrabutyl ammonium salt is converted to the sodium salt by dissolving it in 100-150 ml of 50% ethanol/water and adding excess Oowex 50W (Na). This is stirred for 1-1/2 hours then the resin is filtered, washed with water and the filtrate concentrated. The residue is first triturated with methylene chloride then with methanol and the product (II) is filtered.

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8- difluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the beta-lactam N-[2-(acetyloxy)-4-oxo-3-azetidinyl ]-2- amino-alpha-(methoxyimino)-4-thiazo1eacetamide (prepared according to T. Matsuo, et al., Eur. Pat. Appl . EP 53815) -272- Ε ΑΜΡ ε 25 Product V, according to this invention, is made by the following general sequence.

Approximately 0.20 g of the hydroxyethyl sulfide I (prepared as above) is dissolved in approximately 2 ml of dichloromethane along with approximately 0.084 ml of triethyl mine, and the mixture is cooled in an ice bath under an inert atmosphere. -273- Approximately 0.034 ml of methanesulfonyl chloride is added dropwise, and the mixture is stirred approximately 15 minutes longer. The reaction mixture is transferred to a separatory funnel along with approximately 10 ml of dichloromethane used to rinse the reaction flask. The dichloromethane solution is washed sequentially with ice water, cold 10% hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. After drying over NazSO* and concentration of the solution product II is obtained.

Approximately 0.2 g of product II is dissolved in approximately 2 ml of dimethylformamide along with approximately 0.16 g of product III (prepared as above). The mixture is heated to approximately 70*C for approximately 6 hours before cooling to room temperature to provide a solution containing product IV. The addition of approximately 0.32 g of tetra-n-butylammonium fluoride trihydrate is followed by stirring for approximately 16 hours at room temperature. Approximately 1 ml of saturated aqueous sodium bicarbonate is added and the mixture is eluted through a OowexR 50 x 4 (Na cycle) column with deionized water. The appropriate fractions are partially concentrated in vacuo, then lyophilized to give the final product V.

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -274- using the quinolone 7-(3-aminopyrrolidinyl)-l-chloro-l- cycl opropyl -6- f 1 uoro- 1 , 4-di hydro-4-oxo-3-qui nol ine carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Ned. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinoline carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid -275- (prepared according to J.P. Sanchez, et. al . , J. Med. Chem. , 1988, 31, 983) EXAMPLE K [5R-[5or,6a]-3-[[[4-(3-Carboxy-l-cyclopropyl -6-fluoro- 1 ,4-dihydro-4-oxo-7-quinol inyl)-l-piperazinyl ]thiox- omethyl ]thio]methyl ]-6-[(R)-1-hydroxyethyl ]-7-oxo-4-thia- l-azabicyclo[3.2.0]hept-2-ene-2-carboxyl ic Acid Disodium Salt To a solution of approximately 1.2 g of the penem t-butyld1phenylsllyl ester I (prepared according to M. Alpegiani, Ger. Offen. OE 3312393, 6 Apr 1983) and 0.27 ml of trlethylamine In CH2CI2/THF at approximately -20*C is added dropwise a solution of approximately 0.19 ml of methanesulfonyl chloride in THF. After the reaction is stirred for approximately 30 minutes, it is filtered under nitrogen and approximately 1.1 g of II is added and the reaction is stirred at 0-5*C for approximately two hours. To the reaction is added approximately 2.2 g of tetrabutylammonium fluoride and stirring is continued for approximately 30 minutes. The reaction is concentrated to dryness and the residue is stirred with acetone and cooled in an ice bath. The mixture is diluted with a solution of water containing approximately 2.1 g of sodium bicarbonate. The solution is extracted -276- with diethylether and the aqueous phase is further diluted with acetone. The product III is collected by filtration and purified by C- 18 reverse phase chromatography.

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the beta-lactam 6-(l-hydroxyethyl )-3-(hydroxymethyl )-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2-carboxy1ic acid (prepared according to S.M. Schmitt, et al., J. Antibiotics, 1988, 41, 780) which was converted to the t-butyldiphenyl si lyl ester as described for Example 6a (M. Alpegiani, Ger. Offen. OE 3312393) using the quinolone l-ethyl-6-fluoro-l,4-dihydro-4-oxo-7-(l-piperazinyl )-3- quinoline carboxylic acid (prepared according to H. Koga, et. al., J. Med. Chem., 1980, 23, 1358). -277- The following other lactam-quinolones are also prepared by the general procedure of this Example and Examples 13-25, with substantially similar results. -278- -279- 35 -281- -283- -285- EXAMPLE 27 [5R-[5o, 60] ]-3-[[ [4- (3-carboxy- 1-cyclopropyl -6-fl uoro- 1,4-dihydro-4-oxo-7-qu1nolinyl)-l-piperazinyl] -2,2,2- trichloroethoxy] phosphiny] Joxymethyl]-6-[ (R)-l-hydroxymethyl ]- 7-0X0-4- thi a- 1-azabicyc1o[3.2.0]hept-2-ene-2-carboxylic acid; and [5R-[5a,6a]]-3- [[[4- (3-carboxy- 1 -cycl opropyl -6-fluoro-l,4-dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]hydroxyphosphinyl]oxymethyl]-6-[(R)-l-hydroxymethyl]-7-oxo-4-thia-l-azabicyc1o[3.2.0]hept-2-ene-2-carboxylic acid, according to this invention, are made as follows. First, ciprofloxacin allyl ester is made by the fol owing general reaction sequence. -286- To a solution of approximately 5 g of ciprofloxacin I in approximately 50 ml of water and 15 ml of IN NaOH is added approximately 50 ml of dioxane followed by approximately 4.9 g of di-t-butyl dicarbonate. The mixture 1s stirred at room temperature for approximately 6 hours and is concentrated to approximately 10 ml in vacuo. The mixture is diluted with acetone and t-BOC -ciprofloxacin sodium salt II is collected by filtration. To a mixture of approximately 4.5 g of II in approximately 70 ml of dimethyl formamide is added approximately 1.1 ml of allyl iodide at approximately 3-5*C. The reaction is stirred for approximately 45 hours and is concentrated to dryness in vacuo. The residue 1s stirred In water and the product is extracted with CH2CI2. The extract is dried over Na2S0 , filtered and the filtrate is concentrated to dryness to give the allyl ester III. A solution of approximately 3.8 g of III in approximately 50 ml of trifluoroacetic acid and 50 ml of CH2CI 2 Is stirred at room temperature for approximately 6 hours and is concentrated to dryness in vacuo. The residue is triturated 1n anhydrous ether and ciprofloxacin allyl ester IV 1s collected by filtration.

The product of this Invention is then made by the following general reaction sequence. -287 -288- Approximately 4.0 g of bis-2,2,2-trichloroethyl phosphoro-chloridate, in approximately 60 ml of pyridine, is stirred under a nitrogen atmosphere and cooled with an ice bath. Ciprofloxacin ally! ester (I) (approximately 4.9 g), in approximately 40 ml of dichloromethane, is slowly added. The reaction is allowed to stir for approximately 12 hours, concentrated, and 1-cyclopropyl -6-fluoro-4-oxo-7-[4-[bis-(2,2,2-trichloroethoxy)phosphonyl piperazinyl-3-quinolone carboxylic acid allyl ester (II) is isolated by silica gel chromatography.

Approximately 2.0 g of Product (II) is dissolved in approximately 20 ml of t-butyl alcohol containing cesium fluoride (approximately 1.25 g) and approximately 1.3 g of Compound (III), made according to U.S. Patent 4,631,150, Battistini et al., issued December 23, 1986 (incorporated by reference herein). This solution is then stirred for approximatel 2 days at room temperature, evaporated and a Product (IV) is obtained after chromatography.

A portion of Product (IV) (approximately 0.5 g) is then taken up in approximately 5 ml of tetrahydrofuran. Acetic acid (approximately 0.25 ml) and approximately 0.35 g (as approximately a 1 M solution in THF) of tetrabutylammonium fluoride is added at room temperature. The reaction mixture is stirred at room temperature for approximately 24 hours under nitrogen. The solvent is removed and the residue dissolved in ethyl acetate, washed with a saturated solution of sodium bicarbonate and dried over sodium sulfate. After evaporation, the crude product is taken up in a mixture of approximately 10 ml of dichloromethane, approximately 60 ml of water and approximately 18 mg of bis(triphenylphosphine)palladium chloride Pd(PPh3)2Cl. The mixture is treated with approximately 700 microliters of tributyltin hydride while maintaining a temperature of approximately 2TC (70eF) . After rapid stirring for approximately 5 minutes product (IV) is isolated.

Product (IV) is then heated, in the presence of Zn/Cu in DMF (dimethyl formamide) at approximately 50*C (122'F), according to -289- the procedure of A. Franke et al ; 101 Chem. Ber. 944 (1968), to yield product (VI).

EXAMPLE 28 [5R-[5a,6a]]-3-[2-[[4-(3-carboxy-l-cyclopropyl-6-fluoro-l- 4-d1hydro-4-oxo-7-qu1nol1nyl)-l-p1perazinyl]carboxylamino] ethylth1o]-6-[(R)-hydroxyethy1J-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxyl 1c acid, having the formula according to this invention, 1s made by dissolving approximately 0.5g of Ι, -carbonyldlImidazole in approximately 10 ml of anhydrous DMF. While stirring under a nitrogen atmosphere, the solution 1s chilled with an ice bath and approximately 1 g of ciprofloxacin allyl ester (in a small quantity of dried and distilled DMF is then added. Stirring is continued for approximately one hour at this temperature. A solution of thienamycin (made by the procedure of T. Salzmann et al., 102 JL Am. Chem. Soc. 616 (1980)) and an equimolar amount of triethylamine in DMF is then slowly added and the mixture 1s allowed to slowly warm to room temperature over a period of about 12 hours. The solvent 1s then removed and the residue is triturated with acetone-water.

Approximately 0.5g of the above crude product is dissolved in approximately 10 ml of DMF and approximately 60 ml of water is added, followed by 9 mg of bis(triphenylphosphine) palladium -290- chloride. While maintaining this solution at approximately 21"C (70*F), approximately 350 microliters of tributyltin hydride is added. After rapid stirring for approximately 5 minutes the final product is isolated.

EXAMPLE 29 According to the general procedure of Example 28, the following lactam-quinolone is made: using the beta-lactam 3-[(2-aminoethyl)thio]-6-(l-hydroxyethyl)-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (prepared according to O.H. Shih, et al., Tet. Lett. 1985, 26, 587).

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -291- using the quinolone 7-(3-aminopyrrol idinylV1-cyclopropyl -6- fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrol idinyl )-l-cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-l ,8-naphthyridine-3-carboxyl ic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-(piperazinyl)-3-quinoline carboxylic acid (prepared according to K. Grohe, et al., Ger. Offen. OE 3142854).

EXAMPLE 30 According to the general procedure of Example 28, the following lactam-quinolone is made. using the beta-lactara 3-[(2-aminoethy1)thio]-6-(l-hydroxyethyl )- 7-oxo-4-thia-l-azabicyclo[3.2.0]hept-2-ene-2-carboxyl c acid (prepared according to T. Hayashi, et al . , Chem. Pharm. Bull., 1981, 29, 3158).

Similarly, the following lactam quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrol idinyl )-8-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyl c acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrol idinyl}-l-cyclopropyl -6-fluoro-1 ,4-dihydro-4-oxo-3-quinol ine carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyrldlnone 7-(3-am1nopyrrol1d1ny1 )-l-cyc1opropy?-6-f1uoro-l,4-d1hydro-4-oxo-l,8-naphthyr1dine-3-carboxyl1c acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone l-cyclopropyl-6-fluoro-l,4-d1hydro-4-oxo-7-(piperazinyl)- 3-quinollne carboxyilc add (prepared according to K. Grohe, et al., Ger. Of fen. DE 3142854). -294- EXAHPLE 31 [6R- [6or, 7β] ] -3-[[[ (3-Carboxy-l -cyclopropyl -6-fl uoro-1 , 4-dihydro -oxo-7-quinol1nyl)-4-piperazinyl]carbonylamino]methyl ]-8-oxo-7 [(2-th1enylacetyl)am1no]-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2 carboxyiic Acid Disodium Salt VI -295- A mixture of approximately 7.2 g of ciprofloxacin, water (100 ml), acetone (70 ml) and IN NaOH (26 ml) is cooled to approximately 3eC and a solution of approximately 4.7 ml of benzyl chloroformate in acetone (30 ml) is added dropwise while maintaining the pH at approximately 9-10 by adding additional IN NaOH. The mixture is stirred at 2-5'C for approximately 30 minutes and at room temperature for approximately 2 hours. The mixture is concentrated to approximately 100 ml under reduced pressure, is cooled in an ice bath and is acidified with 2N HC1. The product is collected by filtration, triturated in ethyl acetate and is dried to afford I. A mixture of approximately 5.6 g of I, 120 ml of CH2CI2, 6 ml of H2SO4 and 40 ml of isobutylene is shaken in a pressure bottle for approximately 21 hours. The mixture is poured into cold 0.25N NaOH and is stirred rapidly. The organic phase is separated, dried over Na2S04, filtered and is concentrated to dryness to give II. A mixture of approximately 4.5 g of II, 75 ml of dimethyl formamide and 4 g of 10% Pd/C is subjected to hydrogenation for approximately 16 hours and the catalyst is removed by filtration. The filtrate is concentrated to dryness in vacuo, the residue is triturated in ethyl acetate and the product III is collected by filtration and is dried.

A solution of approximately 2.4 g of III and 0.9 ml of triethyl amine in approximately 100 ml of CH2CI2 is added dropwise to a solution of excess phosgene in CH CI at approximately 2-5'C . After the reaction is stirred for an additional one hour, the mixture is filtered and the filtrate is concentrated to dryness under reduced pressure. The residue is dissolved in approximately 30 ml of dimethyl formamide and is added slowly to a mixture of approximately 2.2 g of [6R-[6or,70]]-3-aminomethyl -8-oxo-7- [(2-thienyl acetyl) amino] -5-thi a- l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid IV and 1.8 ml of triethyl amine in 30 ml of dimethyl formamide at approximately 2-5"C. The reaction is stirred for approximately 4 hours and concentrated to dryness in vacuo. The residue is stirred in water and CH2C12 » then cooled in an ice bath and acidified with 10% citric acid. The organic -296- phase Is separated, dried over Na2S0 , filtered and concentrated to dryness. The residue is purified by silica gel chromatography to give V. To a solution of approximately 0.8 g of V and 10 ml of anisole is added approximately 10 ml of trifluoroacetlc acid dropwlse at approximately -15*C. The solution is stirred at ambient temperature for approximately 20 minutes and then concentrated to dryness In vacuo. The residue is triturated in anhydrous ether and the product is collected by filtration. This free acid of the title compound (approximately 0.47 g) is added to a solution of water and approximately 0.12 g of sodium bicarbonate. Some acetone 1s added to the stirring mixture to effect solution and then approximately 2.5 volumes of acetone is added to precipitate the product which is collected by filtration to afford VI as the disodium salt.

Similarly, the following lactam-qulnolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminOpyrrolidinyl)-l-cyclopropyl-6,8-d1fluoro-l,4-d1hydro-4-oxo-3-quinol1ne carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -297- using the quinolone 7-(3-aminopyrrol idinyl )-8-chloro-l- cyclopropyl -6-fluoro-l ,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the quinolone 7- (3-aminopyrrol idinyl -cyciopropyl -6-fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983).

EXAMPLE 32 According to the general procedure of Example 31, the following lactam-quinolone is made. using the beta-lactam 3-(acetyloxymethyl)-7-[[(2-amino-4-thiazolyl ) acetyl]amino]-8-oxo-5-th a-l-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid (prepared as described herein) Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-8-chloro-l-cyclopropyl -6-fluoro-l ,4-dihydro-4-oxo-3-quinol ine carboxyl ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -299- using the qulnolone 7-(3-aminopyrrolidinyl-l-cyclopropy1 -6- fluoro-l,4-dihydro-4-oxo-3-quinol ine carboxylic add (prepared according to J. . Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the naphthyridlnone 7-(3-am1nopyrrol1dinyl)-l-cyclopropyl-6-fluoro-l,4-d1hydro-4-oxo-l,8-naphthyrid1ne-3-carboxyl ic acid (prepared according to J. P. Sanchez, et. al . , J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrol Idinyl )-l-cyc1opropyl -6,8-d1fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared -300- accordlng to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983).

EXAMPLE 33 According to the general procedure of Example 28, the following lactam-quinolone is made.

¾^OH 0 0 using the beta-lactam 3-(aminomethyl)-6-(l-hydroxyethyl)-7-oxo-4-thia-l-azabicyclo[3.2.0]hept-2-ene-2-carboxyl1c acid (prepared according to M. Lang, et al . , Helv. Chim. Acta, 1986, 69, 1576).

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the qulnolone 7-(3-aminopyrrol idinyl)-l-chloro-l-cyclopropyl -6-f1uoro-1, -dihydro-4-oxo-3-quinol 1ne carboxyl 1c acid (prepared according to J.P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) -301- using the qulnolone 7-(3-am1nopyrrolid1nyl-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J. P. Sanchez, et. ah, J. Med. Chem., 1988, 31, 983) using the naphthyrldinone 7-(3-aminopyrrolidinyl)-l-cyc1opropyl-6-f1uoro-l,4-dihydro-4-oxo-l,8-naphthyrid1ne-3-carboxy1 ic acid (prepared according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983) using the qulnolone 7-(3-aminopyrrolidinyl )-l-cyclopropyl -6,8-d1fluoro-l,4-dihydro-4-oxo-3-quinoline carboxylic add (prepared -302-according to J. P. Sanchez, et. al., J. Med. Chem., 1988, 31, 983).

EXAMPLE 34 3- [ [ [ [ (3-Carboxy-8-chl oro- 1 -cyclopropyl -6-f 1 uoro-1 ,4-d1hydro-4-oxo-7-qu1nol inyl ) -3 -pyrrol Idlnylaminocarbonyl ]methyl th1o]th1oxomethy1]am1nomethyl]-8-oxo-7-[(2-th1enylacetyl)amino]-5-th1a-l-azab1cyc1o[4.2.0]oct-2-ene-2-carboxyl1c acid dlsodlum salt, according to this Invention, 1s made by the following general reaction sequence. -303- A mixture of 7-(3-amino-l-pyrrol idinyl ) -8-chloro-l-cyclo-propyl-6-fluoro-l,4-dihydro-8-oxo-3-quinolinecarboxyl c acid (1.5g) (made by procedure of 31 J. Med. Chem. 983 (1988)), and 50% aqueous acetone is adjusted to pH 10 with IN NaOH. A solution of bromoacetyl chloride (1.3g) in acetone is added drop-wise at approximately 7*C (45*F) while maintaining the reaction at pH of from 9 to 11. The mixture is stirred for approximately 2 hours, concentrated to half volume and washed once with ethyl acetate. The aqueous phase is acidified with IN HC1 and the product is collected by filtration. Product (I) is obtained by recrystall ization from DMF.

A solution of commercial cephalothin sodium salt (5.0 g), sodium bicarbonate (1.06 g), sodium azide (0.82 g) and water (75 ml) is heated at approximately 50'C (122'F) until TLC (thin layer chromatography) shows the starting material is consumed. The reaction is cooled to approximately 3eC (37*F), covered with ethyl acetate and acidified with IN HC1. The ethyl acetate extract is dried over a2$04, filtered and the filtrate is concentrated to dryness to give [6R[6a,7B]]-3-(azidomethyl )-8-oxo-7-](2-thienylacetyl )amino]-5-thia-l-azabicyclo[4.2.0]oct-2-ene-3-carboxylic acid. A mixture of this azido intermediate (1.0 g), 10% Pd/C (1.0 g), NaHC03 (1.54 g) and 75% methanol/^ is subjected to hydrogenation at room temperature until TLC shows the disappearance of starting azide. The catalyst is removed by filtration and the filtrate is concentrated to dryness. The residue is dissolved in water, acidified with IN HC1 and the solution is washed with CHCI3. The aqueous phase is concentrated to dryness and the crude product is purified using 50W-X4 cation exchange resin to give product (II).

To a mixture of approximately 1.0 g of product (II) in 4N NaOH (1.5ml) is added carbon disulfide (0.13 ml) dropwise and the reaction is stirred for approximately 2 hours at approximately 2"C (36eF). More carbon disulfide (approximately 0.13 ml) is added and stirring is continued for another hour. The reaction is stirred for an additional 2 hours at ambient temperature, then -304- cooled to approximately 2'C and diluted with acetone. Product (III) is collected by filtration.

Approximately 0.2 g of product (III) and 0.19 g of product (I) are dissolved in OMF (25 ml), containing sodium bicarbonate (0.035 g). This mixture is stirred at room temperature for approximately 18 hours and concentrated to dryness in vacuo. The residue Is dissolved in water and the final product (IV) is precipitated with acetone.

EXHPE 35 (3S)-2-[[[2-[3-Carboxy-6-fluoro-l,4-dihydro-4-oxo-7-(l- piperazinyl)-l-quinol inyl ]ethoxy]thioxomethyl]thio]-4-oxo-3- [(phenoxyacetyl)amino]-l-azetidinesulfonic acid disodium salt, according to this invention, is made by the following general reaction sequence.

A mixture of approximately 3.3 g of 6-fluoro-l,4-dihydro-l-(2-hydroxyethyl)-4-oxo-7-(l-piperazinyl)-quinol ine-3-carboxyl ic acid (I) (prepared according to 23 J. Med. Chem.. 1358 (1980)), -305- 1.5g of triethyl amine, 2.8 g of methyl iodide, and 40 ml of D F is heated at approximately 85*C (185'F) with stirring. After approximately 2 hours, the mixture is concentrated to dryness and the residue recrystal 1 ized to give product (II).

Approximately 0.55 g of the product (I) is suspended in 0.78 ml of 4N NaOH and 1 ml of water and cooled in an ice bath. 0.093 ml of carbon disulfide is added slowly via syringe. The reaction is stirred in ice for approximately 110 minutes. An additional 0.093 ml of carbon disulfide is added and the solution stirred for 1 hour at approximately 0*C (32*F) and then 3 hours at room temperature. A solid is precipitated by the addition of acetone, collected by filtration, and washed with acetone yielding product (HI).

Approximately 0.26 of product (III) is dissolved in 0.4 ml water and added to a mixture of 0.10 g of 2-(acetyloxy)-4-oxo-3- ( (phenoxyacetyl ) ami no) azetidine prepared according to JCS Perkin Trans. I. 447 (1976)) in approximately 0.13 ml of water. This mixture is stirred approximately 30 minutes until the reaction is complete. The product (IV) is isolated by filtration, and recrystal 1 ized.

To a solution of 0.1 g of product (IV) in approximately 0.4 ml of dry DMF, is added 0.1 g of DMF · SO3 complex (prepared according to Synthesis. 699 (1979)). The mixture is stirred for approximately 2 hours at room temperature. The mixture is then diluted with approximately 4 ml of dichloromethane and approximately 4 ml of 0.5 N potassium hydrogen phosphate solution. The pH is adjusted to approximately 6 with IN NaOH. Approximately 0.05 g of tetrabutylammoniumhydrogensulfate is then added, with stirring. The layers are separated and the organic layer is washed with water, dried and concentrated. This residue is taken up in approximately 1 ml of water with approximately 0.2 ml of methanol and filtered to yield product (V). -306- EXAMPLE 36 [3S]-2-[2-[4-(3-Carboxy-l-cyclopropy1-6-fl uoro -1,4 -dl hydro -4-oxo-7-quinol inyl )-l-piperaz1nyl]ethylthio]-4-oxo-3-[(phenoxy acetyl )amino]-l-azetidinesulfonic acid di sodium salt, according to this invention, is made according to the following general synthetic sequence. -307- Approximately 22.5 ml of 2-mercaptoethanol and approximately 89.2 g of triphenylmethyl chloride are stirred in 200 ml of DMF at room temperature for approximately 5 hours. The reaction mixture is then poured into a mixture of 1000 ml of water and 500 ml of ethyl acetate. The layers are separated and the aqueous layer is extracted with ethyl acetate. The combined organic layers are washed with water, dried and evaporated to an oil which solidifies upon standing. This is triturated with hexane and collected by filtration to yield triphenylmethylthioethanol (I).

Approximately 2.0 g of product (I) and 9.6 ml of triethylamine are stirred in 700 ml of dichloromethane and cooled to approximately 14'C (57"F) . A solution of 5.3 ml of methanesulfonyl chloride in 200 ml of dichloromethane is added dropwise, keeping the temperature at approximately 14'C. The icebath is removed and the reaction is stirred at room temperature for approximately 25 minutes. The reaction mixture is then diluted with dichloromethane and washed with water, and 5% sodium bicarbonate solution, then dried and concentrated. The resulting solid is taken up in 100 ml of DMF with 6.9 g of 1-cyclopropyl-6-fluoro-l,4-dihydro-7-(l-piperazinyl )-4-0X0-3-quinol inecarboxyl ic acid (II) and 4.3 ml of triethylamine and heated at approximately 82'C (180eF) for 2.5 hours. The reaction mixture is cooled to room temperature, precipitating a solid product (III).

A solution of 6.0 g of product (III) in 250 ml of glacial acetic acid is treated with 80 ml of 1 N HC1 solution. The solution is heated for approximately 1.5 hours and the acid evaporated. The residue is triturated with acetone and the product filtered. This is then taken up in 30 ml of 1 N NaOH solution which upon evaporation yields product (IV).

Approximately 2.04 g of product (IV) is dissolved in approximately 4 ml water, at 0*C (32*F) , and then added to a solution of approximately 1.02 g of 2-(acetyloxy)-4-oxo-3-((phenoxy-acetyl )amino)-azetidine, in approximately 28 ml of methanol. After being stirred approximately 1 hour at room temperature, the -308- mixture is concentrated. The resulting product (V) is recrystallized from water and acetone.

-To a solution of 1.0 g of product (V) In approximately 4 ml of dry OMF, Is added 1.0 g of DMF-S03 complex (prepared according to Synthesis. 699 (1979)). The mixture Is stirred for approximately 2 hours at room temperature. The mixture is then diluted with approximately 40 ml of dlchloromethane and approximately 40 ml of 0.5 N potassium hydrogen phosphate solution. The pH 1s adjusted to approximately 6 with IN NaOH. Approximately 0.49 g of tetrabutylammonlumhydrogensulfate 1s then added, with stirring. The layers are separated and the organic layer is washed with water, dried and concentrated. This residue Is taken up in approximately 10 ml of water with approximately 2 ml of methanol and filtered to yield product (VI).

Similarly, the following other lactam-qulnolones are prepared by the general procedure of this Example, with substantially similar results. -309 - EXAMPLE 37 [6R-(6β,70)]-3-[[4-(3-Carboxy-1-cyclopropyl -6-fluoro-1 ,4- dihydro-4-oxo-7-quinolinyl)-l-piperazinyl]methyl]-8-oxo-7-[(2- thienylacetyl )amino]-5-thia-l-azabicyclo[4.2.0]oct- 2-ene-2-carboxylic Acid To a mixture of approximately 3.2 g of ciprofloxacin allyl ester I in 30 ml of 50% ONF/dioxane is added approximately 4.3 g of 10-iodo cephem II in portions. The mixture is stirred at room temperature for approximately 2 hours and is concentrated to dryness in vacuo. The residue is added to a mixture of 10% -310- sodium bicarbonate and CH2CI 2 and is stirred rapidly. The organic phase is separated, dried over a2S04, filtered and the filtrate is concentrated to dryness. The residue is purified by flash chromatography (silica gel) to give III. To a solution of approximately 1.7 g of III, 20 ml of CH2CI2 and 0.03 g of bis(triphenylphosphine)pa11adium chloride is added approximately 0.2 ml of water and 1.4 ml of tributyltinhydride at approximately 20*C. The mixture is stirred for approximately 15 minutes and then diluted with ether and the precipitate is collected by filtration. The solid is triturated with acetone to afford the product IV.

Similarly, the following lactam-qulnolone is prepared by the general procedure of this Example, with substantially similar results. using the beta-lactam [6R-[6a,7b(Z)]]-3-(iodomethyl )-7-[[[2-(trimethylsilylamino) -4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-5-thia-l-a2abicyclo(4.2.0]oct-2-ene-2-carboxylic acid trimethylsilyl ester (prepared according to I. Saito et al., Eur. Pat. Appl. EP 189916 A2, 6 Aug 1986) The following other lactam-quinolones are also prepared by the general procedure of this Example and Example 37, with substantially similar results.

EXAMP E 38 [6R-[6a,7B]]-4-(3-Carboxy-l-cyclopropyl-6-fl uoro-1,4-dihydro-4-oxo-7-quinolinyl)-l-[[2-carboxy-8-oxo-7-[(2-thienyl acetyl ) amino] -5-thia-l-azabicyclo[4.2.0]oct-2-en-3-yl ] methyl ]-l -methylpiperazinium sodium salt, having the formula -312- is made by mixing the product of Example 37 and iodomethane (0.020g) in DMF (20 ml). This mixture is stirred at room temperature for approximately 17 hours and concentrated to dryness in vacuo. The residue is repeatedly triturated in aqueous acetone to give the final product.

Similarly, the following lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 9-fluoro-4,7-dihydro-3-methyl-10-(l-piperazinyl)-7-oxo-2H-pyrido[l,2,3-de]-l,4-benzoxazine-6-carboxylic acid (prepared according to I. Hayakawa, et. al., Chem. Pharm. Bull., 1984, 32, 4907) using the quinolone 9-cyclopropyl-6-fluoro-2,3,4,9-tetrahydro-7-(1-piperazinyl )1sothiazolo[5,4-b]quinol ine-3,4-dione (prepared according to O.T.W. Chu, EP 227,088). -313- EXAHP 39 [6R-[6a,7b]]-4-[3-Carboxy-1-ethyl-6-f1uoro-1 ,4-dihydro-4- oxo-7-quinolinyl]-l-[[2-carboxy-8-oxo-7-(2-thienylacetyl )amino]- 5-thia-l-azabicyclo[4.2.0]oct-2-ene-3-yl]-l-methylpiperazinium sodium salt, of the formula according to this Invention, is made as follows.

Approximately 7.9 ml of thionyl chloride is added to a mixture of pefloxacin hydrochloride (2.0 g) (which is made by the procedure of 23 J. Med. Chem. 1358 (1980)) in absolute methanol (54 ml), at approximately 6*C (43*F). The mixture is refluxed for 15 hours and concentrated to dryness. Cold aqueous Na2C03 is added to the residue, the product is extracted with dlchloromethane. The extract is dried over Na2S04, filtered and concentrated to dryness. The solid Is recrystallized from acetonltrlle to give pefloxacin methyl ester.

Approximately 0.23 g of 60% NaH (dispersion in mineral oil) Is added to a solution of allyl alcohol (16 ml) in dry THF (160 ml) (0.23 g), followed by 4 Angstrom molecular sieves (92 g) and pefloxacin methyl ester (16 g). The mixture 1s stirred at room temperature for 2.5 days, cooled, water (1 ml) is added and then filtered. The filtrate is concentrated to dryness, the residue is dissolved In dichloromethane and washed with water. The organic phase is concentrated to dryness and the solid is recrystallized from ethyl acetate to afford pefloxacin allyl ester.

Pefloxacin allyl ester (0.69 g) is added to a solution of [6R-[6a,7b]]3-(iodomethyl )-8-oxo-7-[(2-thienylacetyl )amino]-5-thia-l-azab1cyclo[4.2.0]oct-2-ene-2-carboxylic acid allyl ester -314- (1.5 g) in 50% OMF/dioxane (6 ml) and the mixture is stirred for 6 hours at room temperature. The mixture is concentrated to dryness IQ vacuo and the residue is triturated repeatedly with ethyl acetate and DMF/ethyl acetate to yield [6R-[6a,7bl]-4-[3- [(allyloxy)carbonyl ]-l-ethyl -6-fluoro-l,4-dihydro-4-oxo-7- quinolinyl]-l-[2-[(allyloxy)carbonyl]-8-oxo-7-[(2-thienylacetyl )- amino]-5-thia-l-azabicyclo[4.2.0]oct-2-en-3-yl]-l-methylpipera- zinium iodide.

Approximately 0.20 g of this intermediate is added to a mixture of dichloromethane/DMF (2 ml) and bis(triphenylphos- phine)palladium chloride (0.003 g). Water (20 microliters) and tributyltinhydride (0.14 ml) are then added, at approximately 19'C (66*F). The mixture is stirred for 20 minutes, diluted with dichloromethane and the precipitate is collected by filtration. This solid is stirred in water and NaHC03 (0.043 g), diluted with acetone and the product is collected by filtration. Repeated trituration with aqueous acetone yields the final product.

Similarly, the following other lactam-quinolones are prepared by the general procedure of this Example, with substantially similar results. using the quinolone 6,8-difluoro-l-(2-fluoroethyl)-l,4-dihydro-4-oxo-7-(4-methyl-l-piperazinyl)-3-qu1noline carboxylic acid (prepared according to T. Irikura, Aust. Pat. Specif. AU 537813) -315- using the quinolone 6-fluoro-l-(4-fluorophenyl)-l,4-dihydro-4- oxo-7(4-methyl-l-piperazinyl)3-quinoline carboxylic acid (prepared according to D.T.W. Chu, et al., J. Med. Chem., 1985, 28, 1558).

EXAMPLE 40 Product III, according to this invention, is made by the following general sequence.

Approximately 7.9 ml of thionyl chloride is added to a mixture containing approximately 2.0 g of pefloxacin hydrochloride (which is made by the procedure of 23 J. Med. Chem. 1358 (1980)), and 10 g of 2-(trimethylsilyl )ethanol in approximately 150 ml of dichloromethane. The mixture is refluxed approximately 24 hours, cooled to room temperature, and extracted with saturated aqueous sodium bicarbonate. The dichloromethane solution is dried over Na2S0a, filtered, and concentrated to -316-dryness. The residue is recrystall ized from ethyl acetate to afford pefloxacin 2-(trimethylsilyl )ethyl ester II.

Approximately 0.16 g of ester II and 0.20 g of mesylate I (prepared as above) are dissolved in approximately 2 ml of dimethyl formamide. After the mixture is stirred approximately 24 hours at room temperature approximately 0.50 g of tetra-n-butylammonium fluoride is added. The mixture is stirred approximately 8 hours longer at room temperature. Approximately 1 ml of saturated aqueous sodium bicarbonate is added and the mixture is eluted through a DowexR 50 x 4 (Na cycle) column with deionized water. The appropriate fractions are concentrated in vacuo, then lyophilized to give the final product III.

The following other lactam-quinolones are made by the general procedures of this Example and Examples 38 and 39, with substantially similar results. -318- EXAMPLE 41 [6R- [6a, 7b] ] -3- [ [ [ (3-Carboxy- 1 -cycl opropyl -6- f 1 uoro- 1,4-dihydro-4-oxo-7-quinol inyl )-4-piperaziny ]thioxomethyl ]amino methyl] -8-0X0-7- [(2-thienyl acetyl )amino]-5-thia-l-azabicyclo [4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt, of the following formula -319- according to this invention, is made as follows. A mixture of approximately 0.80 g of [6R-[6a,7b]]-3-(isothiocyanatomethyl)-8- oxo-7-[(2-thienylacetyl)amino]-5-thia-l-azabicyclo[4.2.0]oct-2- ene-2-carboxyl ic acid (made by the process of Belgium Patent 719,711), NaHC03 (0.35 g) and ciprofloxacin (0.69 g) in DMF (50 ml) is heated at approximately 40*C (104*F) for 24 hours and concentrated to dryness in vacuo. The residue is recrystallized from aqueous acetone to afford the final product.

Similarly, the following lactam-quinolones are made according to the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-d1hydro-4-oxo-3-quinolinecarboxylic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983 using the quinolone 7-(3-aminopyrrolidinyl)-8-chloro-l-cyclopropyl -6-fluoro-l,4-dihydro -4-oxo-3-quinol inecarboxyl ic -320- acid (prepared according to J. P. Sanchez, et al . , J. Med. Chem. , 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro -4-oxo-3-quinol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Ned. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrol idinyl )-l-cyclopropyl -6-fluoro-l,4-dihydro -4-oxo-l,8-naphthyridine-3-carboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983). -321- EXAMPLE 42 [5R-[5a,6c.]]-3-[[[(3-Carboxy-l-cyclopropyl -6-fluoro-l ,4-dihydro- 4-oxo-7-quinol inyl )-4-piperazinyl ]thioxomethyl ]aminomethyl ] -6- [(R)-l-hydroxyethyl1-7-0X0-4-thia-l-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic Acid Oisodium Salt To a solution of approximately 2.2 ml of thiophosgene in 10 ml of CH2CI2 is added dropwise a solution of approximately 2.2 g of ciprofloxacin t-butyl ester I and 0.8 g of triethyl amine in approximately 30 ml of CH2CI2 at approximately 2-5'C. The mixture is stirred for approximately one hour in the cold, then is filtered and the filtrate is concentrated to dryness. The -322- residue is stirred with acetone and is added slowly to a solution of approximately 1.4 g of II and 2.9 g of sodium bicarbonate in 20 ml of water at approximately 2-5*C. The reaction is stirred at ambient temperature for approximately 2 hours, is diluted with water and is cooled in an ice bath. The mixture is acidified with 10% citric acid and the product is extracted with CH2C12- The extract is dried over Na2S0 , filtered and the filtrate is concentrated to dryness. The residue is purified by flash chromatography (silica gel) to give III. To a solution of approximately 1.0 g of III in 20 ml of anisole is added approximately 20 ml of trifluoroacetic acid dropwise at approximately -10*C. The solution is stirred at ambient temperature for approximately 50 minutes and is concentrated to dryness in vacuo. The residue is triturated in diethyl ether and the solid is collected by filtration and suspended in water. To this mixture is added approximately 0.22 g of sodium bicarbonate and acetone is added to effect dissolution. The solution is concentrated to dryness and the residue is purified by C-18 reverse phase chromatography to afford the title compound IV as the disodium salt.

Similarly, the following lactam-quinolones are made according to the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrro1idinyl)-I-cyclopropyl-6,8- difluoro-l,4-dihydro-4-oxo-3-quinol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al . , J. Med. Chem., 1988, 31, 983) -323- using the quinolone 7- (3-aminopyrrol idinyl )-8-chloro-l-cyclopropyl -6-fluoro-l ,4-dihydro-4-oxo-3-quinol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983) using the quinolone 7- (3-aminopyrrol idinyl )-l-cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-3-quinol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983) -324- using the naphthyridinone 7-(3-aminopyrrol idiny )-l-cyclopropyl - 6-fluoro-l ,4-dihydro-4-oxo-l ,8-naphthyridine-3-carboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983) using the beta-lactam 3-[(2-aminoethyl)thio]-6-(l-hydroxyethyl)-7-oxo-4-thia-l-azabicyclo[3.2.0]hept-2-ene-2-carboxyl ic acid (prepared according to T. Hayashi, et al., Chem. Pharm. Bull., 1981, 29, 3158) using the beta-lactam 3-[(2-aminoethyl )thio]-6-(l-hydroxyethyl)-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2-carboxyl ic acid (prepared according to O.H. Shih, et al., Tet. Lett. 1985, 26, 587) EXAMPLE A3 According to the general procedure of Example 42, the following lactam-quinolone is made: -325- using the beta-lactam [6R-[6a,7b(Z)]]-3-(aminomethyl )-7-[[(2- amino-4-thiazolyl)(methoxyimino)acetylJamino]-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (prepared according to F. H. Jung, Eur. Pat. Appl . EP 182633 A2, 28 May 1986) Similarly, the following lactam quinolones are made according to the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrol idinyl )-l-cyclopropyl -6,8-difluoro-l,4-dihydro-4-oxo-3-quinol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al . , J. Med. Chem., 1988, 31, 983) -326- using the quinolone 7-(3-aminopyrrolidinyl)-8-chloro-l-cyclopropyl -6-fluoro-l ,4-dihydro-4-oxo-3-quinol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983) using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983) -327- using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983) The following other lactam-quinolones are also made by the general procedure of this Example and Examples 41 and 42, with substantially similar results. o EXAMPLE 44 [6R-[6a,7b]]-3-[[[(3-Carboxy-1-cyclopropyl -6-fluoro-1 ,4-dihydro-4-oxo-7-quinol inyl)-4-piperazinyl]iminomethyl Jthio methyl]-8-0X0-7-[(2-thienylacetyl )amino]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxyl ic acid sodium salt, of the following formula -329- according to this invention, is made as follows. A solution of benzoyl isothiocyanate (0.92 g) in THF (20 ml) is added to a mixture of ciprofloxacin sodium salt (2.0 g) in THF (300 ml), and the reaction is stirred for 20 hours. The reaction is concentrated to dryness and the residue is triturated with acetone. The resultant benzoylurea is added to a preheated at approximately 80*C (176*F) solution of 5% aqueous NaOH and the reaction is stirred for 30 minutes. The mixture is cooled to approximately 5*C (41*F) and acidified with IN HC1. The solid is collected by filtration and recrystall ized from DMF to yield 7-[4-(aminothioxomethyl )-l-piperazinyl]-l-cyclopropyl -6-fluoro- l,4-dihydro-4-oxo-3-quinolinecarboxylic acid.

A solution of this intermediate (approximately 0.40 g), NaHC03 (0.17 g) and cephalothin (0.40 g) in H20 (10 ml) is heated at approximately 55'C (131'F) for 20 hours and diluted with saturated aqueous NaCl. The mixture is centrifuged, the aqueous layer is decanted and the residue is purified by recrystall ization from methanol/water to give the final product.

Similarly, the following lactam-quinolone is made according to the general procedure of this Example, with substantially similar results. using the beta-lactam [6R-[6a,7b(Z)]]-3-[(acetyloxy)methyl ]-7- [[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia- l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (preparation described herein). -330- EXAMPLE 45 According to the general procedure of Example 44, the following lactam-quinolone is made: using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinolinecarboxylic acid (prepared according to J. P. Sanchez, et al . , J. Med. Chem., 1988, 31, 983) Similarly, the following lactam-quinolone is made by the general procedure of this Example with substantially similar results. using the beta-lactam [6R-[6a,7b(Z)]]-3-[(acetyloxy)methyl ]-7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl Jamino] -8-oxo-5- thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (preparation described herein) .

EXAMPLE 46 According to the general procedure of Example 44, the following lactam-quinolone is made: -331- using the quinolone 7-(3-aminopyrrolidinyl)-8-chloro-l- cycl opropyl -6- f 1 uoro- 1 , 4 -di hydro-4-oxo-3-qui nol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983).

Similarly, the following lactam-quinolone is made by the general procedure of this Example with substantially similar results. using the beta-lactam [6R-[6a,7b(Z)]]-3-[(acetyloxy)methyl ]-7-[ f(2-amino-4- thi azolyl)(methoxyimino) acetyl ]ami o] -8-0X0-5- thi a-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (preparation described herein).

EXAMPLE 47 According to the general procedure of Example 44, the following lactam-quinolone is made: -332- using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6- fluoro-l,4-dihydro-4-oxo-3-quinolinecarboxylic acid (prepared according to J. P. Sanchez, et al., J. Med. C em., 1988, 31, 983).

Similarly, the following lactam-quinolone is made by the general procedure of this Example with substantially similar results. using the beta-lactam [6R-[6a,7b(Z)]]-3-[(acetyloxy)methyl]-7-[[(2-amino-4-thiazolyl ) (methoxyimino)acetyl ]amino]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (preparation described herein) . -333- EXAMPLE 48 According to the general procedure of Example 44, the following lactam quinolone is made: using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl- 6-f1uoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983).

Similarly, the following lactam-quinolone is made by the general procedure of this Example with substantially similar results. using the beta- lactam [6R-[6a,7b(Z)]]-3-[(acety1oxy)methyl]-7-[[(2-amino-4-thiazolyl ) (methoxyimi no) acetyl ]amino]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (preparation described herein). -334- EXAMPLE 49 [5R-[40,5a,6aJ]-3-[2-[[(4-(3-carboxy-l-cyclopropyl-6-fluoro- l,4-dihydro-4-oxo-7-quinol inyl )-l-piperizinyl ]iminomethyl ]thio] ethylthio]-6-[(R) -1-hydroxyethyl ]-4-methyl -7-oxo-l-azabicyclo [3.2.0]hept-2-ene-2-carboxyl ic acid monosodium salt To a mixture of approximately 2.0 g of ciprofloxacin I in 70 ml of DMF at 0*C is added a solution of approximately 1.2 g of thiocarbonyldi imidazole in 10 ml of DMF and the reaction is stirred cold for approximately one hour. To the reaction is added an excess of saturated NH3/Me0H and the mixture is stirred cold for one hour and overnight at room temperature. The -335- solution is concentrated to dryness in vacuo and the residue is dissolved in a small amount of water containing approximately S.l ml of IN NaOH. The solution is concentrated to dryness and the residue is purified by C-18 reverse phase chromatography. The quinolone sodium salt is stirred in a mixture of Bio-RadR AG 50W-X4 (hydrogen form) in aqueous DMF, filtered, and the filtrate is concentrated in vacuo to give II.

A mixture of approximately 0.8 g of mesylate III and 0.5 g of II in approximately 8 ml of OMF is stirred approximately 20 hours at room temperature. To the reaction is added approximately 2.1 g of tetra-n-butylammonium fluoride and stirring is continued for approximately eight hours. Approximately 4 ml of saturated aqueous sodium bicarbonate is added and the mixture is eluted through a DowexR 50 x 4 (Na cycle) column with deionized water. The appropriate fractions are concentrated in vacuo and then lyophilized to give the title compound IV.

Similarly, the following lactam-quinolones are made by the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6,8-difluoro-l,4-dihydro-4-oxo-3-quinolinecarboxylic acid (prepared according to J. P. Sanchez, et al . , J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-8-chloro-l- cyclopropyl -6-fluoro-l ,4-dihydro -4-oxo-3-quinol inecarboxyl ic acid (prepared according to J. P. Sanchez, et al . , J. Med. Chem., 1988, 31, 983) using the quinolone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-d1hydro-4-oxo-3-quino1 inecarboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983) -337-using the naphthyridinone 7-(3-aminopyrrolidinyl)-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxyl ic acid (prepared according to J. P. Sanchez, et al., J. Med. Chem., 1988, 31, 983).

The following other actam-quino ones are also made by the general procedure of this Example and Examples 44-48, with substantially similar results.

EXAMPLE 50 [5R-[5a,6a]]-3-[[[(3-Carboxy-l-cyclopropyl-7-fluoro-l,4-dihydro-4-oxo-7-quinol inyl )-4-piperazinyl Jiminomethyl ]amino methyl]-6-[(R)-l-hydroxyethyl)]-7-oxo-4-thia-l-azabicyclo[3.2.0] hept-2-ene-2-carboxyl ic acid hydroiodide, of the following formula -339- is made as follows. A mixture of 7-[4-(aminothioxomethyl )piper- azinyl ]-l-cyclopropyl -7-fluoro-1 ,4-dihydro-4-oxo-3-quinol inecar- boxylic acid (1.0 g) and iodomethane (0.36 g) in DMF (50 ml) is stirred for 18 hours and concentrated to dryness in vacuo. The residue is recrystal1 ized from DMF to yield the isothiouronium compound. This quinolone (0.5 g) is refluxed with [5R-[5a,Sails'(aminomethyl)-6-[(R)-l-hydroxyethyl )]-7-ΟΧΟ-4-thia-l-azabi-cyclo[3.2.0]hept-2-ene-2-carboxyl ic acid (0.63 g), triethylamine (0.52 g) and a small amount of t-butanol in acetonitrile/DMF for 24 hours. The reaction is concentrated to dryness, stirred in water and the mixture is acidified with aqueous hydrogen iodide. The solid is collected by filtration and recrystal1 ized from aqueous methanol to give the final product.

EXAMPLE 51 [6R-[6a,7b]]-4-(3-Carboxy-l-ethyl-l,4-dihydro-4-oxo-7-quinol inyl)-l-[[2-carboxy-8-oxo-7-[(2-thienylacetyl )amino]-5-thia-l-azab1cyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinium sodium salt, of the formula according to this invention, is made as follows. A solution of cephalothin sodium salt (1.0 g), rosoxacin (0.70 g) (made according to U.S. Patent 3,907,808, 1975), NaHC03 (0.20 g) and -340- Η2θ (25 ml) is heated at approximately 45*C (113*F) for 18 hours and diluted with saturated aqueous NaCl. The mixture is centrifuged and the aqueous layer is decanted. The solid is triturated with aqueous acetone to yield the final compound.

The following lactam-quinoione is made according to the general procedure of this Example, with substantially similar results. using the quinolone l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7- (4-pyridyl)-3-quinoline carboxylic acid (prepared according to Y. Nishimura, et al., J. Med. Chem., 1987, 30, 1622).

EXAMPLE 52 According to the general procedure of Example 51, the following lactam-quinoione is made: using the beta-lactam 3-(acetyloxymethyl)-7-[[(2 amino-4-thiazolyl)acetyl] amino]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid (prepared as described herein).

Similarly, the following lactam-quinoione is made according to the general procedure of this Example, with substantially similar results. using the quinolone l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-(4-pyridyl)- 3-quinoline carboxyiic acid (prepared according to Y. Nishimura, et al., J. Med. Chem., 1987, 30, 1622).

The following other lactam-quinolones are also made according to the general procedures of this Example and Example 51, with substantially similar results.

EXAMPLE 53 [6R-(6a,70)]-3-[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-I,4- dihydro-4-oxo-7-quinol inyl) -1-piperazinyl Jcarbonyl ]-8-oxo- 7- [(2-thienyl acetyl ) amino] -5-thia-l -azabicyclo[4.2.0]oct-2- ene-2-carboxyl ic Acid Di sodium Salt A mixture of approximately 4.6 g of [6R-(6or,70))-3-carboxy- 8-0X0-7- [(2-thienyl acetyl ) amino] -5-thia-l -azabicyclo[4.2. O]oct -2- ene-2-carboxyl ic acid di phenyl methyl ester I (prepared according to Helv. Chim. Acta 1975, 58, 2450) and 1.1 ml of 2,6-lutidine in 75 ml of CH2CI 2 is cooled in an ice bath and approximately 0.79 -343- ml of oxalyl chloride is added slowly at 0-5'C. After the mixture is stirred in the cold for approximately 2 hours, a solution of approximately 3.3 g of ciprofloxacin t-butyl ester II and 1.1 ml of 2,6-lutidine in approximately 100 ml of CH2C 2 added slowly at 0-5*C. The mixture is stirred in the cold for approximately four hours and then is washed with dilute HC1, 10% NaHC03 and water. The organic phase is dried over Na2S04, filtered and the filtrate is concentrated to dryness. The product III is isolated by silica gel chromatography. To a solution of approximately 1.4 g of III in 30 ml of anisole is added approximately 30 ml of trifluoroacetic acid dropwise at approximately -15'C. The solution is stirred at ambient temperature for approximately 20 minutes and is concentrated to dryness in vacuo. The product is triturated in diethyl ether, collected by filtration and the solid is suspended in water. To this mixture is added approximately 0.26 g of NaHC03 and acetone is added to attain a solution. The solution is concentrated to dryness and the residue is purified by C-18 reverse phase chromatography to afford the title compound IV.

Similarly, the following lactam-quinolone is made according to the general procedure of this Example, with substantially similar results. using the quinolone 7-(3-aminopyrrolidinyl )-l-cyclopropyl -6,8-dif1uoro-l,4-dihydro-4-oxo-3-quinoline carboxylic acid (prepared according to J.P. Sanchez, et. al., J. Ned. Chem., 1988, 31, 983). -344- The following other lactam-quinolones are also made according to the procedure of this Example, with substantially similar results. -345- EXAMPLE 54 An antimicrobial composition for parenteral administration, according to this invention, is made comprising: Component Amount [6R-[6a,7b]]-[[[4-(3-Carboxy- 1- cyclopropyl -6-fluoro-l ,4- dihydro-4-oxo-7-quinol inyl )-l- piperazinyl]carbonyloxy]methyl]- 8-0X0-7- [(2- thienyl acetyl) ami no] - 5-thia-l-azabicyclo[4.2.0]oct- 2- ene-2-carboxyl ic acid disodium salt1 100 mg/ml carrier Carrier: sodium citrate buffer with (percent by weight of carrier): lecithin 0.48% carboxymethyl eel 1 ul ose 0.53 povidone 0.50 methyl paraben 0.11 propyl paraben 0.011 lactam-quinolone, made according to Example The above ingredients are mixed, forming a suspension. Approximately 2.0 ml of the suspension is systemically administered, via intramuscular injection, to a human subject suffering from a lower respiratory tract infection, with Streptococcus pneumoniae present. This dosage is repeated twice daily, for approximately 14 days. After 4 days, symptoms of the disease subside, indicating that the pathogen has been substantially eradicated.

EXAMPLE 55 An enteric coated antimicrobial composition for oral administration, according to this invention, is made comprising the following core tablet: -346- Component Amount { a) [6R-[6a,7b]]-[[[4-(3-Carboxy- 1-cyclopropyl -6-fluoro-l,4- dihydro-4-oxo-7-quinol inyl )-l- piperazi yl ]carbonyloxy]methyl ] - 8-0X0-7- [(2-thienyl acetyl )amino]- 5-thia-l-azabicyclo[4.2.0]oct- 2-ene-2-carboxyl ic acid disodium salt1 350.0 starch 30.0 magnesium stearate 5.0 microcrystall ine cellulose 100.0 colloidal silicon dioxide 2.5 povidone 12.5 1; a lactam-quinolone, made according to Example 1 The components are admixed into a bulk mixture. Compressed tablets are formed, using tabletting methods known in the art. The tablet is then coated with a suspension of methacrylic acid/methacryl ic acid ester polymer in isopropanol/acetone. A human subject, having a urinary tract infection with Escherichia col i present, is orally administered two of the tablets, every 8 hours',, for 14 days. Symptoms of the disease then subside, indicating substantial eradication of the pathogen.

DLS/ewl/N529R(PA2)

Claims (2)

92032/2 -347- CLAIMS:

1. A compound of the general formula Q - i - B wherein Q, L and B are defined as follows: Q is a structure according to Formula (I) 1 wherein R (A) (1) A1 is N or C(R7); where (i) is hydrogen, hydroxy, alkoxy, nitro, cyano, halogen, alkyl, or N(R8)(R9), and (ii) R8 and R9 are, independently, R8A where R8A is hydrogen, alkyl, alkenyl, carbocyclic ring, or heterocyclic ring; or R8 and R9 together comprise a heterocyclic ring including the nitrogen to which they are bonded; (2) A2 is N or C(R2); where R2 is hydrogen or halogen; (3) A3 is N or C(R5); where R5 is hydrogen; (4) R1 is hydrogen or R15, where R15 is alkyl, a carbocyclic ring, a heterocyclic ring, alkoxy, hydroxy, alkenyl, aryl alkyl, or N(R8)(R9); (5) R3 is hydrogen, halogen, or R*6, where Rl6 is alkyl, a carbocyclic ring, or a heterocyclic ring; _ (6) R4 is hydroxy; and (7) 6 is hydrogen, halogen, nitro, or N(R8)(R9}; - 348 - 92032/2 and further that (1) when is C(R7), R* and R7 may together comprise a heterocyclic ring including N' and A*; (2 J when A2 is C(R2), R2 and R3 may together comprise -0-(CH2)n-0-, where n is an integer from 1 to 4; (3) when A3 is C(≠), R* and «5 may together comprise a heterocyclic ring including the carbon atoms to which R4 and R5 are bonded and the carbon atom of Formula (I) to which said carbon atoms are bonded; and (4) when A3 is C(R5), R1 and R5 may together comprise a heterocyclic ring including N' and the adjacent carbon to w ich R5 is bonded; and either R1 is R15 or R3 is R16 and said R15 or~R16 is also the Q' or Q" of the moiety L thereby forming the linkag< between the Q and L moieties; B is a structure according to Formula (II): where L is bonded to R14 or if a, b and R14 are nil L is bonded direct to R12 or R13; wherein (A) R10 is hydrogen, halogen, alkyl, alkenyl, heteroalkyl, a (1) m is an integer from 0 to 9\ (2) R17 is hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, a carbocyclic ring, or a heterocyclic ring; (3) l8 is Rl7, .Yl, or -CH(Y2) (R17) 5 (4) R19 is Rl7, arylalkyl, heteroaryl alky , -C(R22)(R23)COOH, -C(=0)0-Rl7, or -C(-0)NH-R17, where 92032/2 -349- R2 and 23 are, independently, Rl7 or together comprise a carbocyclic ring or a heterocyclic ring including the carbon atom to which R22 and R3 are bonded; (5) R20 is 19, halogen, -γΐ, or -CH(Y2) (R17) . (6) Yl is -C(-0)0R21, -C(=0)R21, -N(R24)R21, -S(0)pR29, or -0R29; and γ2 is Yl or -OH, -5H, or -SO3H; (a) p is an integer from 0 to 2; (b) R 4 is hydrogen; alkyl; alkenyl; heteroalkyl; heteroalkenyl ; a carbocyclic ring; a heterocyclic ring; -SO3H; -C(=0)R25; 0r, when R18 is -CH(N(R24)R21)(R17)> R24 may- ' comprise a moiety bonded to R21 to form a heterocyclic ring; and (c) R5 is Rl7, NH(Rl7), N(R17)(R26)) O(R26), or S(R26)J where R26 is alkyl, alkenyl, a carbocyclic ring, a heterocyclic ring, or when R25 is N(Rl7) (R26) , R26 may be a moiety bonded to Rl to form a heterocyclic ring; and (7) R21 is R29 0r hydrogen; where R29 is alkyl; alkenyl; arylalkyl; heteroalkyl; heteroalkenyl; heteroaryl alkyl ; a carbocyclic ring; a heterocyclic ring; or, when Y is N(R24)R21 and R21 is R29, R21 and R4 may together comprise a heterocyclic ring including the nitrogen atom to which R24 is bonded; (B) Rll is hydrogen, halogen, alkoxy, or R27c(=0)NH- , where R27 is hydrogen or alkyl; (C) bond "a" is a single bond or is nil; and bond "b" is a single bond, a double bond, or is nil; except bond "a" and bond "b" are not both nil; (Q) if (a) is nil and (b) is a single bond: Rn is C (RSa) X' or CHjR32, wherein (i) X1 is -R21; -OR30; -S(O) ^30, where r is an integer from 0 to 2, preferably 0; -OC=0)R30; or N(R30)R31; and 92032/2 - 350 - (ii) R30 and R31 are, independently, alkyl, alkenyl, carbocyclic ring or heterocyclic ring substituents; or R30 and R31 together comprise a heterocyclic ring including the nitrogen atom to which R30 and R31 are bonded;" or R32 is -CfR8*) (R21) , -0-, or -NR8\ and R32 is directly bonded to N" in Formula (II) to form a 5- membered ring; R13 is C(0)NHS02; and R14 is nil; if (a) is nil and (b) is a double bond: R12 is C(Rta) X' or CHjR32 wherein (i) X1 is -R21; -OR30; -S(0) ^R30, where r is an integer from 0 to 2, preferably 0; -OC=0)R30; or N(R30)R31; and (ii) R30 and R31 are, independently, alkyl, alkenyl, carbocyclic ring or heterocyclic ring substituents; or R30 and R31 together comprise a heterocyclic ring including the nitrogen atom to which R30 and R31 are bonded; or R32 is -C(R8*) (R21) , -0-, or -NR8*, and R32 is directly bonded to N" in Formula (II) to form a 5- membered ring; R13 is —c (R33) ; R14 is nil if (a) is a single bond and (b) is nil: R12 is -C(R8a)-, or -CH,-R28-, preferably -C(R8*)-; where R28 is -C(R8*), -0-, or -N-, and R28 is directly bonded to N" in Formula (II) to form a~5-membered ring; Rt3 is hydrogen, -S03H, -POiOR^OH, .-CfOjNHSO^R34) (R3S) , -OS03H, -CH(R33)COOH, or -OCHiR^COOH, preferably hydrogen, -S03H or -CiOJNHSOjNiR34) (R3S) ; where R34 is hydrogen, alkyl, alkenyl, a carbocyclic ring, or a heterocyclic ring; and R35 is hydrogen, alkyl, alkenyl, or -NHR8*; or, if R13 is -CiOJNHSO^fR34) (R3S) , R and R35 may together comprise a heterocyclic ring including the nitrogen to which R34 and R33 are bonded; and R14 is nil,- 92032/2 - 351 - if (a) and (b) are both single bonds: Rn is -C(R8*)-, or -CH,-R28-, preferably -C (R ) - ; where R28 is -C(Ria) , -0-, or -N-, and R28 is directly bonded to N" in Formula (II) to form a .5-membered ringj R13 is -CH(R33)-; or -C*(R33J- if R14 contains a R36 moiety; where R33 is hydrogen or COOH, preferably COOH, and C* is linked to R36 to form a 3-membered ring; R14 is -W-C"/=C(R8*) -R37-, or -W-C" (R^J-R37-; if (a) is a single bond and (b) is a double bond:. R12 is -C(R*»)-, or -CH,-R28-/ preferably -C(R8*)-; where R28 is -C(R8*), -0-, or -N-, and R2s is directly bonded to N" in Formula (II) to form a 5-membered ring} R13 is C(R33)/ R14 is -C(R8*)R38)-W-C', -R37-;-W-C(R8'1) (R38) -C -R37-; or -W-C'"-R37; preferably -W-C (R8*) (R38) -C'-R37- or -W-C'-R37-; where (a) W is 0; S(0)a/ where s is an integer from 0 to 2, preferably 0; or C(R38) , where R38 is hydrogen, alkyl or alkoxy; (b) R36 hydrogen; alkyl; alkenyl; -COOH; or, if R13 is -C*(R33), R36 may be linked to C' to form a 3-membered carbocyclic ring; (c) R37 is nil, alkyl, alkenyl, a carbocyclic ring, or a heterocyclic ring; and (d) C"' is directly bonded to R13 to form a 5- or 6-membered ring; (III) L links Q to B; and L is L' , -X2t-R39-L', or -X3t-R39-L\ where L' is Q' , -X2-Q", -X3-Q", -X4t- (=Y3u)-Z-Q", .X5t. po(Y4uR8a) .Z ' .Q " , or X5t-S02-Z' -Q" ; (1) t and u are, independently, 0 or 1; (2) R39 is alkyl, alkenyl, heteroalkyl, heteroal kenyl , a carbocyclic ring, or a heterocyclic ring; (3) X2 is oxygen, or S(0)v, where v is an integer from 0 to 2; 92032/2 - 352 - (4) X is nitrogen; N(R4°); N+(R41) (R42) ; or R43-N(R4 ); and is linked to R4 by a single or double bond; or, if R^4 is nil, X3 is linked to B by a single or double bond; where (a) R40 is R8a; -0R8a; or -C(=0)R8a; (b) R4 and R42 are, independently, hydrogen; alkyl; alkenyl; carbocyclic rings; heterocyclic rings; or, together with Q", comprise a heterocyclic ring as Rl5 or R6; (c) R43 is N(R41), oxygen or sulfur; (5) X4 is oxygen, sulfur, NR40, or R43-NR4 ; (6) X5 is oxygen or NR4*; (7) Y3 is oxygen, sulfur, NR4° or N+(R4 ) (R42) ; (8) Y4 is oxygen or (9) Z is nil, oxygen, sulfur, nitrogen, NR40, or N( 41)- 43; (10) V is nil, oxygen, nitrogen, or NR4*; (11) Q' is Rl5 or Rl6; and (12) Q" is Q'; or together with χ2, X3, Z or Ζ', is an R15 or R16 group; and pharmaceutically-acceptable salts and biohydrolyzable esters thereof, and hydrates thereof. - 353 -

2. A compound, according to Claim '1, wherein said lactam-containing moiety is selected from the group consisting of cephems, oxacephems., carbacephems, isocephems, iso-oxacephems, penems, carbapenems, clavems, penicillins, clavams, 2,3-methyleno-penems, 2,3-methyleno-carbapenems, and pyrazol idinones.

3. A compound, according to Claim 2, wherein said lactam-containing moiety is selected from the group consisting of cephems, penems, and carbapenems. 4... A compound, according to Claim 4', wherein said lactam-containing moiety is selected from the group consisting of monobactams, monophosphams, monocarbams, monosulfactams, nocardicins, lactivicin analogs, and gamma -lactams.

5. A compound according to Claim 2 or 4, wherein R11 is hydrogen or alkoxy and R12 is -C(R8a)-.

6. A compound according to Claim 1, whrein: A1 is nitrogen, A2 is R2), and A3 is C(R5). 92032/2 - 354 -

7. A compound according to Claim 19, wherein Q is a 6-fl uoroquinolone moiety, a 8-halo-6-fluoroquinolone moiety, a pyridobenzoxazine moiety, a pyridobenthiazine moiety, a isothiazoloquinol inedione, or isoxazoloquinol inedione moiety.

8. . A compound, according to Claim 19, wherein R is alkyl, aryl, cycloalkyl or alkyamino; and R2 is hydrogen, chlorine or fluorine.

9. A compound, according to Claim 21, wherein R is ethyl, 2- fluoroethyl , 2-hydroxyethyl , t-butyl, 4-fluorophenyl , 2,4-difluorophenyl , methylamino or cylcopropyl.

10. A compound, according to Claim 7, 8 or 9, wherein R3 is piperazine, 3-methylpiperazine, 3-aminopyrrol idine, 3- aminomethyl pyrrol idine, Ν,Ν-dimethyl ami nomethyl pyrrol idine, N-methy 1 ami nomethyl pyrrol idine, N-eth 1 ami nomethyl pyrrol idine, pyridine, 4-dithiocarbamoyl piperazine, 3-(di thiocarbamoylami -nomethyl ) pyrrol idine, N-methylpiperazine, 3,5-dimethylpiperazine, or 3-(dithiocarbamoylamino)pyrrol idine. 92032/2 - 355 -

11. A compound, according to Claim 10, wherein R1 is cyclopropyl, R2 is fluorine and R3 is piperazine.

12. A compound, according to Claim 1, wherein L comprises a linking moiety selected from the group consisting of carbamate, dithiocarbamate, urea, thiourea, isouronium, isothiouronium, guanidine, carbonate, trithiocarbonate, reversed carbamate, xanthate, reversed isouronium, reversed dithiocarbamate, reversed isothiouronium, amine, imine, ammonium, heteroaryl ium, ether, thioether, phosphono, phosphoramide, phosphate, sulfonamide, ester, thioester, amide and hydrazide groups. 13/. A compound, according to Claim12 , wherein L is L', and L' is -X2-Q\ -X3-Q", or x4t-C(=Y3u)-Z-q"-. ">4· A compound, according to Claim 13, wherein Q" is R*6, or together with χ2, χ3, Z or Ζ', is and wherein said linking moiety is a carbamate or dithiocarbamate group. 92032/2 -356- 15. A compound, according to Claim 29, wherein: (1) if bond "a" or bond "b" is nil, then RH-L is I; (2) if bond "a" and "b" are single bonds, RH-L is -W-C*"=C(R8a)-R37-L, or -H-C"' (R36).R37.L; or (3) if bond "a" is a single bond and bond "b" Is a double bond, RH-L is -C(R8a)(R38)-W-CM'-R37-L; -W'-C(R8a)(R38)-C*"-R37-L, or -W-C"'-R37-L; where R43.n(R41).Q», -Z'-Qn, or

16. A compound selected from the group consisting of [6R-[6a,7b]]-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo- 7-quinol inyl ) -1-piperazinyl ]carbonyloxy]methyl ] -8-oxo- 7 -[(2-thienylacetyl)amino]-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2- . carboxylic acid di sodium salt; 92032/2 - 357 - [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo- 7-quinol inyl ) -1-piperazinyl ]thioxomethylthio] methyl ]-8-oxo-7-[(2-thienyl acetyl )amino]-5-thia-l-azabicyclo [4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b(Z)]]-7-[[[(2-Amino-4-thiazolyl )methoxy imi no] acetyl ] amino] -3- [[[[4- (3-carboxy-l-cyclopropyl -6-fluoro-l ,4-dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl ] thi oxomethyl ]thio]methyl ]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl ] thi oxomethyl ] th i omethyl] -6- [(R)-l -hydroxyethyl ]-7-oxo-4- thi a- 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid disodium salt; [6R-[6a,7b]]-3-[[[4-[6-Carboxy-8-ethyl-5,8-dihydro-5-oxo-pyri-do[2,3-d]pyrimidin-2-yl ] -1 -piperazinyl ] thi oxomethyl ] thi omethyl ]-7-[[[[[3-[(3,4-dihydroxyphenyl )methyleneamino] -2-oxo-l-imidazol i -dinyl ]carbonyl ami no] phenyl ] cetyl ]amino]-5-thia-l-azabi-cyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[[[4-(3-Carboxy-cyclopropyl -6-fl uoro-1 ,4-d hydro-4-oxo-7-quinol inyl ) -1-piperazinyl ] iminomethyl ] thi omethyl ] -6-[ (R) -1 -hydroxyethyl] -7-oxo- 1-azabi cyclop.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4,-oxo-7-quinol inyl )-3-pyrrol idinylamino]iminomethyl ]-thi omethyl ] -7- [ [ (R) -hydroxy (phenyl ) acetyl ] ami no] -7-methoxy-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid sodium salt; (3S)-2-[[[4-[3-Carboxy-l-cyclopropyl -6-fluoro-l ,4-di hydro-4-oxo-7-quinol inyl ] -1-piperazinyl ] iminomethyl ]thio]-3-[[phenoxyacetyl ] -amino]-4-oxo-l-azetidinesul fonic acid sodium salt; 92032/2 - 358 - [5R-[4b,5a,6a]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl )-l-piperazinyl ]methyl iminomethyl ]me-thylthio] -6- [(R) -1-hydroxyethyl ] -4-methyl -7-0X0-4-thia-1-azabi -cyclo[3.2.0]hept-l-ene-2-carboxylic acid disodium salt; [5R-[5a,6a]]-3-[2-[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6-fluoro-1 ,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinyl amino] iminomethyl ]amino]ethyl thio] -6- (R)-l-hydroxyethyl -7-oxo-1-azabi -cyclo[3.2.0]hept-2-ene-2-carboxyl ic acid monosodium salt; [5R- [5a,6a]] -3-[[[l-[3-Carboxy-1- (2,4-di fluorophenyl )-6-fluoro-l,4-dihydro-4-oxo-l ,8-naphthyridin-7-yl ] -3-pyrrol idinyl amino] -carbonyloxy]methyl ] -6-[(R)-l-hydroxymethyl ]-7-oxo-4-thia-l-aza-bicyclo[3.2.0]hept-2-ene-2-carboxyl ic acid, disodium salt; [6R-(6a,7b)]-7-[[[(2-Aminocarbonyl -2-fluoro)ethenylthio]acetyl ] amino]-3-[[[l-(3-carboxy-8-chloro-l-cyclopropyl -6-fluoro-l ,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinyl amino]carbonyloxy]-methyl ] -8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [3S]-3-[[(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amino]-2-[[[1- (3-carboxy-l-cyclopropyl -8-chloro-6-fluoro-l ,4-dihydro-4-oxo-7-quinol inyl") -3-pyrrol idinyl amino]thioxomethyl ]thio] -4-oxo-1-azetidinesul fonic acid disodium salt; [6R-[6a,7b(Z)]]-7-(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amino] -3-[[[4- (3-carboxy-l-cyclopropyl -6-fluoro-1,4-dihydro-4-oxo-7-quinol inyl )-l-piperazinyl ]carbonyloxy]methyl ]-8-oxo-5-thi a- 1-azabicyclo[4.2.0] oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b(Z)]] -7-(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amino] -3- [[[1- (3-carboxy-l-cyclopropyl -6-fluoro-1, 4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinyl amino]carbonyloxy]methyl ] -8-oxo-5-thia-l-azabicyclo[4.2.0] oct-2-ene-2-carboxyl ic acid disodium salt; 92032/2 - 359 - [6R-[6a,7b(Z)]]-7-(2-Amino-4-thiazolyl) (methoxyimino)acetyl ]am-ino]-3-[[[l-(3-carboxy-l-cyclopropyl -6,8-difluoro-l,4-dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinyl amino]carbonyloxy]methyl ]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid di-sodium salt; [6R-[6a,7b(Z) ]] -7-(2-Amino-4-thiazolyl ) (methoxyimi no)acetyl ]amino] -3- [[[l-(3-carboxy-8-chloro-l-cyclopropyl-6-fl uoro-1,4-dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]carbonylox-y]methyl ]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R- [6a,7b(Z)]] -7- (2-Amino-4-thiazolyl) (methoxyimino)acetyl ] amino] -3- [[[1- (3-carboxy-l-cyclopropyl -6-fl oro-l,4-dihydro-4-oxo- 1 ,8-naphthyridin-7-yl ] -3-pyrrol idinyl aminojcarbonyl ox-y]methyl]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-ethyl-6-fluoro-l,4-dihydro-4-ox-o-7-quinol inyl ) -1-piperazinyl ]carbonyloxy]methyl ] -8-oxo-7- [ (2-thienyl acetyl) amino]-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt; [6R-[6a,7b]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihy-dro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]carbonyloxy]methyl ]- > 8-oxo-7- [(2-thienyl acetyl ) amino] -5-thia-l-azabicyclo[4.2.O]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[l-(3-Carboxy-l-cyclopropy1-6,8-difluoro-l,4-di-hydro-4-oxo-7-quinol inyl )-3-pyrrol idinyl ami no]carbonyl ox-y]methyl ]-8-oxo-7-[ (2-thienyl acetyl)amino] -5-thi a- 1-azabi-cyclo[4.2.0]oct-2-ene-2- carboxylic acid disodium salt; 92032/2 - 360 - [6R-[6a,7b]]-3-[[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6-f1uoro- 1 ,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylaminojcarbonyloxyJ methyl ]-8-oxo-7-[(2-thienylacetyl )amino]-5-thia-l-azabicyclo [4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydr- o-4-oxo-1 ,8-naphthyrid n-7-yl ) -3-pyrrol idinylaminojcarbonyloxyjmethyl ]-8-oxo-7-[(2-thienyl acetyl )amino]-5-thia-1-azabi - cyclof4.2.0]oct-2-ene-2-carboxy1 ic acid disodium salt; [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydr- 0-4-oxo-7-quinol inyl)-l-piperazinyl Jcarbonyloxy]methyl]-8-oxo- 7-[(phenoxyacetyl ) amino]-5-thia-l-azabicyclo[4.2.0]oct-2-ene- 2-carboxylic acid disodium salt; [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4-di- hydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylaminojcarbonyloxyjmethyl] -8-oxo-7- [(phenoxyacetyl )amino] -5-thi a-1-azabicyclo[4.2.0]oct-2- ene-2-carboxyl ic acid disodium salt; i6R-[7a,7bJ]-7-[[(2-amino-4-thiazolyl)acety1]aminoJ-3-[[[4-(3- carboxy-l-cyclopropyl-6-fluoro-l ,4-dihydro-4-oxo-7-quinol inyl ]- 1-piperazinyl Jthioxomethyl thiojmethyl J-8-oxo-5-thia- 1 -azabi- cylclo[4.2.0Joct-2-ene-2-carboxyl ic acid disodium salt; [6R-[7a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydr-o-4-oxo-7-quinol inyl J -1 -piperazinyl Jthioxomethyl thiojmethyl J -8-oxo-7-((2-phenoxyacetyl )aminoJ-5-thia-l-azabicylclo[4.2.0Joct- 2-ene-2-carboxyl ic acid disodium salt; [6R-[7a,7bJJ-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydr-0-4-oxo-7-quinol inyl]-l-piperazinyl Jthioxomethyl thiojmethyl J-8-oxo-7-[[(4-pyridinyl thio)acetyl JaminoJ-5-thia- 1-azabi -cylclo[4.2.0Joct-2-ene-2-carboxyl ic acid disodium salt; 92032/2 - 361 [5R-[5a,6a(R*)]-3-[[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-di- hydro-4-oxo-7-quinol inyl)-l-piperazinyl]thioxomethylthio]acetyl ]aminometyl]-6-(1-hydroxyethylj-7-0X0-4-thia-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid disodium salt; [6R-[7a,7b]]-7-[[(2-amino-4-thiazolyl)[[(3,4-dihydroxypheny1)car- bonyl ]amino]acety ]amino]-3-[[[4-(3-Carboxy-l-cyclopropyl -6- fluoro-l ,4-dihydro-4-oxo-7-qunol inyl]-l-piperaziny ]thi-oxomethylthio]methyl ]-8-oxo-5-thia-1-azabicylclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b(Z) ]]-7-(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amin-o]-3-[[[[4-(3-carboxy-l-ethyl -6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl)-l-piperazinyl ] thioxomethyl ]thio]methyl ]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b(Z)]]-3-[[[[4-(3-carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl )-l-piperazinyl Jthioxomethyl ]thio] methyl ]-7-[[2-furyl (methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b(Z) ]]-7-(2-Amino-4-thiazolyl )(methoxyimino)acetyl ]amin-o]-3-[[[[l-(3-carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo- 7-quinol inyl)-3-pyrrol idinylamino]thioxomethyl ]thio]methyl ]-8-oxo-5-thia-l-azabicyclo [4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b(Z)]]-7-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amin-o]-3- [[[[l-(3-carboxy-l-cyclopropyl -6,8-difluoro-l,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylamino]thioxomethyl]thio]methyl]- 8-oxo-5-thia-l-azabicyclo [4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; 92032/2 - 362 - [6R-[6a,7b(Z)]]-7-(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amin-150 o]-3-[[[[l-(3-carboxy-8-chloro-l-cyclopropyl -6-fluoro-l ,4-di - hydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylamino]thioxomethyl ]thi- o]methyl ]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b(Z) ]]-7- (2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amin-155 o]-3-[[[[l-(3-carboxy-l-cyclopropyl -6-fluoro-l,4-dihydro-4-oxo- 1 ,8-naphthyridin-7-yl )-3-pyrrol idinylamino]thioxomethyl ]thi - o]methyl ] -8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt; [6R-[6a,7b]]-3-[[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihyd-160 ro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]thioxomethyl ]thi- o]methy1 ] -8-oxo-7- [(2-thienyl acetyl )amino] -5-thia-1-azabi - cyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[[l-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4-d- ihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]thioxomethyl ]thi-165 o]methyl ] -8-oxo-7-[(2-thienyl acetyl )amino] -5-thia-1-azabi - cyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[[l-(3-Carboxy-8-chloro-l-cyclopropyl -6-fluoro-- 1 ,4-dihydro-4-oxo-7-qu nol inyl ) -3-pyrrol idinyl amino]thiox- omethyl ]thio]methyl ]-8-oxo-7- [(2-thienyl acetyl )amino]-5-thia-170 l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a, 7b]]-3-[[[[l- (3-Carboxy-l-cyclopropyl -6-fluoro-l,4-dihyd- ro-4-oxo-l,8-naphthyridin-7-yl ) -3-pyrrol idinyl amino]thiox- omethyl]thio]methyl ] -8-oxo-7- [(2-thienyl acetyl )amino] -5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; 175 [6R-[6a,7b]]-3-[[[[l-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4-d: ihydro-4-oxo-7-quinol inyl )-3-pyrrol idinyl amino]thioxomethyl ]thi - o]methyl ] -8-oxo-7- [(phenoxyacetyl )amino] -5-thia- 1-azabi - cyclo[4.2.0]o ct-2-ene-2-carboxyl ic acid disodium salt; 92032/2 - 363 - [5R-[5a,6a]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydr-180 o-4-oxo-7-quinol inyl ) -3 -pyrrol idinyl amino ]carbonyloxy]methyl ] -6- [ (R) - 1 -hydroxyethyl ]-7-oxo-4- thi a- 1-azabicylo [3.2.0] hept-2-ene- 2-carboxylic acid disodium salt; [5R-[5a,6a]]-3-[[[4-(3-Carboxy-l-cyclopropyl -6-f 1 uoro-1, -dihydr- o-4-oxo-7-quinol inyl ) - 1 - p perazinyl ]carbonyloxy]methyl ] -6- [ (R) - 1 -185 hydroxyethyl ]-7-oxo-4- thi a- 1-azabi cylo [3.2.0]hept-2-ene- 2- carboxylic acid disodium salt; [5R-[5a,6a]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4-di- hydro-4-oxoi-7-quinol inyl )-3-pyrrol idinylamino]carbonyloxy]me- thyl] -6- [(R)-l -hydroxyethyl ]-7-oxo-4-thia-l-azabicylo[3.2.0]hept-190 2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6-f1uoro- 1 ,4-dihydro-4-oxo-7-quinol inyl ) -3 -pyrrol idinyl amino]carbonylox- y]methyl ] -6- [(R)-l -hydroxyethyl ] -7-0X0-4- thi a- 1-azabi - cylo[3.2.0]hept-2-ene- 2-c arboxylic acid disodium salt; 195 [5R-[5a,6a]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydr- o -4-oxo- l,8-naphthyridin-7-yl ) -3- pyrrol idinyl ami no] carbonylox- y]methyl ] -6- [(R)-l -hydroxyethyl ] -7-0X0-4- thi a- 1-azabi - cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dih-200 ydro-4-oxo-7-quinol inyl )-l-piperazinyl ]carbonyloxy]methyl ]-6- [(R)-l-hydroxyethyl]-4-methyl-7-oxo-l-azabicylo[3.2.0]hept-2- ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dih- ydro-4-oxo-7-quinol inyl )-3-pyrrol idinyl ami no]carbonylox ]methyl ]-205 6- [(R)-l -hydroxyethyl ]-4-methyl -7-oxo- l-azabicylo[3.2.0]hept-2- ' ene-2-carboxyl ic acid disodium salt; 92032/2 - 364 - [5R-[4b,5a,6a]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4- -dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]carbonyloxy]me- thyl ]-6-[(R)-l-hydroxyethyl ]-4-methyl -7-oxo-l-azabi -210 cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[[[l-(3-Carboxy-8-chloro-l-cyclopropyl -6-fluor- o-l,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinyl amino]carbonylox- y]methyl ]-6-[(R)-l-hydroxyethyl ]-4-methyl -7-oxo-l-azabi - cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; 215 [5R-[4b,5a,6a]]-3-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-l,8-napththyridin-7-yl )-3-pyrrol idinyl amino]car- bony!oxy]methyl ] -6-[(R)-l-hydroxyethyl ]-4-methyl -7-oxo-l- azabicylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[4-(3-Carboxy-l-cyc1opropyl-6-fluoro-l,4-dihy-220 dro-4-oxo-7-quinol inyl ) -1-piperazinyl ]carbonyloxy]ethyl thio] -6- [(R)-l-hydroxyethyl 1-7-0X0-4-thi a- l-azabicylo[3.2.0]hept-2- ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[l-(3-Carboxy-l-cyclopropyl -6-fluoro-l,4-dihy- dro-4-oxo-7-quinol inyl )-3-pyrrol idinyl amino]carbonyloxy]ethyl thi -225 o] -6- [(R)-l-hydroxyethyl ] -7-0X0-4-thia-l-azabicylo[3.2.0]hept-2- ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[l-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4- dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinyl amino]carbonylo - y]ethylthio]-6-[(R)-l-hydroxyethyl]-7-oxo-4-thia-l-azabi-230 cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6-fl uoro- l,4-dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]carbonylox- y]ethylthio]-6-[(R)-l-hydroxyethyl]-7-oxo-4-thia-l-azabi- cylo[3.2.0]hepti2-ene-2-carboxylic acid disodium salt; 92032/2 - 365 - 235 [5R-[5a,6a]]-3-[2-[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihy- dro-4-oxo-l ,8-naphthyridin-7-yl ) -3-pyrrol idinylamino]carbonylox- y]ethylthio]-6-[(R)-l-hydroxyethyl ] -7-oxo-4-thia-l-azabi - cylo[3.2.0] ept-2-ene -2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-240 dihydro-4-oxo-7-quinol inyl )-l-piperazinyl ]carbonyloxy]ethylthio]- 6-[(R)-l-hydroxyethyl ]-4-methyl -7-oxo-l-azabicylo[3.2.0]hept-2- ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylaminojcarbonylox-245 y]ethyl thio] -6- [(R)-l-hydroxyethyl ] -4-methyl -7-oxo-l-azabi - cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[l-(3-Carboxy-l-cyclopropyl-6,8-difluoro- 1 ,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylamino]carbonylox- y]ethyl thio] -6- [(R) -1-hydroxyethyl ] -4-methyl -7-oxo-l-azabi -250 cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6-flu- oro-l,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylamino]car- O bonyloxyjethyl thio]-6- [(R)-l-hydroxyethyl] -4-methyl -7-oxo-l- azabicylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; 55 [5R-[4b,5a,6a]]-3-[2-[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-l,8-napththyridin-7-yl ) -3-pyrrol idinyl amino]car- bonyloxy]ethyl thio] -6-[(R)-l-hydroxyethyl] -4-methyl -7-oxo-l- azabicylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[[[[l-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4- 60 dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]thioxomethyl ]thi - o]methyl ] -6- [(R)-l-hydroxyethyl] -7-0X0-4-thia-1-azabi - cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; 92032/2 - 366 - [5R-[4b,5a,6a]]-3-[[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-di- hydro-4-oxo-7-quinol inyl ) -1-piperazinyl J hioxomethyl ]thi -265 ojmethyl ] -6- [(R)-l -hydroxyethyl] -4-methyl-7-oxo- 1-azabi- cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[[[[l-(3-Carboxy-l-cyclopropyl -6,8-di fluoro- 1 ,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylamino]thiox- omethyl ]thio]methyl ] -6- [ (R) - 1 -hydroxyethyl ] -4-methyl -7-oxo- 1 -270 azabicylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- di hydro-4-oxo-7-quinol inyl ) -l'-piperazinyl Jthioxomethyl ]thi - o]ethyl thio] -6- [(R)-l -hydroxyethyl ]-7-oxo-4-thi a-1-azabi - cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; 75 [5R-[5a,6a]]-3-[2-[[[l-(3-Carboxy-l-cyclopropyl -6,8-difluoro- 1 ,4-dihydro-4-oxo-7-quinol inyl ) -3-pyrrol idinylamino]thiox- omethyl ]thio]ethyl thio] -6- [(R)-l -hydroxyethyl ]-7-oxo-4-thi a- 1- azabicylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6- 80 fluoro-l,4-dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]thi- oxomethyl]thio] ethyl thio] -6- [(R)-l -hydroxyethyl ]-7-oxo-4-thi a- l-azabicylo[3.2.0]hept-2-ene -2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-l,8-naphthyridin-7-yl )-3-pyrrol idinylamino]thiox- 85 omethyl]thio]ethylthio] -6- [(R)-l -hydroxyethyl ]-7-oxo-4-thi a- 1- azabicylo[ 3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- di ydro-4-oxo-7-quinol inyl ) -1-piperazinyl jthioxomethyl ]thi - o]ethyl thi o] -6- [(R)-l-hydroxyethyl] -4-methyl -7-oxo- 1-azabi - 90 cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; - 367 - 92032/2 [SR-t^^a^aJl-S-ta-tCtl-iS-Carbox -l-cclopropyl-e^-difluoro-1 ,4-dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]thiax-omethyl ]thio]ethylthio]-6-[(R)-l-hydroxyethyl ]-4-methyl -7-oxo-l-azabicy1o[3.2.0]hept-2-ene-2-carboxylic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[[l-(3-Carboxy-8-chloro-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]thio-xomethyl ]thio] ethylthio]-6-[ (R) -1-hydroxyethyl ] -4-methyl -7-oxo-l-azabicylo[3.2.0]hept-2-ene-2-carboxylic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[[l-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-l ,8-napththyridin-7-yl )-3-pyrrol idinylamino]thiox-omethyl ]thio] ethylthio]-6-[(R) -1-hydroxyethyl ]-4-methyl -7-oxo-l-azabicylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl ] iminomethyl ]thi -omethyl ]-8-oxo-7-[(2-thienylacetyl )amino]-5-thia-1-azabi -cyclo[4.2.0]oct-2-ene-2-carboxyl ic acid sodium salt; [6R-[6a,7b]]-3-[[[4-(3-Carboxy-l-cyclopropyl-6,8-difluoro-l,4-di-hydro-4-oxo-7-quinol inyl )-1-piperazinyl ] iminomethyl ]thi -omethyl ]-8-0X0-7-[(2-thienyl acetyl )amino]-5-thia-1-azabi -cyclo[4.2.0]oct-2-ene-2-carboxyl ic acid sodium salt; [6R-[6a,7b(Z)]]-7-[[(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amino]-3-[[[4-(3-carboxy-l-cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-7-quinol nyl )-1-piperazinyl ]iminomethyl ]thiomethyl ]-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid sodium salt; [6R-[6a,7b(Z)]]-7-[[(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ]amino]-3-[[[4-(3-carboxy-l-cyclopropyl -6,8-di luoro-l,4-dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl Jiminomethyl Jthiomethyl ]-5-thia- . l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt; 92032/2 - 368 - [5R-[5a,6a]]-3-[[[4-(3-Carboxy-l-cyclopropyl -6-fluoro-l,4-320 dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl ]iminomethyl ]thi - omethyl ]-6-[(R) -1-hydroxyethyl] -7-oxo-4-thia-I-azabi- cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[5a,6a]]-3-[2-[[[4-(3-Carboxy-l-cyc1opropyl-6-fluoro-l,4- di hydro -4 -oxo -7-quinol nyl ) -1-piperaz nyl ] im nomethyl]thi -325 o]ethyl thio] -6- [(R) -1-hydroxyethyl ] -7-oxo-4-thi a- 1-azabi - cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [5R-[4b,5a,6a]]-3-[2-[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- di hydro-4-oxo-7 -qui nol inyl ) -1-piperazinyl ]iminomethyl ]thi - o]ethylthio]-6-[(R)-l-hydroxyethyl]-4-methyl -7-oxo- 1-azabi -330 cylo[3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; l-Cyclopropyl-6-fluoro-l ,4-dihydro-4-oxo-7-[4-[[[(2S-trans)-3- [(phenoxyacetyl )amino]-2-azetidinyl ]thio]thioxomethyl ]-l- piperazinyl J-3-quinolinecarboxylic acid sodium salt; 1-Cyclopropyl -6-fluoro-l,4-dihydro-4-oxo-7-[4-[[[(2S-trans)-3-335 [(pherioxyacetylamino]-l-sul o-2-azetidinyl ]thio]thioxomethyl ]-l- piperazinyl ]-3-quinol inecarboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[[[4-(3-Carboxy-l-cyclopropyl-6-fluoro-l,4- dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl ]thioxomethyl ]ami - no]methyl ] -8-0X0-7- [ (2- thienyl acetyl ) ami no] -5-thi a- 1-azabi -340 cyclo[4.2.0]oct-2-ene-2-carboxyl ic acid sodium salt; [6«-[6a,7b(Z)]]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]am- ino]-3-[[[[l-(3-carboxy-l-cyclopropyl-6,8-difl uoro-1,4- dihydro-4-oxo-7-quinol inyl )-3-pyrrol idinylamino]thioxomethyl ]ami - no]methyl]-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 345 sodium salt; 92032/2 - 369 - [5R-[5a,6a]] -3- [[[[4-(3-Carboxy-l-cyclopropyl -6-fluoro-l,4- dihydro-4-oxo-7-qu1nol inyl ) -1-piperazinyl ]thioxomethyl ] mino] methyl ] -6- [(R)-l-hydroxyethyl ] -7-oxo-4-thia-l-azabicylo[3.2.0] hept-2-ene-2-carboxyl ic acid disodium salt; 350 [5R-[4b,5a,6a]]-3-[2-[[[4-(3-Carboxy-l-cyclopropyl-6-fIuoro-l,4- dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl]thioxomethyl ]amino] ethyl thio] -6- [ (R) -1-hydroxyethyl ]-4-methyl -7-oxo-l-azabicylo [3.2.0]hept-2-ene-2-carboxyl ic acid disodium salt; [6R-[6a,7b]]-3-[[4-(3-Carboxy-l-cyclopropyl -6-fluoro-l,4-dihydro-355 4-oxo-7-quinol inyl ) -1-piperazinyl ]methyl]-8-oxo-7-[(2-thienyl acetyl )amino]-5-thi a-l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid sodium salt; [6R- [6a,7b(Z)]] -7- (2-Amino-4-thiazolyl) (methoxyimino)acetyl ]amino] -3-[[4- (3-carboxy-l-cyclopropyl -6-fluoro-l ,4-dihydro-4-oxo-7-360 quinol inyl )- 1-piperazinyl ]methyl ]-8-oxo-5-t ia-l-azabi- cyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt; [6R- [6a, 7b]] -3-[[[ [4- (3-Carboxy-l-cyclopropyl -6-fluoro-l, 4- dihydro-4-oxo-7-quinol inyl ) -1-piperazinyl ]carbonyl ]amino]methyl ] - 8-0X0-7- [(2-thienyl cetyl )amino] -5-thia-l-azabicyclo[4.2.0]oct-365 2-ene-2- carboxylic acid sodium salt; [6R-[6a,7b(Z)]]-7-[[(2-Amino-4-thiazolyl ) (methoxyimino)acetyl ] amino] -3- [[[ [1- (3-carboxy-l-cyclopropyl -6,8-difluoro-l ,4-dihydro-4- oxo-7-quinol inyl ) -3-pyrrol idinyl amino]carbonyl ]amino]methyl ] -5- thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt; 370 [5R-[5a,6a]]-3-[[[[4-(3-Carboxy-l-cyclopropyl -6-fluoro-l,4- dihydro-4-oxo-7-quinol inyl)-l-piperazinyl]carbonyl]amino]methyl ]- 6-C( )-1-hydroxyethyl ] -7-oxo-4-thia-l-azabicylo[3.2.0]hept-2- ene-2-carboxyl ic acid disodium salt; and 92032/2 - 370 - [6R-[6a,7b]]-3-[[[[4-(3-Carboxy-l-cyclopropyl-6-fl uoro-1,4- dihydro-4-oxo-7-quinol inyl ) -1-piperazi'nyl Jthioxomethyl Jthio] methyl ]-7-methoxy-8-oxo-7-[(thieny1 acetyl ) ami no] -S-thi a- 1- azabicyclo[4.2.0]-oct-2-ene-2-carboxy1 ic acid disodium salt.

17. A compound, according to Claim 16 , which is [6R-[6a,7b(Z)]]-7-[[[(2-Amino-4-thiazolyl)methoxyimino]acetyl ]am-ino]-3-[[[[4-(3-carboxy-l-cyclopropyl -6-fluoro-l ,4-di hydro-4-oxo--7-quinol inyl )-l-piperazinyl ]thioxomethyl]thio]methyl j-S-oxo-S-thia-l-azabicyclo^^.Ojoct^-ene^-carboxyl ic acid disodium salt. 18.. A compound, according to Claim 16., which is [6R- [6a, 7b]] -3- [[[l-(3-Carboxy-l -cyclopropyl -6-fluoro-l, 4-dihy-dro-4-oxo-7-quinol inyl )-3-pyrrol idinyl ami no] carbonyloxyjmethyl ] -8-0X0-7- [(2-thienyl acetyl ) amino] -5- thi a- l-azabicyclo[4.2.0]oct-2-ene-2-carboxyl ic acid disodium salt. 19'.. A composition for treating or preventing an infectious disorder in a human or other animal subject, comprising: (1) a safe and effective amount of a compound of any of Claims 1 to 18; and (2) a pharmaceutical ly-acceptable carrier.

20. . A composition for treating or preventing an infectious disorder in a human or other animal subject, according to Claim 19, wherein said composition is suitable for parenteral administration.

21. . A composition for treating or preventing an infectious disorder in a human or other animal subject, according to Claim 19, wherein said composition is suitable for oral administration. 92032/ 2 - 371 -

22. A compound according to any of Claims 1 to 18 for use as a medicament for preventing or treating an infectious disorder in a human or other animal subject. For the Applicants, DR. REINHOLD COHN AND PARTNERS By: